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SUMMARY
Purines and pteridines (more commonly referred to as ‘folates’) are fundamental 
components in a number of reactions involved in DNA and RNA synthesis and are 
inextricably linked to the basic metabolic pathways of the normal functioning cell. 
The aim of this project was to examine the ways in which existing biochemical and 
molecular techniques could be used to better effect in the diagnosis of a number of 
genetic disorders associated with purine and pteridine metabolism. The disorders 
under study covered a spectrum of inheritance patterns, notably Lesch-Nyhan 
Syndrome (LNS) and gout (X-linked); adenosine deaminase (ADA) and purine 
nucleoside phosphorylase (PNP) deficiency (autosomal) and neural tube defects 
(multifactorial).
Phase 1: Purines
Lesch-Nyhan Syndrome
The first phase of the project was an investigation of purine metabolism and as a 
first step, reliable reference ranges in various tissues were established which 
could be utilised in the diagnosis of patients with specific enzyme deficiencies. 
Control samples taken from subjects with no known history of metabolic disorders 
were analysed for the purine enzymes; hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT); adenine phosphoribosyl transferase (APRT); ADA; PNP and 
phosphoribosyl pyrophosphate synthetase (PRPP-S) in various tissues, notably 
adult, fetal and cord red cells; cultured and fresh chorionic villi (CV); fibroblasts and 
cultured amniotic fluid cells. A critical analysis of the distribution parameters 
(Kolmogorov-Smirnov (KS) test) confirmed that all enzymes exhibited Gaussian 
distributions after logio transformation of the data and this was carried out for all 
reference ranges.
The method used in this study for measurement of the purine salvage enzymes, 
was a radiolabelled enzyme assay with separation of the products by thin layer 
chromatography. This is a simple and cost effective technique and is much less 
labour intensive than other more sensitive detection systems such as high 
performance liquid chromatography (HPLC).
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Over the period of the study, prenatal diagnosis by analysis of HGPRT and APRT 
activity was performed on 23 pregnancies in 15 women known or suspected 
through family history to be carriers for Lesch-Nyhan Syndrome. Three successive 
pregnancies were investigated in two patients, and two in each of four other 
obligate carriers, while nine other women had prenatal investigation in only one 
pregnancy. In 8 of these cases, CV was obtained in the first trimester of pregnancy 
and in 3 cases in the second trimester while amniotic fluid samples were obtained 
in the second trimester from 10 cases. No gestation was specified in 2 cases of 
cultured CV. Normal HGPRT/ APRT ratios were obtained in 19 pregnancies of 
which 13 were subsequently verified as having a normal outcome; 2 miscarried and 
4 failed to have the outcome clinically verified. The remaining 4 pregnancies gave 
abnormal enzyme ratios with the parents opting for termination of pregnancy. 
HGPRT activity in the affected pregnancies was observed to be between 0.06 and 
13.9% of the mean of the appropriate reference range.
A wide range of reference values was observed for HGPRT, APRT, ADA and PNP 
in cultured and uncultured tissues. Control ranges for HGPRT and APRT in CV 
tissue compared well with other reported studies on prenatal diagnosis, although a 
reduction in enzyme activity in CV material stored frozen which had been reported 
by other workers, could not be confirmed in this study. Where CV was not 
available, amniotic fluid cells are a reliable alternative for prenatal diagnosis, with 
the disadvantages of sampling in the second trimester of pregnancy and the 
necessity for cell culture prior to diagnosis.
Enzyme analysés were carried out postnatally on 3 male affected cases, 5 obligate 
carrier mothers of affected children and 33 other members of LNS families. Index 
cases displayed significantly reduced enzyme levels of HGPRT and the 
HGPRT/APRT ratio, but significantly elevated levels of ADA and PNP. HGPRT 
activities were observed to be 0.95 -  4.9% of the reference mean emphasising that 
residual levels of HGPRT are often found in affected individuals. In the obligate 
carriers, HGPRT was observed to be significantly different from the mean of the 
controls. While this reduction may be significant, the degree of overlap between 
the reference and control ranges, prevent this from being diagnostically useful. 
However this data was based on a small number of only 5 samples, further data 
may clarify this. The HGPRT and APRT was found to be significantly reduced in
20
other family members compared to the controls, but with similar problems of 
differentiation between the control and patient ranges.
Gout
Blood samples from 54 patients, consisting of 45 males and 9 females, presenting 
with gout were assayed for HGPRT, APRT and PRPP-S. A significant difference 
was observed in HGPRT activity in male patients only compared to the control 
group. The overlap in the distributions suggests that these enzymes cannot be 
used reliably to distinguish the patient and control populations. Uric add levels 
were not evaluated in relation to the purine enzymes, since all patients were 
undergoing therapy for hyperuricaemia at the time of sampling, and it is unclear 
whether the various medication regimes employed had any effect on the levels of 
purine enzymes observed.
Two male patients, FFR and TGR presented with polyarticular gout, (in contrast to 
the remainder of the population who presented with idiopathic gout of a 
monoarticular nature), and gave reduced HGPRT levels of around 50% of the 
control mean. No significant difference was observed in PRPP-S activity between 
controls and patient groups indicating that PRPP-S superactivity and subsequently 
increased de novo synthesis was not a common cause of the gout. A 2 year old 
male patient, MHD, presenting with elevated uric acid and dyskinetic cerebral palsy 
gave PRPP-S activity of 3.7 times the control mean, however due to non- 
compliance no further investigations could be performed.
ADA and PNP Immunodeficiencies
The activities of ADA and PNP were investigated in 27 patients with suspected 
ADA deficiency, and in 23 patients with suspected PNP deficiency. Where possible 
the ADA and PNP analyses were performed in tandem on all samples from these 
patients presenting with suspected immunodeficiency disorder. Three children were 
identified with a complete deficiency of ADA activity confirming a diagnosis of ADA- 
deficient severe combine immunodeficiency (SCID). There was one prenatal 
diagnostic case based on ADA analysis of cultured amniotic fluid cells which 
showed that the fetus was unaffected. No evidence was found of ADA carrier 
levels In any of the patients tested, although 7 were identified where red cell ADA 
activities were above the upper limit of the reference range.
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Around 50% of the cases referred for PNP investigation originated from two 
families. The index case from family OD was found to have a complete deficiency 
of red cell PNP activity with ADA activity very high at 4.8 multiples of the mean of 
the normal reference range. The parents had approximately half normal red cell 
PNP activities confirming their carrier status, and two sibs of the index case were 
also identified as PNP carriers on the basis of half-normal enzyme activity. Three 
prenatal diagnoses were carried out in this family, all based on the enzyme 
analysis of cultured CV. One affected fetus with zero PNP activity, one possible 
carrier and one unaffected fetus were diagnosed. ADA activities were found to be 
within the reference range in each case, and all fetuses were shown by karyotype 
analysis to be male.
In family FK, PNP deficiency was diagnosed retrospectively in the index case using 
a re-constituted fibroblast cell line after enzyme analysis in red cells from the 
parents had shown approximately 50% normal PNP activities, suggesting carrier 
status. All other patients investigated had PNP activities within the normal 
reference range, except for one case where carrier levels were found.
Phase 2: Pteridines
The second phase of the project involved a case-control study to examine the role 
played by the thermolabile mutation (677C-~>T) of the enzyme 5,10 methylene 
tetrahydrofolate reductase (MTHFR), in the development of neural tube defects 
(NTD) in a Scottish population. Assessment of the allelic frequency of the 
thermolabile variant, and the lymphocyte MTHFR enzyme activity was related to 
the folate and vitamin B12 status in both controls and in populations with a family 
history of NTD.
A total of 262 controls obtained from the general population, were compared to 4 
groups consisting of 40 NTD affected individuals; 85 mothers who had one or more 
NTD affected pregnancies; 35 fathers of affected pregnancies and 36 other family 
members. Using PCR, the genotype frequency for the thermolabile allele (+/+) of 
MTHFR was 11.8% for the controls; 10.0% for the NTD individuals; 15.3% for the 
mothers; 8.3% for the fathers and 11.1% for the others. This translated to odds 
ratios (OR) of 0.9, 1.3, 0.7, 0.9 respectively. There was a significant difference 
(p<0.01) in the mothers group compared to the controls.
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Lymphocyte MTHFR activities showed a marked reduction associated with the + 
allele. The combined data for all groups under study suggests that the specific 
activity in heterozygote (+/-) and +/+ Individuals was around 75% and 55% of 
homozygous normal (-/-) levels respectively. This Indicates that the + allele has 
approximately half of the activity of the normal allele. Consideration of the data 
within each study group indicated the lowest MTHFR activities were associated 
with the NTD group where the +/+ NTD affected group showed 21% of -/- control 
activity. A significant difference in enzyme activity was found for +/+ and +/- 
genotypes of both mothers and NTD affected Individuals compared to the -/- 
controls. Total heat stable residual lymphocyte MTHFR activity for the +/- and 
+/+ genotypes was 38.4%, 37.8%, and 34.0% respectively and under the 
conditions of the study, the variant allele does not appear to be significantly more 
heat labile than the normal - allele.
Optimisation of the lymphocyte MTHFR enzyme assay was performed prior to its 
use in the study. This indicated that a protein and menadione concentration of 
2mg/ml and 0.1 mM respectively were required to allow for enough material for 
subsequent testing of the sample and to reduce the blank value of the assay. In 
addition, optimisation indicated that a 1.5 hour incubation was suitable for maximal 
separation of test and blank activities. Heating of the enzyme for the thermal 
stability work was found to be optimal at 46°C for 5 minutes, which was as quoted 
in the original method. Results suggest that an MTHFR assay for serum was not a 
viable proposition due to low levels of specific activity and the subsequent 
difficulties in differentiating these from background hydrolysis of the assay 
components.
Red cell folate results for each of the respective groups indicates that while +/+ 
affected , mothers and fathers show reduced folate levels of 75%, 68% and 70% 
respectively (with an overall reduction of 81% when the combined data for all 
groups were examined), these are not significantly different from the 
concentrations in -/- controls. Significantly raised levels of plasma vitamin B12 were 
evident in mothers and fathers of affected individuals. This could have implications 
on the recommended daily levels of folate and vitamin B12 intake for both mothers 
and fathers to reduce the risk for both first occurrence and recurrent neural tube 
defects.
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In conclusion, the purine study shows the value of careful statistical assessment of 
the enzyme distribution prior to the establishment of references ranges. 
Confidence in interpretation of enzyme results in individual patients is improved, 
particularly in cases such as LNS where residual enzyme activities may be present, 
and in identification of carriers for ADA and PNP deficiencies. However, for LNS, 
the determination of carrier status can only be reliably achieved by molecular 
methods. Also, specific activity appears to be unhelpful in the assessment of the 
actual causes of gout, although low levels of HGPRT may be of value in 
differentiating cases of monoacticular and polyarticular gout.
The pteridine study provides some support for the view reported elsewhere that a 
common mutation of the MTHFR gene is repsonsible for the development of some 
cases of NTD. While the frequency of the 677C--»T mutation was not found to be 
higher in NTD affected individuals in the Scottish population, the higher frequency 
found in mothers, along with low MTHFR enzyme activities and low red cell folate, 
suggest the maternal component may be a potential risk factor in the development 
of some NTDs.
Future work on purine disorders may concentrate on the analysis of individual 
intermediates in the salvage pathway, while the role of folate in the aetiology of 
NTDs, could be extended to the investigation of folate binding proteins, receptor 
binding and transport during pregnancy.
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CHAPTER 1. INTRODUCTION
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1.1 Purines and Pteridines
Purines and pteridines (referred to as ‘folates’ ) are fundamental compounds 
necessary for the synthesis of DNA and RNA and as such, have a pivotal role in 
human development, where these systems are inextricably linked in the basic 
synthetic and catabolic pathways of the cell. Folate co-enzymes participate in a 
number of critical 1-carbon transfer reactions including those involved in the 
synthesis and degradation of purines, where the mediation of a trifunctional peptide 
links the major source of these carbon units (serine) to the de novo synthetic 
reactions of the purine pathway (Figure 1-1) .
Methionine + tetrhydrofolate
Serine
Glycine
S-Msthyl -tetrahydrofolalB
S.IO-Methylena-tetrafoiate 5.10-Meth8nyltetrafolate 10-Formy Itetrahydrofolate
Riboss-5-phosphate — ►  5-Phosphoribosyl 
Giycinamide
S-phosphortbosyl-N-
formylglycinamide
5-Phosphoribosyl-5- 
‘ ►  Amlno-4-im idazole- 
Carboxamida
5-Phosphoflbosyl-5-
FormsiTiido-4-imidazole-
Carboxamide
Figure 1 ■ 1
Relationship between the pteridine (red) and de novo purine (purple) metabolic 
pathways.
A number of other important metabolic pathways link purine and pteridines, notably 
those of S-adenosylmethionine (SAM) and S-adenosylhomocysteine hydrolase 
(SAHH). The methyl donor SAM is second only to ATP in reactions in which it 
serves as a cofactor, where in addition to its role in méthylation of nucleic acids, 
proteins and lipids, is essential for the salvage of the purine adenine from the 
polyamine pathway, a vital precursor in the synthesis of ATP, while the enzyme S-
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adenosy I homocysteine hydrolase (SAHH) is a vital component in the formation of 
ATP by regulation of the compound deoxyadenosine (Figure 1 - 2).
UREA CYCLE
p f Creatine >  Creatinine
^  S-adenosylhomocysteineSAMi
SAM
5”MTAR
^  Methionine Methionine
HcySH
SAHHATP
AdenosineAMP < ------
Adenine
Figure 1 - 2
Relationship between folate (red) and purine (purple) metabolic pathways via the 
adenine salvage reactions. The dotted line indicates a potential pathway for the 
formation of adenine from 5-adenosylhomocysteine. Key to abbreviations not in 
text:- 5’MTAR = 5’methythloadenosine; SAMI = carboxylated S-adenosyl- 
methionine; HcySH = homocysteine.
Although few disorders of pyrimidine metabolism are known, a surprising number of 
genetically determined defects in the purine salvage pathway and folate-dependent 
homocysteine pathway have been identified. A variety of chemical consequences 
from major congenital malformations to mild or asymptomatic disease may 
associated with metabolic errors in these pathways.
This study focuses on analysis of the enzymic defects and examines their use In 
diagnosis, prenatal diagnosis and carrier detection.
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1.2 Purines
1.2.1 Metabolism
It has long been recognised that within many biological processes, the role of 
purines is a crucial one. By far the most important occurrence of purines is in the 
nucleotides and nucleic acids, compounds which perform some of the most 
essential functions in metabolism.
Purines play a vital part in intracellular metabolic processes as diverse as energy 
stores; the driving of chemical processes (AMP, ADP, ATP); membrane signal 
transduction (GTP, cAMP); cofactors for enzymic reactions (NAD, NADP, FAD) and 
when combined with pyrimidine molecules, providing the basic building blocks for 
the deoxyribo and ribonucleic acids, DNA and RNA.
Purine molecules are low molecular weight compounds consisting of a base 
(adenine or guanine) combining with a pentose sugar of either D-ribose or 2- 
deoxy-D-ribose, through a glycosidic C-N linkage at position 9 of the base, forming 
the nucleoside structure ( e.g. hypoxanthine, xanthine) . This nucleoside can be 
further bonded by the C 5 oxygen to one, two or three phosphate units to form the 
high energy purine nucleotides such as ATP (Figure 1 - 3).
Since purines are required by all cells for survival and growth, there exists within 
these metabolic processes, a number of pathways for the production of new 
purines from simple precursor molecules; the interconversion and catabolism of 
nucleotides and the salvage and re-use of existing purine molecules.
1.2.2 De novo production
The ‘de novo’ biosynthesis of purines involves 11 enzymic reactions , from which 
the purine ring is constructed from small component molecules beginning with a-D- 
Ribose 5-phosphate (R5P) and ending with the formation of Inosine mono­
phosphate (IMP) (Buchanan and Hartman 1959; Gutman and Yu 1965).
The compound 5-phosphoribosyl-a-l-pyrophosphate (PRPP) is generated from the 
pyrophosphorylation of R-5-P by the enzyme PRPP- synthetase at the expense of 
ATP. All in all, 9 high-energy phosphate groups are utilised in the formation of a 
single molecule of IMP.
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Figure 1 - 3
a) Structural formulae of purines, b) Structural formulae of adenosine, indicating 
the numbering of the purine and sugar rings and the phosphate groupings in 
AMP, ADP and ATP. ( Diagram taken from Stone and Simmonds 1991 ).
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PRPP is considered to be a key regulatory substrate in the de novo purine 
pathway since its irreversible condensation with L-glutamine to generate 5-p- 
phosphoribosyl-1-amine catalysed by the enzyme amidophosphoribosyltransferase 
(AMPRT), is the first committed step in the formation of IMP (Holmes 1980) (Figure 
1-4) .
All newly synthesised purines are ultimately derived from IMP which serves as a 
branch point for alternative biosynthetic pathways. There appears to be two distinct 
levels of regulatory mechanisms involved in the de novo pathway:-
a) Regulation of the pathway controlling the synthesis of IMP
b) Regulation of the formation of the branch pathways to the adenylates and 
guanylates.
The enzyme Is inhibited at two distinct ailosteric sites by the adenylates (AMP,ADP 
ATP): and the guanylates (GMP,GDP and GTP), as well as IMP. The inhibition 
appears to be maximal when both groups of nucleotides are present, promoting the 
formation of a catalytically inactive aggregate (Holmes et al 1973).
Cellular levels of PRPP are governed by the relative activity of PRPP-synthetase 
and the rate of PRPP utilisation, PRPP also activates AMPRT , with high levels of 
PRPP driving the reaction forward. The other level of regulation of the de novo 
pathway involves the interconversion and catabolism of IMP to AMP and GMP the 
respective precursors of ADP, ATP GDP and GTP. Each of the end products of 
these branch pathways, stimulates the other by serving as the reactive phosphate 
donor. In addition, AMP and GMP inhibit their respective salvage enzymes, thus 
directly promoting nucleotide catabolism.
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Figure 1 - 4
De novo pathway of purine synthesis indicating the position of PRPP-synthetase 
(PRPP-S) and amidophosphotransferase (AMPRT).
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1.2.3 Catabolism
Catabolism of purine nucleotides involves both the polynucleotides, DNA and RNA 
as well as the adenine and guanine based nucleotides, ATP and GTP.
Mononucleotides released from cells following ischaemia, cell death or extrusion of 
the erythrocyte nucleus during maturation are further degraded to the purine 
bases, hypoxanthine or guanine, by a number of different systems.
Adenine based ribonucleotides are deaminated principally via the enzyme
adenylate deaminase (AMPDA) to IMP, while the adenine deoxyribonucleotides 
which cannot be metabolised by this route and must be dephosphorylated by 5’- 
nucleotidase and deaminated by adenosine deaminase (ADA). Both of these 
products are ultimately converted to Inosine or deoxyinosine and finally to 
hypoxanthine by purine nucleoside phosphorylase (PNP). This is in contrast to 
adenosine which is preferentially converted to AMP by adenosine kinase (AK) 
because of the Michaelis constant (Km) for adenosine which favours deamination. 
The nucleotides GMP and dGMP are also degraded to the corresponding 
nucleosides guanosine and deoxyguanosine by S’-nuclootidase, and subsequently 
xanthine prior to excretion.
1.2.4 Purine salvage
During normal metabolic processes, the degredation of nucleic acids by nucleases 
releases nucleotides which undergo enzymic hydrolysis to yield , utimately , the 
free purine (and pyrimidine) bases.
The salvage pathway (in concert with the processes of nucleotide interconversion) 
ensures the efficient utilisation of preformed purines, thus conserving much of the 
cellular energy which might otherwise be consumed in the synthesis of new 
purines. A small amount of purines catabolised daily are normally excreted, 
predominantly as uric acid, while the vast majority are actively recycled via this 
pathway by the action of the phosphoribosyl transferase enzymes, principally 
hypoxanthine-guanine phosphoribosyl transferase (HGPRT) and adenine- 
phosphoribosyl transferase (APRT). Another salvage pathway, involves the 
sequential actions of PNP to convert purine bases to nucleosides, and then of 
nucleoside kinases, for further phosphorylation to nucleotides. (Murray et al 1970).
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other enzymes involved in the reactions include 5’ nucleosidase and ADA. The 
enzymes 5' nucleotidase and PNP are involved in the production of purines that 
can be either recycled or catabolised to uric acid and excreted. (Figure 1 - 5).
In the early part of this century, Archibald Garrod coined the term’ inborn error of 
metabolism’ to describe disruptions of the normal metabolic pathways by the 
inherited deficiency of an enzyme. While this definition has been modified in the 
intervening years the general premise of the specific, monogenic nature of these 
disorders still holds true.
Since all metabolic processes are carried out by these enzymes and are under 
genetic control, it is possible that some individual will lack any given enzyme 
because of a genetic defect. Although these specific disorders are individually 
rare, there are many enzyme pathways and therefore an enormous potential for 
this enzymic derangement. In specific enzyme deficiencies, substrates will 
accumulate and at high levels may be converted to alternative products not usually 
present. Consequently the normal end products of the reaction may be deficient. 
Since many of these biochemical abnormalities are expressed in a variety of 
tissues, this allows the diagnosis of purine metabolic disorders to be performed in 
material as varied as red cells, amniocytes , fibroblasts and cultured or uncultured 
chorionic villi. Ultra-micro methods of analysis allow for the use of small incubation 
volumes, favourable signal to noise ratios and long Incubation times in the 
measurement of the low enzyme activités present in affected individuals. These 
assays may be utilised for small numbers of uncultured cells thus reducing the time 
taken to perform a prenatal diagnostic assay, or in cases where little cell material 
is available, in cultured cells in order that confirmatory analysis may be performed.
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1.2.5 Hypoxanthine-guanine phosphoribosyl transferase (HGPRT)
Hypoxanthine-guanine phosphoribosyl transferase (HGPRT; HPRT; IMP: pyro­
phosphate phosphoribosyltransferase; inosinate-guanylateipyrophosphate; E.C. 
2.4.2.8) is a soluble cytoplasmic enzyme widely distributed in all tissues, with the 
highest activity in found in rapidly dividing tissues such as brain and testes (Kelley 
and Wyngaarden 1983; Watts et a! 1987). It catalyses the reaction of purine bases 
and PRPP to form purine ribonucleotides. The human enzyme has been highly 
purified and studied extensively with regard to its biochemical characteristics 
(Bakay and Nyhan 1975). Due to the ease in obtaining material, most of the 
definitive work has been done on red cells (Krenitsky et al 1969; Olsen et al
1977)) and has shown the enzyme to be a tetramer composed of identical subunits 
each consisting of a molecular weight of 24,500 (Holden and Kelley 1978) . The 
217 residue amino acid sequence was subsequently elucidated by Wilson et al 
(1982b).
HGPRT binds both 6-oxo or 6-thio compounds such as xanthine, allopurinol, 6- 
mercaptoethanol, 6-thioguanine as substrates in addition to hypoxanthine and 
guanine which have a Michaelis constant in erythrocytes of 1.7 x 10'^ and 5x10'® 
respectively. Kelley et al (1967) and Seegmilier et al (1967) postulated that the 
reactions of hypoxanthine and guanine were catalysed by a single enzyme due to 
identical rates of heat inactivation, electrophoretic mobilities under several 
conditions and the observation that the loss of one reaction was always 
accompanied by the loss of the other. Henderson ef a! (1968) substantiated this 
work by showing on kinetic studies of velocity, product inhibition and isotope 
exchange of HGPRT that PRPP , the only compound known to serve as a donor 
for the phosphoribosyl moiety in the reaction exhibited the same Michaelis 
constants, 2.5 x 10"'' irrespective of whether hypoxanthine or guanine was used as 
a substrate.
1.2.6 HGPRT Deficiency
A deficiency of the enzyme HGPRT is associated with two clinical syndromes in 
humans. An almost complete deficiency of the enzyme results in the Lesch-Nyhan 
Syndrome (Lesch and Nyhan 1964), while a partial deficiency is manifested by a
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severe form of gout, with hyperuricaemla and excessive production of uric acid 
(Seegmilier et al 1967; Kelley et al 1967). While most patients with the classical 
syndrome exhibit almost no HGPRT activity, McDonald and K e lley^971) reported 
red cell and fibroblast HGPRT activities of between 8% and 34% of normal when 
assayed with a lOmM concentration of magnesium 5-phosphoribosyi-1- 
pyrophosphate, as opposed to the normal concentration of ImM. This ten-fold 
increase in the PRPP concentration and the Increased Michaelis constant for 
hypoxanthine and guanine, provided the first evidence of the genetic heterogeneity 
in patients with Lesch-Nyhan Syndrome.
1.2.6.1 Lesch-Nyhan Syndrome (LNS)
LNS is an X-Linked disorder clinically manifested by hyperuricaemla excessive 
production of uric acid and characteristic neurological features including 
choreoathetosis, spasticity, mental retardation and self mutilation (Lesch and 
Nyhan 1964).
The clinical abnormalities associated with HGPRT deficiency are absent at birth 
(Marks et al 1968). Patients may present with hypotonia, recurrent vomiting, 
difficulties with secretions and delay in motor development which appears at the 
first 3 to 4 months of life. By the first year, extrapyrimidal signs such as dystonia, 
chorea, hyper-reflexia and scissoring of the legs begin to appear. A striking feature 
of LNS is the compulsive self-destructive mutilating behaviour observed between 2 
and 16 years of age. Patients exhibit a compulsive tendency to self injurious 
behaviour observed in 85% of cases, and frequently it is this symptom which 
results in the correction of initial diagnoses of cerebral palsy (Mizuno et al 1970). 
This behaviour may be so extreme as to warrant restraint of the individual to 
prevent self injury of the arms or fingers by biting. Patients may also exhibit 
unusual aggressive behaviour towards others, although the degree to which this 
self mutilation and aggressiveness occurs may be quite variable, with patients 
showing mutilative behaviour for weeks or even months at a time before returning 
to normal behavioural patterns. The degree of self mutilation can also vary on a 
day to day basis, and may be exacerbated by aggravating environmental events. 
Patients with partial deficiency of HGPRT do not exhibit mutilatory behaviour. 
Geerdink et al (1973) described an atypical case of an adult patient with gout, but 
without any demonstrable HGPRT activity in red cells, lymphocytes of fibroblasts.
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Few of the neurological abnormalities generally associated in this disease were 
evident, until further psychological tests disclosed some of the behavioural 
anomalies associated with LNS , albeit in a concealed form.
The mechanism by which a decrease in HGPRT activity produces the neurologic 
dysfunction observed in the LNS remains unclear. Rosenbloom et al (1967b) 
demonstrated normal concentrations of uric acid in the CSF of patients examined 
and the failure of anti-hyperuricaemic therapy to alter CNS function. While elevated 
concentrations of oxypurines occur in patients with LNS, the finding of similar levels 
of hypoxanthine and xanthine in the CSF of patients with a partial deficiency of 
HGPRT, and with no evidence of CNS dysfunction suggests that these compounds 
are in themselves not responsible for the CNS disease.
While routine studies of cerebral spinal fluid have been reported to be normal in 
these patients, the levels of specific neurotransmitters and their metabolites have 
been reported to be altered in cases of LNS (Lloyd et al 1981). Other studies have 
demonstrated decreased levels of homovanillic acid and 3-methoxy-4-hydroxy 
phenylethelene glycol, suggesting that reduced dopamine and epinephrine 
turnover may be important in the pathogeneses of the disease (Jankovic et al 
1988; Silverstein et al 1985).
Several animal models which have been developed to examine the neurobiological 
substrates of this disorder. Jinnah et al (1994) described the use of HGPRT 
deficient mice which had similar, albeit more subtle changes in brain dopamine 
function and the relationships to the neurological deficits observed in patients with 
LNS.
Hyperuricaemla is common in patients with a partial or complete HGPRT deficiency 
and is associated with an markedly increased rates of de novo purine synthesis. 
Hypoxanthine is rapidly converted by HGPRT deficient cells to uric acid, which is 
excreted dramatically in the range of 24-184 mg/kg body weight per 24 hours ( the 
normal excretion rate being about 1-14 mg/kg of body weight per 24 hours). 
Patients with a partial deficiency of HGPRT excrete uric acid at levels approaching 
those observed in LNS patients.
Haematological abnormalities have been associated with the Lesch-Nyhan 
Syndrome, In particular a number of studies have shown the presence of 
macrocytic red cells in the peripheral blood and megaloblastic changes in the bone 
marrow of LNS Individuals.
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1.2.6.2 Genetics
The initial suggestion that the Lesch-Nyhan syndrome was an X-linked disorder 
with affected male offspring and carrier females, was provided by Lesch and 
Nyhan on pedigree analysis in their original report in 1964, and subsequently 
confirmed by Hoefnagal et al (1966), while the finding of patients with a partial 
deficiency of HGPRT, and who were able to reproduce, enabled Kelley et al 
(1970), to subsequently confirm the X-linked nature of the disease. The studies of 
(Rosenbloom et al 1 9 6 %  and (Migeon et al 1968) demonstrated that obligate 
heterozygotes for the enzyme defect are mosaics in terms of HGPRT activity and 
in addition to supporting the X-linked hypothesis, were consistent with the Lyon 
hypothesis. The incidence of Lesch-Nyhan syndrome is as yet unclear, but has 
been estimated at between 1:100,000 and 1:380,000 (Seegmilier 1976; Stout and 
Caskey 1985a).
The use of mouse-human somatic cell hybridisation, demonstrated the location of 
HGPRT gene to the long arm of the X chromosome, while subsequent mapping 
using X-autosome translocations in somatic cell hybrids localised it to position 
Xq26-q27 (Pai ef a/ 1980).
In 1968, Hooft et al reported a three year old girl with self mutilating behaviour, 
athetoid movements and mental retardation. The patient had a high urinary uric 
acid excretion rate , but a normal serum uric acid level. However since HGPRT 
activity was not measured, there was no confirmatory data on whether this case 
was LNS.
Hara et al (1982) reported a female patient with the characteristic symptoms of 
LNS, including self mutilation, athetoid movements and mental retardation, in 
addition to hyperuricaemia, hyperuricosuria and decreased HGPRT activity. Further 
work on this patient by Ogasawara et al (1989) proposed that this disease was 
caused by a microdeletion of the active maternal X chromosome and inactivation of 
the HGPRT gene on the paternal X-chromosome. A second patient was described 
by Yukawa et al (1992) with the clinical symptoms of LNS, and with reduced 
HGPRT and raised APRT levels. The patients family were non-consanguineous, 
and there were no other family members with LNS, gout or any other 
psychoneurological disorder. Since the family situation precluded a family study, it 
was assumed that this case represented a spontaneous mutation.
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1.2.6.3 Molecular studies
The cloning of cDNA for the human HGPRT was simplified by the isolation of a 
mouse neuroblastoma cell-line, NBR4 which expressed high levels of a mutant 
HGPRT gene (Melton 1981), and subsequently paved the way for differential 
hybridisation strategies to isolate the first HGPRT cDNA recombinants (Brennand 
et al 1982. Jolly et al (1982) using transfection recombinants in mice cells 
deficient in HGPRT, succeeded in isolating a genomic clone partially encoding 
human HGPRT, and a year later identified a nearly full length human HGPRT 
coding sequence by using HGPRT-specific clones in a cDNA library (Jolly et al 
1983). The isolation of these cDNA recombinants permitted the characterisation of 
the human HGPRT gene structure which is 44kb long and is composed of 9 exons 
and 8 introns (Patel et al 1986). There are 4 non expressed pseudogenes for 
HGPRT in human DNA , located on chromosomes 3, 5 and 11 (Dobrovic et al 
1987; Patel et al 1984).
Initially, HGPRT mutations were described on the basis of altered protein or 
enzymic characteristics , however this approach was limited to those mutants with 
residual HGPRT activity and excluded those patients with the Lesch-Nyhan 
Syndrome who exhibited no noticeable activity. The elucidation of the normal 
HGPRT amino acid sequence allowed structural alterations to be detected by 
comparative mapping of tryptic peptides and the sequences of these aberrant 
peptides were determined by manual Edman degredation reactions on protein 
purified from human red cells (Wilson e ta l 1982a; Wilson et al 1982b).
It was not evident at this time whether the measured lack of HGPRT activity in LNS 
originated at transcription, with unstable mRNA being transcribed or at translation 
resulting in the production of a defective enzyme. Prior to the complete elucidation 
of the nucleotide sequence, Yang et al (1984) utilised 4 different restriction 
endonucleases to examine the genomic DNA from 28 unrelated patients with LNS 
Results showed that the DNA from 23 patients exhibited a restriction pattern 
identical to that of the control while the remaining 5 exhibited distinct differences 
which were reflected in the relative amounts of HGPRT mRNA. This demonstrated 
for the first time that molecular methods could be used to trace the origins of new 
mutations. Wilson et al (1986) subsequently demonstrated that the deficiency of 
enzyme in lymphocyte cell line of 24 unrelated patients, was due to an abnormality 
in enzyme function rather than a deficiency in enzyme structure itself.
39
The discovery that the mutations in the HGPRT gene were heterogeneous in 
nature, provoked a surge of activity to define the mutations and their effect on 
HGPRT function and structure, using a number of novel approaches.
Using the technique first applied by Jolly et al (1983) , a number of single base 
substitutions were defined as HGPRT Rint (Davidson et al 1988); HGPRT Ann Arbor 
(Fujimori et al 1988); HGPRT vaie (Fujimori et al 1989) and HGPRT Ashvnie 
(Davidson ef a/ 1989a).
Gibbs and Caskey (1987) used a method involving ribonuclease A cleavage with a 
poly uridinylic acid-paper affinity chromatography step to identify mutational lesions 
in the HGPRT mRNA of patients with Lesch-Nyhan Syndrome. This method was 
based on the fact that some single base pair mismatch sites in RNA hybrids with 
RNA or DNA will be cleaved by RNAase A. Despite its initial promise, the technique 
only managed to detect 5 mutations out of 14 patients.
A further refinement on these methods has been the ability to automate the 
processes used in the work on the HGPRT gene. Gibbs et al (1989) used 
automated direct DNA sequence analysis of amplified HGPRT cDNA to detect and 
characterise 15 independent mutations, including base substitutions, deletions, 
base insertions and RNA splice errors. Further work by Gibbs et al (1990) 
demonstrated that multiple oligonucleotide primer sets could be constructed for 
simultaneous in-vitro analysis of all nine HGPRT exons and the products of this 
multiplex PGR could be analysed by direct automated fluorescent DNA 
sequencing the identify subtle alterations in the gene.
Tarle e ta l (1991) determined mutations of 17 previously uncharacterised cell lines 
in 16 patients with LNS using the PCR amplification and direct sequencing method 
of Davidson ef al (l989b). In this method, PCR amplified DNA was directly 
sequenced by denaturing the double stranded and amplified cDNA, annealing the 
end-labelled sequencing primer to one strand of the DNA and allowing chain 
termination to proceed through multiple stages of denaturing, annealing and 
extension. Using this method, (Davidson et al 1991) reported that in a study 
involving 22 subjects in 17 unrelated kindred, a clustering of mutations was 
evident, particularly in the evoiutionariiy conserved regions predicted to be involved 
in hypoxanthine guanine and PRPP binding.
Fujimori ef al (1990) described an interesting case involving the first nucleotide 
substitution observed in the Japanese population. A nucleotide substitution at 
codon 51 (CGA TO TGA) was found to be the same codon but a different
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nucleotide substitution to that of HPRT Toronto as described by Wilson et al (1983). 
Whereas the mutation at HPRT Toronto produced a CGA to GGA mutation and a 
partial deficiency of HGPRT activity, HPRT Fujimi produced symptoms of the Lesch- 
Nyhan syndrome. This report provided for the first time evidence that two different 
nucleotide substitutions at the same base position of the human HGPRT gene lead 
to the generation of two different mutant alleles.
A novel mutation in LNS was reported by Yang et al (1988) which showed a 
duplication of exons 2 and 3 and a second reversion event where most of the 
duplicated portion of the mutant gene was deleted. This may have accounted for 
the mild symptoms of the LNS exhibited by this patient.
The examination of a spectrum of phenotypes from classic LNS to clinical gout, 
and including a number of the more unusual variants of the disease, was carried 
out by Sege-Peterson et al (1992) using automated DNA sequencing of PCR- 
amplified HGPRT cDNA. This study examined 22 unrelated individuals and a 
diverse pattern of mutations accounting for the majority of the abnormal HGPRT 
genes.
1.2.6.4 Carrier Detection
Female carriers of the LNS cannot be reliably detected by clinical evaluation. 
Attempts at carrier detection by biochemical methods exploited the fact that the 
Lyon hypothesis postulates inactivation of one of the two X-chromosomes. Cells 
should therefore be encountered that are either HGPRT positive or HGPRT 
negative in women heterozygous for HGPRT deficiency, depending on whether the 
X chromosome carrying the mutant HGPRT gene is the inactive or active X. 
Dancis et al (1969) and Migeon (1970) -  evaluated this method of carrier
detection using skin fibroblasts in which heterozygous females were detected by
'4*'autoradiographic demonstration of mosaicism of mixed populations of HGPRT
and HGPRT cells. As an alternative to fibroblasts, hair follicles may be used as
the majority of hairs arise from a single cell and are therefore clonal in origin. 
Gartler et al (1971) demonstrated that this method for determining carrier status is 
rapid and relatively inexpensive, but is by no means infallable and that the 
methodology is subject to a number of pitfalls, a conclusion supported by a number 
of other studies, (de Bruyn et al 1973; de Bruyn e ta l 1974; Silvers e ta l 1972).
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An improved biochemical assay for HGPRT heterozygotes was described by Page 
et al (1982) whereby thin-layer chromatography and autoradiography was used 
on hair roots to provide a fast and sensitive method.
However, despite all previous biochemical methodologies for heterozygote 
analysis of HGPRT, by far the most reliable method for carrier detection is in 
instances where DNA analysis is diagnostic. This occurs when the mutation can be 
detected directly or when an RFLP is informative for the offspring of known 
heterozyzgotes. When informative, DNA analysis circumvents the problems 
associated with biochemical tests based on X - inactivation.
1.2.6.5 Prenatal diagnosis
Prenatal diagnosis was first reported by Fujimoto et al (1968) who presented 
evidence that the disease could be diagnosed in the fetus, before 20 weeks 
gestation, using a method of ®H-hypoxanthine incorporation into amniotic fluid 
cells. Further workers subsequently reported successful prenatal diagnoses of 
affected fetuses in the second trimester using amniotic fluid fibroblasts (Singh et al 
1976; Van Heesw ijkefa/ 1972).
Hosli et al (1977) successfully used a biochemical ultramicroassay proce dure for 
prenatal diagnosis of a 15 week male fetus and confirmed the diagnosis on 
fibroblasts and erythrocytes after termination of pregnancy.
Since diagnosis of LNS based on amniocentesis cannot be carried out before 
about 15 weeks gestation and cell culture requires a further 2-3 weeks, this leads 
to the late termination of the affected fetus. This is a very distressing situation for 
the families concerned, and so alternative procedures were sought.
The first instance of prenatal diagnosis for LNS in the first trimester of pregnancy 
was reported by Gibbs et al (1984), who used chorionic villi (CV) taken at 8-9 
weeks gestation in four pregnancies at risk for the disease. Radiochemical assay of 
HGPRT showed that 3 fetuses were affected, the diagnosis confirmed by analysis 
of culture fibroblasts after therapeutic abortion in 2 cases and spontaneous 
abortion in one.
Stout et al (1985b) confirmed the advantages early sampling LNS and 
demonstrated that other enzymes in the metabolic pathway, such as ADA and PNP 
also appeared amenable to early prenatal diagnosis by this method.
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A number of other workers have reported their experience with prenatal diagnosis 
of LNS in both the first and second trimesters of pregnancy. Zoref-Shani ef al 
(1989) reported results of between 5.5-17% of residual HGPRT activities in tissues 
at-risk of LNS.
A note of caution was introduced by the work of Page and Broock (1990), who 
drew attention to the possible deleterious effects of long term storage on CV 
samples, which appear to show reduced HGPRT activities when reassayed. This 
fact coupled with the presence of substantial residual activities and the relatively 
low specific activities associated with CV material may lead to difficulties in 
interpretation of results for pre-natal diagnosis.
1.2.6.6 Hyperuricemia and Gout.
Gout may be regarded as a heterogeneous group of genetic and acquired 
metabolic aberrations, with many factors promoting and influencing the saturation 
and deposition of monosodium urate and uric acid crystals in the tissues of 
individuals,
Kelley et al ( 1967) demonstrated this partial HGPRT deficiency in 5 male patients 
from 2 different families, with gout, and demonstrated that the characteristics of 
relative activity and heat stability of the defective enzyme showed similarities within 
each family, but differed when other families were tested.
Hyperuricaemia in these patients frequently leads to uric acid crystalluria, 
nephrolithiasis, and obstructive nephropathy. While patients with compiete or 
partial HGPRT deficiency both have hyperuricaemia, it is unusual for patients with 
LNS to develop gouty arthritis. In contrast, greater that 80% of patients with a 
partial deficiency, will eventually go on to develop gouty arthritis during the course 
of the disease. Treatment of the hyperuricaemia can be adequately controlled by 
the drug allopurinol which inhibits xanthine oxidase activity. The deposition of 
monosodium urate and uric acid crystals in the tissues of individuals as a result of 
the saturation of the extracellular fluids with urate, constitutes the main 
pathophysiological symptom defining gout.
Serum urate concentration varies with age in patterns that are distinctive in men 
and women. During childhood, men exhibit levels of 3 to 4 mg/IOOmIs which rise 
through puberty (Munan et al 1977) and remain relatively constant thereafter.
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while women show little change in this level until the menopause when values 
approach those of adult men. (Becker et al 1995a).
Hyperuricemia is defined as a serum urate concentration exceeding T.Omg/IOOmls 
in men and 6.0mg/100mls in women. Serum values in excess of 7.0mg/100mls 
confer an increased risk for gouty arthritis (Hall et al 1967) and are influenced by 
factors such as age, sex, body weight, blood pressure and ethnicity. The majority 
of hyperuricaemic individuals never manifest the clinical features of gout and 
moderate fiyperuricaemia appears to confer no substantial independent risk for the 
development of chronic renal insufficiency (Langford et al 1987; Yu et al 1982). 
The range of clinical manifestations in gout is narrow and includes recurrent 
attacks of characteristic acute inflammatory arthritis (acute gouty arthritis); 
accumulation of potentially destructive and deforming crystalline aggregates in 
connective tissues (tophi) and uric acid urolithiasis. The incidence of gout is 
estimated at 0.2 to 0.35 per 1000 births with and overall population prevalence of 2 
to 2.6 per 1000 (Zalokar et al 1981). Only in a minority of hyperuricaemic 
individuals do the symptoms of gout appear and usually after sustained 
hyperuricaemia over a number of years. As an untreated disorder, the disease 
process of gout follows 3 main stages, acute gouty arthritis, intercritical gout and 
chronic tophaceous gout.
Episodes of painful inflammatory arthritis are the most common manifestations of 
gout. They are monoarticular in 80-90% of cases with around 50% involving the 
first metatarsophalangeal joint (Grahame and Scott 1970), although other target 
joints include midtarsal joints, ankles, wrists and interphalangeal joints. Occurrence 
of gouty arthritis in men tends to be around 40 to 60 years of age and around 60 to 
80 years in women (Laliy et al 1986; Grahame et al 1970 ). Attacks of gouty 
arthritis appear to be incited by a range of circumstances, including trauma, 
excessive ingestion of alcohol of purine rich foods, or certain drugs. In addition to 
extracellular fluid urate supersaturation, a number of additional factors may 
contribute to regulate the urate crystal deposition in tissues, including lower 
temperature, and local increases in urate concentrations in joint structures ( Becker 
e ta l 1995a).
Intercritical gout is described as the intervening periods between the remission and 
onset of gout attacks. During an intercritical period, the establishment of gout in an 
individual may be difficult due to the heterogeneous nature of the condition, where 
with repeated recurrences, the intercritical periods generally diminish in length.
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Becker et al (1995a) showed that of a series of individuals with gout, only 62% had 
second attacks within the first year and 78% within 2 years, while 7% were free of 
recurrences for 10 years or more
An untreated patient may experience a series of severe, longer lasting and 
polyarticular attacks with sometimes resulting in the disappearance of the 
intercritical remission stage. Accompanying this, deposition of solid urate crystals or 
tophi, often occur in articular and other areas of connective tissue, with the 
accompanying end result of destructive arthropathy. Tophaceous gout is usually 
associated with an early age of onset, frequent attacks, a high serum urate and a 
history of upper extremity and polyarticular episodes (O'Duffy et al 1975; 
Nakayama et al 1984). Elderly patients in particular women, who may be receiving 
urico-retentive diuretics and anti-inflammatory drugs, and who may have a mild 
renal insufficiency, may also be at higher risk for tophus formation and polyarticular 
gout (Lally et al 1986).
1.2.6.7 Diagnosis and Treatment
While a complete deficiency of HGPRT is responsible for LNS, a partial deficiency 
of this enzyme is responsible for the onset of juvenile or gouty arthritis with only a 
minority of patients suffering major neurological symptoms. (Kelley et al 1969). On 
the basis of erythrocyte HGPRT activity, a number of studies could not differentiate 
between patients with LNS and gout (Emerson and Thomson 1973; de Bruyn et al 
1976). The severity of the neurological symptoms is thought to be related to the 
enzyme activity but it is uncertain whether these differences in the phenotypic 
expression of HGPRT deficiency are accompanied in differences in purine 
metabolism. In order to clarify this, Mateos and Puig (1994) studied the enzyme 
activities, plasma and oxypurine concentrations and adenine nucleotide 
degradation in patients with LNS and gout.
These workers found increased purine overproduction and adenine nucleotide 
degradation compared with normal subjects, suggesting that if the HGPRT activity 
determines the phenotypic expression, the enzyme defect appeared to be 
accompanied with an increased purine over production. These workers found 
similarly decreased HGPRT and increased APRT levels, as well as no substantial 
difference in plasma and oxypurine levels between LNS and gout patients and as
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such could not reliably be used to differentiate between these HGPRT deficient 
groups.
The aim of treatment in gouty arthritis is specifically to terminate the attack as 
quickly and effectively a possible, in addition to preventing recurrences and 
complications resulting from the urate deposition in joints and other soft tissues. 
Treatment must be targeted at the effective management of both the acute 
inflammatory response and the accompanying hyperuricaemia, since the drugs 
used in reducing the acute inflammation have no value in controlling the 
hyperuricaemia.
Acute gouty arthritis is usually responsive to a broad array of non-steroidal drugs 
such as ibuprofen and indomethacin, with the most complete resolution of the 
symptoms occurring the earlier the commencement of the treatment (Wallace and 
Singer 1988).
Prophylactic measures may be effective in reducing the frequency of recurrent 
bouts of gouty arthritis in patients with a prior history of gout, with one of the most 
widely used methods being the twice daily administration of 0.6mg oral colchicine, 
or 25mg indomethacin in cases of contraindication. These measures may be used 
in conjunction with hyperuricaemic drugs early in treatment when patients are at a 
higher risk for gouty attacks.
Anti-hyperuricaemic therapy generally aims at reducing serum urate levels by 
enhancing renal excretion of uric acid (uricosuria) or by decreasing uric acid 
synthesis. The most widely used of these uricosuric drugs are probenicid and 
sulphinpyrazone, and when used in conjunction with allopurinol, to reduce uric acid 
synthesis, are effective means of control. While uricosuric drugs and allopurinol are 
effective treatments for most gouty patients, their use is associated with a number 
of side effects, notably skin rashes, gastrointestinal intolerance and precipitation of 
attacks of gouty arthritis.
1.2.7 Phosphoribosyl pyrophosphate synthetase superactivity
Phosphoribosyl pyrophosphate synthetase (PRPP-S; PP-ribose-P synthetase; 
PRPS; EC 2.7.6.1 ) catalyses the synthesis of PRPP from MgATP and R-5-P in a 
reaction requiring inorganic phosphate and free magnesium ions. Human red cell 
PRPP-S is an ailosteric enzyme with at least 3 regulatory sites (Becker et al 1975). 
These sites are defined by 1) competitive inhibition by ADP with respect to MgATP;
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2) competitive inhibition by 2,3-diphosphoglycerate with respect to R-5-P and 3) 
non-competitive inhibiton with respect to its substrates by purines nucleotides, 
particularly nucleoside diphosphates and triphosphates (Fox and Kelley 1971).
The subunit of the erythrocyte enzyme has a molecular weight 34 kDa and can 
undergo reversible subunit association to exist as a complex aggregate of up to 32 
of these subunits, with the enzyme activity residing in only the 16 and 32 multimers 
(Meyer and Becker 1977).
1.2.7.1 Clinical
PRPP-S superactivity as a basis of some cases of gout, was first recognised as 
the cause for purine overproduction in brothers presenting in adolescence with 
urolithiasis and gout associated with hyperuricaemia and hyperuricosuria (Sperling 
et al 1972). Sperling et al (1973) subsequently demonstrated that this was due to 
a variant form of PRPP-S with normal catalytic activity, but a defect in the 
feedback inhibition by guanosinediphosphate and adenosinediphosphate. To date, 
this disorder has been demonstrated in over 20 families with considerable 
heterogeneity in the kinetic aberrations underlying the excessive enzymic activity, 
including regulatory defects, catalytic defects, a combination of both of these, and 
increased affinity for the substrate R-5-P (Becker 1976; Akaoka et al 1981; Becker 
et al 1982). Of these, catalytic superactivity is the most commonly reported class 
of kinetic defect.
PRPP-S superactivity is expressed in two clinical phenotypes, one affecting early 
childhood and an the other a late-juvenile or early adult onset variety. In families 
with the more severe early childhood variety, affected hemizygous males show 
signs of uric acid overproduction in association with neurodevelopmentai 
impairment including sensorial deafness. In four of the five families studied with this 
disorder, cultured cells of the affected patients showed regulatory or combined 
defects of the enzyme along with severe functional derangements of PRPP and 
purine metabolism. (Becker eta/  1987; Becker ef a/ 1988)
The late-juvenile to early onset variety of PRPP-S is restricted to males who show 
gout and or urolithiasis, but with absent neurological symptoms, and can be 
associated with catalytic defects of the enzyme (Becker ef al 1987). This defect 
should be suspected in any child or young adolescent, of either sex, with marked 
hyperuricaemia and or hyperuricosuria at a level of between 2 and 4 times normal
47
48
'4m
%
HGPRT and APRT in lysed cells. The prognosis for patients presenting in 
adolescence is good. Allopurinol, as in LNS, is used to treat the condition, with 
care to avoid xanthine neuropathy. A high fluid intake and alkalisation of the urine 
may also help and in renal failure the dose of allopurinol must be reduced.
1.2.7.2 Genetics
PRPP-S superactivity is transmitted as an X-linked disorder, with molecular studies 
studies localising two genes PRPS1 and PRPS2, coding for two isoforms of the 
enzyme at regions Xq22-q24 and Xp22.2-22.3 respectively (Becker et al 1990). 
Both PRPS1 and PRPS2 genes encode transcripts of 317 amino acids long, which 
vary in their tissue distribution. In general, growing tissues contain higher levels of 
PRPS2 than do tissues with little active growth, suggesting that the expression of
PRPS2 may be responsive to cell events associated with mitosis and 
transformation (Becker et al 1995a).
The presence of 2 PRPS1 related genes on chromosomes 7 and 9 has also been 
reported, fuelling speculation that these autosomal genes may play an essential 
part in the cell’s survival in the event of X-inactivation of the PRPS1 and 2 genes 
during spermatogenesis (Becker e ta l 1990; Taira e ta l 1990).
With the elucidation of the nucleotide sequence of the PRPS1 and 2 genes, an 
effort was made to differentiate the molecular mechanisms responsible for 
regulatory and catalytic defects in PRPP-S superactivity.
Becker et al (l995b) studied PRPP-S superactivity in 6 families associated with 
purine nucleotide inhibitor resistance and showed that after reverse transcription 
and PCR amplification, each PRPS1 cDNA contained a single base substitution, 
resulting in an amino add substitution of the transcribed protein. Subsequent 
kinetic analysis revealed that these point mutations resulted in the alteration of the 
ailosteric mechanisms regulating both the inhibitory and activation feedback system 
by purine nucleotides and inorganic phosphate.
In a second and more common class of PRPP-S superactivity , this regulation by 
nucleotide Inhibitors and the affinity for its substrates is normal (Becker et al 
1996), showed that in patients with this deficiency, the catalytic superactivity is not 
associated with PRPS1 or PRPS2 sequence alterations, but rather the 
accumulating increases in a PRPS1 isoform with normal sequence, suggested a a
post-transitional derangement which regulated the expression of PRPS1 in the 
catalytic superactivity of PRPP-S.
1.2.8 Adenosine deamininase (ADA) deficiency
The enzyme adenosine deaminase (adenosine aminohydrolase; ADA: EC 3.5.4.4) 
normally catalyses the deamination of adenosine or 2’-deoxyadenosine to inosine 
or 2’-deoxyinosine respectively. Deficiency in the activity of red cell ADA was 
reported by Giblett et al (1972) in two females with severe combined immuno­
deficiency (SCID) and since then more than a 100 cases have been identified.
1.2.8.1 Clinical
The incidence of ADA deficiency is about 1:1,000,000 and is responsible for 20- 
30% of cases with recessiveiy inherited SCID (Hirschhorn 1983), a life threatening 
syndrome that presents during infancy as recurrent opportunistic viral, fungal and 
protozoal infections, failure to thrive and lymphocytopenia, and frequently present 
with chronic diahorrea pulmonary infections and perioral candidasis. There is 
deficiency of both B and T cell-mediated immunity. The age of onset has varied, 
but is usually within the first 2 years of life (Morgan et a! 1987), although in about a 
fifth of ADA deficient patients the immune deficiency is initially less severe and 
they present later in childhood. Indeed, a few older patients have been diagnosed 
at 15-40 years of age with chronic pulmonary insufficiency due to recurrent 
respiratory infections and other manifestations of immune deficiency and 
dysregulation (Santisteban et a! 1993; Shovlin et a! 1993). In the late presenters 
however the defect may not be easily recognised due to the fact that lymphocyte 
numbers are not reduced and cellular immunodeficiency may not be so profound.
In addition to red cells, the enzyme deficiency has been demonstrated in serum 
and lymphocytes (Meuwissen et a! 1975) and cultured fibroblasts (Hirschhorn et a! 
1976).
The relationship between ADA deficiency and the immunological dysfunction is 
unknown. It has been suggested that the immunodeficiency results from an 
accumulation and toxicity of adenosine or adenine nucleotides including ATP and 
cyclic AMP which inhibit purine biosynthesis (Kredich and Hershfieid 1983).
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However, Simmonds et al (1978) showed that urinary purines from a child with 
ADA deficiency were deoxyadenosine rather than adenosine. Since deoxy- 
adenosine is inhibitory at much lower concentrations in vivo (1p.mol/l compared 
with 100|o,mol/l of adenosine), a more convincing possibility was that deoxy­
adenosine and not adenosine Is toxic to proliferating lymphocytes. This also gave 
the first evidence of the importance of ADA for the catabolism of these toxic 
deoxynucleotides.
1.2.8.2 Genetics
Genetic polymorphism of the erythrocyte ADA was discovered by Spencer et a! 
(1968) who demonstrated the presence of 3 phenotypes representing homozygous 
or heterozygous expression, designated ADA1, ADA2 and ADA2-1 of the alleles 
ADA^ and ADA^ . Tissues other than red cells show more complex electrophoretic 
patterns due to a high molecular weight binding protein, one molecule of which 
binds two molecules of ADA, with severely affected children having no detectable 
ADA isoenzymes in any tissues, but exhibiting normal binding protein (Hirschhorn
1983).
Originally assigned to chromosome 20 by the use of mouse/somatic cell 
hybridisation studies (Tischfield et al 1974), the gene was subsequently localised 
to 20q 13.2-qter and sequenced by Wiginton et al (1986). The gene for ADA is 
encoded as a single 32kb locus containing 12 exons. This information has 
permitted the analysis of ADA gene regulation and the relationship of phenotype to 
genotype in ADA deficient patients To date, over 40 distinct mutations have been 
identified (Hershfieid et al 1995), with about 75% of these being single base 
changes causing amino acid substitutions, followed by splicing mutations, then 
small and a few large deletions (Hirschhorn 1995). Santisteban et al (1993) 
observed that the spectrum of mutations appears to change with clinical severity, 
but since most of the mutations have occurred in only a single patient or a few 
patients, establishing a precise correlation has been difficult.
Most obligate heterozygotes have approximately half the normal levels of ADA 
activities in red cells. Carrier detection is however, unreliable, due to the fact that 
there is an overlap in ADA activities between obligate heterozygotes and 
approximately 10 % of the normal population (Scott et al 1974), Chen et al (1975) 
studied the expression of ADA activity in cultured skin fibroblasts and amniotic
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fluid cells and found that these were unsuitable for heterozygote detection, due to 
the variability in the ADA levels. Higher levels of residual ADA activity have been 
found in cells lines from healthy individuals due to a ‘partial’ ADA deficiency, with 
this residual activity shown to differ from the normal levels with respect to 
electrophoretic mobility, heat lability or both. (Hirschhorn and Ellenbogen 1986). 
Seven ADA mutations have been found in seven individuals with this ‘partial’ 
phenotype, and of these five have been shown to be compound heterozygotes. Of 
these seven ‘partial’ individuals, one was shown to have a mutation also identified 
in SCID, a finding which was suggested to be due to a ‘null’ mutation resulting in 
the absence of enzyme. (Hirschhorn et al 1990)
1.2.8.3 Prenatal Diagnosis
Prenatal diagnosis of ADA deficiency has been reported in cultured amniotic fluid 
cells (Hirschhorn et al 1975; Ziegler et al 1981) and chorionic villi (Aitken et al 
1986; Dooley et al 1987),while analysis of fetal blood taken in the second trimester 
has demonstrated severe lymphopenia with complete absence of T cells, and 
raised dATP levels indicating the early onset of lymphocyte toxicity (Linch et al
1984).
1.2.8.4 Treatment and Therapy
Despite the fact that there appears to be no generally effective therapy in ADA 
deficiency, a number of different treatment strategies have proven beneficial. Bone 
marrow transplantation (BMT) when an HLA compatible sibling is available, has 
been shown to be the only successful long-term treatment (Markert et al 1987). 
Parkman e ta l (1975) and Pahwa e ta l (1978) showed that BMT restored complete 
immunological function and in addition, evidence of the restoration of ADA activity 
following BMT was the reduction in erythrocyte deoxy ATP levels (Chen et al
1978).
In most cases however, an HLA compatable sibling is not available. In these 
patients, repeated exchange transfusions of red cell enzyme have been reported to 
restore some Immunological function, but not as completely as in BMT (Hirschhorn 
et al 1980). This therapy regime has been reported by some workers as successful 
in correcting the immunodeficiency while others have reported failure (Polmar et al
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1976). Indeed, Ziegler et al (1981) suggested that the response to enzyme 
replacement whether by plasma or erythrocyte infusion, may be more likely when 
there is already present an appreciable residual ADA activity.
Hershfieid et al (1987) showed that the intramuscular injection of PEG-ADA 
(bovine ADA covalently modified with polyethylene glycol) could maintain much 
higher circulating levels of plasma ADA activity. At weekly or twice weekly doses , 
immune function has been reported to improve after a lag of several weeks, during 
which mature lymphocytes differentiate from early progenitors (Weinberg et al 
1993). Recovery of partial immune function , has been found to be sufficient to 
sustain resistance to opportunistic infections. To date, 60 patients in 9 countries 
have been treated with PEG-ADA, with 40 patients receiving it for 2-10.5 years. 
The candidates for this treatment lack an HLA-matched bone marrow donor and 
are usually too ill to undergo a mismatched transplantation.
Since 1990, 11 ADA deficient patients receiving PEG-ADA, have entered the first 
human trials of somatic cell gene therapy, conducted at centres in the United 
States, Europe and Japan. The therapy involves T-cells (arising as a response to 
PEG-ADA) or stem-cell enriched preparations isolated from marrow, induced to 
divide and treated in vitro with retroviral vectors carrying ADA cDNA, before being 
reinfused. Preliminary reports on 10 patients suggest that the efficiency of the ADA 
gene transduction into target cells was variable and quite low in most cases, as 
were the levels of expressed ADA in circulating T-cells (Blaese et al 1995; 
Hoogerbrugge et al 1996; Kohn et al 1995), and 1.5-3 years after the last infusion 
of ADA gene-treated cells, all patients were still receiving PEG-ADA injections on a 
weekly basis.
1.2.9 Purine Nucleosidase Phosphorylase (PNP) deficiency
Purine nucleoside phosphorylase deficiency is a rare inherited disease 
characterised by profound T-cell immunodeficiency. An enzyme of purine 
metabolism. Purine nucleoside phosphorylase ( PNP; EC 2.4.2.1) catalyses the 
dégradation of the nucleosides, inosine and guanosine and their deoxyanalogues 
to the corresponding base (Kredich and Hershfieid 1983 ; Stoop et al 1977) and 
was first described by Giblett et al (1975), after screening other SCID patients for 
errors in the purine metabolic pathway. PNP deficiency is a heterogeneous
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disorder which can be considered a subset of SCID, and to date more than 30 
patients have been identified.
1.2.9.1 Clinical
All patients so far studied have suffered from recurrent infection, usually beginning 
in the first year of life, although some patients may be asymptotic until several 
years of age. The range of infections is similar to that observed in ADA deficiency, 
including sinusitis, urinary tract infections thrush and diarrhoea in addition to the 
usual respiratory pathogens Haemophilus influenzae and Streptococcus 
pneumoniae. Neurological problems are common in PNP deficient patients with 
symptoms such as spastic tetraparesis, retardation of motor function, tremor, 
hypotonia, developmental delay and mild to severe mental retardation, in these 
patients there is gross overproduction and excretion of purines in the form of 
nucleosides and deoxynucleotides with uric acid always very low or even absent.
1.2.9.2 Biochemistry
PNP in human erythrocytes is a protein of 289 amino acids composed of 3 
identical 32,000 Dalton subunits each with a substrate binding site (Zannis et al 
1978; Williams et al 1984) and an isoelectric point of the native enzyme of 5.0-6.1. 
The human enzyme has a Km for inosine in the range of 2.2 x10^ to 10.0x10*^ M 
and is found in a range of tissues such as kidney, heart, brain small intestine, 
lymphoid tissues and in peripheral granulocytes (Carson et al 1977).
12.9.3 Genetics
Using earlier work based on somatic cell hybridisation and gene dosage studies, 
which had determined the structural locus of PNP to chromosome 14q13 (Aitken et 
al 1978; Ricciuti et al 1973), Remes et al (1984) presented additional deletion 
mapping data to place the location at 14q13.1.
An autosomal recessive mode of inheritance has been demonstrated in kindreds 
with a deficiency of this enzyme and consanguinity is frequent (Kredich and 
Hershfieid 1983). The gene coding for PNP includes six exons dispersed across 
lOkb of DNA, the mutant gene cloned from an offspring of a consanguineous
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mating showed the deficiency was caused by a single base change in the third 
exon at position 89, resulting in a G to A transition (Williams et al 1987). A number 
of other mutations in the PNP gene have subsequently been reported (Aust et al 
1992; Markertef a/ 1997; Williams e ta l 1984).
12.9.4 Prenatal Diagnosis
Carapella de Luca et al (1986) and Kleijer et al (1989) have reported prenatal 
testing for PNP deficiency in cultured 16 week amniotic fluid cells of women who 
had previously had affected offspring. One fetus was identified as normal and the 
other as affected. The purine profile of the normal amniotic fluid showed a normal 
PNP activity, uric acid in the normal range and undetectable levels of 
hypoxanthine, xanthine, guanine, inosine, deoxyinosine, guanosine and 
deoxyguanoslne, while the affected fetus showed undetectable levels of PNP 
activity and raised levels of inosine, deoxyinosine, guanosine and deoxyguanoslne. 
Prenatal diagnosis using chorionic villi has was first reported by Perignon et al 
(1987) and subsequently by Kleijer et al (1989) who showed that in the second 
trimester of pregnancy, there is a significantly higher level of specific activity of 
PNP in amniocytes than in cultured fibroblasts, and even higher levels in chorionic 
villi. It would therefore, appear that the latter is an ideal tissue for prenatal 
diagnosis.
1.2,9.5 Treatment and Therapy
Markert (1991) reviewed the treatment of 33 patients with PNP deficiency, 
including bone marrow transplantation, red cell transfusion, fetal thymus 
transplantation, and deoxycytidine or guanine administration.
She concluded that the best available treatment was that of bone marrow 
transplantation, however even with this treatment there appeared limited success, 
with only 2 of the first 5 patients treated, still living at the time of the review. Of the 
33 patients reviewed, 29 had died with infections. Graft versus Host disease and 
tumour being the most significant causes of mortality.
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1.3 Pteridines
The terms “folic acid” and "folate” are the preferred synonyms for the pteridine 
compounds pteroylglutamic acid (PteGlu) and pterolglutamate respectively, which 
are heterocyclic compounds of pteroic acid conjugated with one or more glutamate 
residues.
1.3.1 Folate metabolism
l i
■‘■■Ag
The term folate is used in the generic sense to designate members of the family of 
naturally occurring polyglutamate forms having various reduction of the pteridine
ring, while folic acid is used to describe the synthetic monoglutamate form . The 
compound tetrahdrofolate (THF) is the parent compound of all biologically active 
folates which have substituents at positions 5 or 10 of the pteridine ring, with the 
predominant folate in serum and in tissues being 5-methyl-THF.
Folate is a key factor in two fundamental biological processes. First, folate acts as 
a cofactor for enzymes involved in DNA and RNA biosynthesis, where THF accepts 
single carbon units from a variety of donors, mainly serine, to form a pool of
interchangeable cofactors such as 5,10-methylene-THF, 5,10-methenyl-THF, and 
10-formyl-THF. While 10-formyl-THF donates its formyl group to two of the 
enzymes in the de novo pathway of purine synthesis forming adenine and 
guanine, 5,10-methylene-THF donates its C1 group to an enzyme in the de novo 
synthesis of pyrimidines, thymidylate kinase. Since the requirements for folate 
dramatically increase during periods of rapid growth of the embryo, any deficiency Î
t
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in production or supply will inhibit DNA synthesis and subsequent mitosis, leading 
to imbalanced cell growth and cell death.
Second, the methyl group of 5-methyl-THF is used by methionine synthase, a 
vitamin B12 dependent enzyme, to methylate homocysteine to methionine, an 
essential amino acid. A disruption of this remethylation pathway leads to raised 
homocysteine levels and it is this hyperhomocysteinaeimia or reduced methionine 
which may cause developmental defects. The disturbance in the remethylation also 
compromises the cells ability to methylate other important compounds such as 
proteins, lipids and DNA. It is not clear as yet whether this is due to folate 
deficiency or a metabolic block in the pathways processing folate.
Methionine is continuously converted to homocysteine via SAM which is then de- 
methylated to form the S-adenosylhomocysteine (SAH), which is subsequently 
hydrolysed to adenosine and homocysteine. Significant amounts of methionine are 
subsequently regenerated via the remethylation of homocysteine, a reaction 
catalysed by the enzyme methionine synthase (methyltetrahydrofolate; L- 
homocysteine S-methyltransferase ; EC 2.1.1.13). This reaction requires the 
enzyme 5,10-methylenetetrahydrofolate reductase ( MTHFR; EC 1.5.1.20 ) and is 
also dependent on the co-factor methylcobalamine, a form of vitamin B12. The 
majority of homocysteine is not remethylated but catabolised via a pyridoxal-5’- 
phosphate (Vitamin Be) - dependent condensation with serine to form 
cystathionine, catalysed by the enzyme cystathionine p-synthase (CBS; CpS; EC 
4.2.1.22), and ultimately metabolised to cysteine and alphaketobutyrate. This is 
referred to as the transsulphuration pathway (Figure 1 - 6).
Two distinct transport systems have been described for the transport of folate 
across mammalian cell membranes. (Fan et al 1992). One operates in relatively 
high folate concentrations, (“micromolecular system”), while the other has been 
characterised using lower folate concentrations (“nanomolecular system”), and both 
systems may not be operational in all cell types. The folate receptor has been 
shown to be a membrane protein anchored by glycosylphosphatidylinositol. The 
gene for the folate binding protein has been mapped to chromosome 11q13.3- 
q14.1 (Campbell e ta l 1991). These folate receptors are found on the cell surface 
in clusters in association with the plasmalemmal vesicles in stuctures known as 
uncoated pits, and have been shown not to be internalised into a vesicular 
compartment.
Human cells need a critical concentration of intracellular folate to allow activity of
folate dependent enzymes. The amount required to maintain an optimal rate of
growth varies from about 50nM in fibroblasts to about IpM  in lymphocytes and
certain tumour cells (Watkins and Cooper 1983). The Km for monoglutamate folate
of many of the folate-dependent coenzymes Is greater than 1pM so that the folate-
dependent enzyme reactions cannot progress in cells in the absence of the
conversion of folate to the polyglutamate forms. The polyglutamate forms have
much lower Km values for some folate dependent reactions allowing folate
metabolism to proceed at the optimal cellular concentration The folate
polyglutamates from dietary sources are hydrolysed in the intestine prior to
absorption, and the monoglutamates are released into the circulation where they
are fully reduced to THF. Two distinct forms of the human pterolypolyglutamate
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hydrolase have been described, one in the intestinal brush border and another 
within the lysosomes.
1.3.2 Folate and NTDs
The possibility that folic acid might be one of the important factors in the aetiology 
of NTDs, was first suggested by Hibbard (1964).
The first major clinical trial involving folic acid was performed by Smithells et af 
(1981) in which women were supplemented with a multivitamin preparation 
containing iron and folic acid (Pregnvite Forte F (Bencard)), at a physiological dose 
of 360pg/day at least 28 days prior to conception and for the first 8  weeks of the 
pregnancy. The intervention study involved women who were at risk of an affected 
pregnancy, by virtue of the fact that they had previously had affected children 
(recurrent NTD). Results showed that the NTD rate in supplemented women was 
0.6% compared to 5.0% in unsupplemented women, a reduction of 84%.The 
results of this study have been criticised on a number of counts. Firstly, that 
possible bias had been introduced into the study design due to the non­
randomised nature of the supplemented group which contained more women from 
a higher social class than the control group (Wald and Polani 1984). Secondly, that 
the women from the supplemented group were self-selected while the controls 
were not, so that the former were self-motivated and thus more likely per se to 
have better compliance with the vitamin supplementation regime. (MRC Vitamin 
Study 1991)
Despite this, the results were confirmed in a second cohort of women where the 
recurrence rate was reduced by 82% in supplemented women (Smithells et al 
1983), while Holmes-Siedle et al (1992) independently produced similar results. A 
second smaller randomised trial by Laurence et al (1981) examined the effects of 
folic acid alone in a pharmacological dose (4mg/day). This study yielded 
inconclusive results when analysed according to the randomly allocated treatment 
group, possibly because of the small numbers of individuals studied.
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In 1983, the Medical Research Council, launched a randomised double-blind 
prevention trial comprising 33 centres in seven countries to determine whether 
supplementation with folic acid or a mixture of seven other vitamins (A,6 ,6 1 ,6 2 ,Be,0 
and nicotinamide) around the time of conception could prevent NTDs. A total of 
1817 women with a recurrence risk were allocated at random to one of four 
groups, namely folic acid, other vitamins, both or neither. Of 1195 completed 
pregnancies in which the fetus was known to have or not have an NTD, 27 had an 
NTD, with 6  in the folic acid group and 21 in the other two groups, a 72% protective 
effect (MRC Vitamin Study 1991).
Czeizel and Dudas(l992) studied the extent to which vitamin supplementation 
could reduce the first occurrence of NTD. Women planning the first pregnancy 
were randomly assigned to receive either a single tablet of vitamin supplement 
(containing 12 vitamins including SOOpg of folic acid, four minerals and three trace 
elements); or a trace-element supplement (containing copper, manganese, zinc 
and a very low dose of vitamin C) daily for at least 1 month prior to conception and 
until the date of the second missed menstrual period. Results showed that in a total 
of 4763 women who complied, congenital malformations were significantly more 
prevalent in the trace-element group (22.9/1000), than in the vitamin supplemented 
group (13.3/1000), and that there were 6  cases of NTD in trace -element group, 
and none in the group receiving vitamin supplements.
While the results of these randomised trials put beyond doubt the effectiveness of 
periconceptual folic acid supplementation as a primary means of preventing NTDs, 
it remains unclear as to the mechanism of this prophylactic effect. Efforts to 
determine a significant difference in the serum folate and Vitamin B12 concentration 
of mothers carrying an NTD fetus and controls have found that on average, during 
the first trimester of pregnancy, that levels were lower in cases and controls, but 
not significantly so. (Yates et al 1987; Wald et ai 1996). Similarly, the work on red 
cell folate, a more stable indicator of folate intake, have either been inconclusive, 
or found no significant differences between cases and controls (Economides et ai 
1992;Smithells ef a/ 1976; Yates ef a/ 1987)
Yates et al (1987) investigated women with who had two or more NTD affected 
infants and demonstrated an association between these offspring and depressed 
levels of red cell folate in the mothers. Since this could not be entirely attributed to 
a lower dietary intake of folate. It was postulated that one of the factors 
predisposing to the occurrence of NTDs was an inherited disorder of folate 
metabolism.
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1.3.3 Neural Tube Defects
The term Neural Tube Defect (NTD) can be applied to any malformation of the 
developing neural tube. NTDs are a group of morphologically heterogeneous 
disorders where there may be involvement of the whole of the neural tube or more 
commonly a localised lesion at some point producing varied abnormalities. Lem ire 
(1988) qualified the terminology of NTDs in terms of whether the lesions are open, 
(neurulation defects where neural tissue exposed to the surface); or closed, 
(postneurulation defects which are skin covered). Three general categories of 
neurulation defects exist from the clinical perspective, notably craniorachischisis, 
anencephaly and meningomyelocoele. Craniorachischisis is a condition where both 
the brain and spinal cord are exposed to the surface with many of these cases lost 
in early spontaneous abortion.
1.3.4 Embryology
The human embryonic period is divided into 23 stages, each comprising 2-3 days 
and encompasses the first 54-60 days following ovulation (O'Rahilly 1986). In 
man, neural tube formation occurs around the 17-18*^ day after conception, when 
the central part of the ectoderm of the embryonic disc is induced to thicken and 
differentiate into the neural plate by the underlying mesoderm. Neurulation occurs 
as the embryonic disc elongates forming a longitudinal groove on its dorsal surface 
midline, and the lateral edges of the neural plate rise up forming the neural folds, 
which in turn arch over and gradually meet in the dorsal midline. As the embryo 
elongates and increases in size, fusion occurs concurrently in both the cephalic 
and caudal directions. Neurulation is complete when the extreme ends, the 
neuropores, seal around days 24-25 anteriorly and days 26-28 posteriorly. Failure 
of the neuropores to fuse, give rise to the NTDs anencephaly and 
meningomyelocoele.
Anenecephaly exists when brain tissue is exposed to the surface, but with no 
involvement of the spinal cord. The term meningomyelocoele incorporates spina 
bifida cystica, and can occur anywhere along the spinal axis, but most commonly 
in the lumbrosacral region, where 75-80% of cases are open lesions with 
remainder being closed. Overall, anencephaly accounts for 40% of neutral tube 
defects, spina bifida for 55% and encephalocoeles for 5%.
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1.3.5 Prevalence
NTDs vary not only in morphology but also in aetiology. For a small number of 
NTDs the cause may be secondary to chromosomal abnormalities such as trisomy 
18, trisomy 13 or triploidy, or as part of a recognised genetic disorder as in the 
case of the autosomal recessive Meckel syndrome. However the vast majority, 90- 
95%, of NTDs are of unknown origin, and are referred to as the multifactorial type. 
Khoury et al (1982) found that 80% of all NTDs occurred in the absence of defects 
in any other body systems, and exhibited different epidemiological characteristics, 
proposing that these were different aetiologically from those which occurred In 
conjunction with subsequent abnormalities. Further work (Carter 1974) analysed 
the association with NTDs and other defects, and found a clustering according to 
the site of the NTD lesion which conformed to a definite pattern. Hall et al (1988) 
examined the clinical, genetic and epidemiological factors of 512 probands from 
the population of British Columbia. They found that when data were analysed after 
grouping the probands by four different classifications with respect to pathological 
and putative mechanisms, apparently unrelated congenital abnormalities occurred 
more frequently among probands with craniorachischisis (62%), encephalocoele 
(30%) or multiple NTDs (25%) than among probands with anencephaly (14.7%) or 
spina bifida {10%).
There is a marked geographical variation in the pregnancy prevalence of open 
NTDs, with the British isles, and the west of Scotland having a prevalence in 1990 
of ~2 cases per 1000 pregnancies, compared with a lower rate in England and 
other countries in Europe. (Dr D. Aitken. personal communication). There is also 
an observable East-West gradient, highest in the British Isles and lowest in Japan 
where prevalence is estimated at 0.1-0.6 / 1000 births (Le mi re 1988), with the 
United States being in between. Even within the United States itself, there appears 
to be a gradient effect with a higher prevalence of open NTDS on the East coast 
compared to the West coast, a fact which has been attributed to migration patterns 
and ethnic differences (Chung and Myrianthopoulos 1968).
The work of Borman and Cryer (1990) has called into question the validity of many 
of the epidemiological studies concerning the estimation of incidence and 
prevalence of NTDs, citing a lack of scientific rigour in design, and a lack of a 
standardised nomenclature and classification for NTDs.
The work of Van Allen (1996) on the use of monogenic mice models suggested
that NTDs may be better classified using a multisite closure model, rather than the
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single-site closure method presently used. This study suggested that classification 
of NTDs by closure site, may be better in defining aetiologies and environmental 
susceptibilities, particularly in view of the heterogeneous nature of this disorder. 
Recurrence risk after an affected pregnancy is 1 in 25-33 and for second degree 
relatives the risk of recurrence is 1 in 70. After 2 or more affected pregnancies the 
recurrence risk is 1 in 10. (Connor and Ferguson-Smith 1993)
1.3.6 Prenatal diagnosis
An important advance in the secondary prevention of NTD births has been the 
introduction of large scale prenatal screening and diagnostic programmes used in 
conjunction with ultrasonography, such as the one in use at the present time in the 
west of Scotland. Since more than 95% of all women with a neural tube defect 
pregnancy have no previous family history, most affected pregnancies can be 
identified only by screening the entire pregnant population. In pregnancies where 
the fetus has a neural tube defect, maternal serum alphafetoprotein (MSAFP) and 
amniotic fluid AFP are elevated due to leakage from exposed fetal capillaries. 
MSAFP measurement is undertaken at between 15-20 weeks gestation, and if the 
level above the 95'’’ centile, a second blood sample may be requested along with 
an ultrasound scan to check for fetal abnormality, confirm gestation or exclude 
other causes such as missed abortion or multiple pregnancy. If MSAFP level in a 
second sample also exceeds the 95*  ^ centile, further ultrasound examination and 
possibly prenatal diagnosis by amniocentesis are indicated. It is essential that a 
differential diagnosis be made to distinguish pregnancies at risk for NTDs and other 
types of fetal abnormalities, associated with raised MSAFP such as anterior 
abdominal wall defects (AAWDs) which may be surgically repaired. This may be 
acheived by examination of the pattern of cholinesterases in the amniotic fluid by 
polyacrylamide gel electrophoresis (PAGE). Normal amniotic fluid produces a 
single band of pseudocholinesterase, while open NTDs also produce a second 
faster band of acetylcholinesterase (ACHE), as do around 50% of abdominal wall 
defects, although the pattern of ACHE bands appears different between NTDs and 
AAWDs (Burton 1986 ; Rasmussen Loft et al (1990)).
When both AFP and ACHE determinations are combined, and abnormal results 
are obtained, it is stong evidence of open NTD and helps to minimise the false- 
positive results associated with the raised levels of AFP found in other conditions
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(Aitken et al 1984; Amniotic fluid acetylcholinesterase collaborative study 1981). It 
is important to note that the biochemistry results should always be interpreted in 
conjunction with the data obtained from ultrasound findings, such that a differential 
diagnosis of these abnormalities may be made.
1.3.7 Aetiology
Epidemiological studies on the aetiology of human NTDs show that it is a 
multifactorial disorder where both genetic and environmental influences are 
implicated. While the examination of the potential teratogenicity In a number of 
environmental factors has been sought, none has been more extensively studied 
than those of nutritional factors. A number of studies in the UK showed that the 
NTD rate was higher in less privileged socio-economic groups Carter et al (1974), 
and that women from social classes III -V had lower intakes of several nutrients as 
compared to women in social classes I and II (Smithells et al 1977). Data both for 
and against the case of nutrition as a contributory factor have been cited. Al-Awadi 
et al (1984) quoted the dramatically falling prevalence of anencephaly in the 
Kuwaiti population, which was attributed to dietary improvement with an increase in 
both food consumption and food quality, in the absence of prenatal diagnosis or 
termination of pregnancy.
Paradoxically, within the African and Asian populations where poor nutrition or 
malnutrition is endemic, NTD rates are low. This may be due to the multifactorial 
nature of the disorder, where both the genetic and environmental factors must be 
present.
1.3.8 Homocysteine metabolism and cardiovascular disease
Kang et al (1988a; 1988b ) examined a thermolabile variant of MTHFR shown to 
be different from that which caused the severe form of MTHFR deficiency. These 
workers showed that this variant exhibited in-vitro thermolability at 4 6 X  which 
provided a clear distinction between the mutant and the normal enzyme, and 
subsequently compared two patients with an 8-15 fold increase in plasma 
homocysteine with normal controls. After heat treatment, the residual MTHFR 
activity for the controls was 37% , but only 15.2 and 15.1% in the patients. Further 
work (Kang et al 1991) to elucidate the association thermolabile MTHFR with the
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development of coronary heart disease showed that in 212 patients with proven 
coronary artery disease and 202 controls with out clinical evidence of 
atherosclerotic vascular disease, 36 (17%) of the patients and 10 (5%) of the 
controls exhibited the thermolabile MTHFR. The results were consistent with 
autosomal recessive inheritance of the thermolabile trait.
The importance of the thermolabile allele as a contributory factor in 
homocysteinemia was subsequently confirmed by other workers (Engbersen et al 
1995; Haworth et al 1993). The subsequent isolation of the cDNA for human 
MTHFR and mapping to the chromosomal region 1p36.3 (Goyette et al 1994) 
enabled Goyette et al (1995) to identify 9 mutations in this gene, in a severely 
deficient group of patients, using single-strand conformational polymorphism 
(SSCP) analysis and direct sequencing of polymerase chain reaction (PCR) 
fragments. The SSCP protocol identified a 0  to T (C-^T) substitution at bp677 
which resulted in the substitution of a valine codon for the evolutionarily conserved 
alanine residue. This alteration which created a Hinf^ restriction site was 
subsequently shown to encode the thermolabile variant of MTHFR (Frosst et al 
1995). Studies from several populations have confirmed the association of this 
MTHFR mutation with hyperhomocysteinemia, as has the increased prevalence of 
the homozygous mutant genotype in cardiovascular cases compared to controls 
(Rozen 1997).
The recent work on the role of the thermolabile variant of MTHFR and the 
677C->T mutation in cardiovascular disease by Frosst et al (1995), prompted 
Whitehead et al (1995) to examine the relationship of this genetic abnormality and 
NTDs since both appeared to have similar aetiologies, notably a disruption of 
homocysteine metabolism. Of the 82 people with NTDs studied, 15 (18.3%) were 
homozygous for the abnormal, thermolabile allele. This was significantly higher 
than the 6 (6.1%) controls found to have the mutation.
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CHAPTER 2. AIMS
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The aim of this work was to use biochemical genetic methods and procedures to 
examine the effectiveness of enzyme measurements for the diagnosis of a number 
of genetic disorders, notably LNS and gout (X-linked); ADA and PNP deficiencies 
(autosomal recessive) and NTDs (multifactorial), which are linked through their 
respective purine and homocysteine pathways. The work was divided into two 
phases:
Phase I Purines
The role of the purine enzymes was investigated by:
a) Establishment of reliable reference ranges for the purine enzymes HGPRT, 
APRT, ADA, PNP and PRPP-S in adult red cells, uncultured and cultured 
chorionic villi, amniotic fluid cells, fibroblasts, fetal red cells and cord red cells, 
by critical analysis of the parameters of the enzyme distributions.
b) Assessment of the usefulness of these reference ranges in the diagnosis or 
prenatal diagnosis of the X-linked disorders, LNS and gout and the autosomal 
recessive disorders, ADA and PNP deficiency.
Phase II :- Folate resistant NTDs
The role of the enzyme MTHFR in the development of NTDs was investigated by:
a) Assessment of the allele frequencies of the thermolabile variant of MTHFR in 
patients with NTD, their parents and other relatives and in a series of controls 
drawn from the Scottish population.
b) Assessment of MTHFR enzyme activity in lymphocytes, from each of these 
groups.
c) Relating the enzyme activity and nutritional status as assessed by folate and 
plasma vitamin B12 measurements to the genotype in the study populations.
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CHAPTER 3. PATIENT AND CONTROL SAMPLES
67
3.1 Purine Study
3.1.1 Lesch-Nyhan Syndrome (LNS) Study
Prior to the analysis of samples from those individuals with a family history of LNS, 
it was necessary to establish reliable reference ranges for the purine enzymes 
under investigation. The term 'reference range’ can be applied to the analytical 
values obtained for a specific analyte, from a population which exhibit no known 
occurrence of the diseases in question, in this case, no known family history of 
LNS. Control material for the study of the red cell purine enzymes was obtained by 
the voluntary donation of approximately 10mls of whole blood taken into plastic 
lithium heparin tubes (Sarstedt), from both male and female workers in Institute of 
Medical Genetics, Yorkhili Hospitals, Glasgow in 3 batches over the course of 2 
years. Samples were separated and the constituents stored immediately after 
donation at -20°C until use.
Whole blood from affected individuals and their relatives, was obtained by 
collection of a 10ml lithium heparin sample, which was separated and the 
constuents stored immediately upon receipt with the department, usually within 48 
hours of collection. In the cases of very young children, or where difficulty in 
obtaining blood was experienced, samples were typically smaller, usually between '1 and 3mls.
Cord blood was collected at parturation, by theatre staff from routine obstetric 
deliveries performed during the working week, at the Queen Mothers Hospital,
Glasgow. Approximately 2mis of whole blood was collected into plastic lithium 
heparin tubes and stored at 4°C for not more than 24 hours prior to separation of 
the constituents.
Approximately 0.5-1 ml of fetal blood was obtained from a number of pregnancies 
undergoing routine fetal blood sampling for chromosomal indications and with no
'family history of LNS, at the Fetal Medicine Unit of the Queen Mothers Hospital,
.»■
Glasgow. These samples were collected into plastic lithium heparin tubes, 
separated and the constituents stored within 2 hours of the procedure.
Control amniotic fluid cells for the reference ranges were obtained from patients 
who had undergone routine karyotyping by the West of Scotland Prenatal 
Diagnosis Service at the Institute of Medical Genetics, between 15 and 21 weeks 
gestation. In addition to amniotic fluid cell preparations for the reference ranges,
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individual diagnostic samples were used as intra-assay quality controls for the 
prenatal diagnoses of LNS. where amniocentesis had been performed. These cells 
underwent culture and harvesting in the same batch as the preparation for the 
prenatal diagnosis, and as such, were subjected to the same conditions as the 
diagnostic sample.
Amniotic fluid cells from pregnancies undergoing prenatal diagnosis for LNS were 
cultured and harvested identically to all other routine samples.
CV controls were obtained at between 8 and 11 weeks gestation from elective 
terminations performed at the Western Infirmary, Glasgow over a 2 year period. 
Where enough material was available, CV samples obtained for chromosomal 
diagnoses, were used as intra-assay controls for the specific LNS prenatal 
diagnoses. These were cultured in the same batch and under identical conditions 
as the test sample.
Control fibroblast material was obtained from tissues, received at Institute of 
Medical Genetics, Yorkhili Hospitals, Glasgow for chromosome analysis where 
there was no indication of congenital metabolic defect.
Samples of fibroblast tissue obtained from pregnancies deemed to be affected 
after prenatal diagnosis for LNS, were collected at termination and the fibroblast 
cells cultured and harvested prior to enzymic analysis.
As with amniotic fluid and CV cell preparations, routine fibroblast cultures were 
used as intra-assay controls from the same culture and harvesting regime as the
diagnostic sample.
3.1.2 Gout Study
A random selection of the red cell preparations originally used to provide the LNS 
reference ranges, were selected to provide a reference range for comparison with 
patients under investigation in the gout study.
Whole blood was obtained from 54 individuals (45 males, 9 females), undergoing 
treatment for gout at the Department of Rheumatology, Glasgow Royal Infirmary 
over 2 years. A total of 20m!s of blood was collected and divided equally between 
plastic sodium EDTA and lithium heparin tubes. The EOTA samples were used to 
extract DNA in the event that the enzyme results indicated the requirement for 
molecular analysis, which was then stored at -70“C until use. The heparin samples 
were separated and the constituents stored at -20°C until use.
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3.1.3 ADA and PNP Studies
I
3.2 Pteridine Study
3.2.1 MTHFR
Controls for both the ADA and PNP investigations were those used for the Lesch- 
Nyhan Syndrome as previously described in Section 3.1.1.
Control blood for the NTD study was by voluntary donation from individuals with no 
known family history of neural tube defect. Where possible, samples from the 
control population were collected from friends of NTD couples, in an attempt to 
allow for partial matching of social class and diet. Since it was not always possible 
to obtain control material from this source, the reference range included a large 
number of random samples from individuals taken from the general population who
■ ihad no known family history of neural tube defect. A whole blood sample was collected from both parents where a pregnancy had resulted in an NTD and from 
any affected or normal offspring and any other first or second degree relatives 
within the family willing to give a donation.
Control and at-risk samples were collected from families identified from 3 sources:
( i ) The database of the West of Scotland Maternal Serum Screening program for 
NTDs, housed in the Institute of Medical Genetics. Yorkhili Hospitals, Glasgow,
( ii ) The database of patients recruited from the West of Scotland to the MRC 
Vitamin Supplementation trial (MRC Vitamin Trial 1991) which contains 
comprehensive information of families who have undergone one or more NTD 
pregnancies.
( iii ) The records of the Scottish Spina bifida Association to identify affected 
individuals and families not included in the previous 2 sources.
Consent forms (Appendix A) describing the proposed study were forwarded to 
subjects and controls, inviting them to donate a 20ml sample of blood. On return of 
the consent form, a box was dispatched containing the following items; a copy of
the consent from and a covering letter to the subject’s GP; a return stamped
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addressed envelope and a 10ml EDTA and 10ml Lithium Heparin sample bottle. 
Individuals were invited to take these to their GPs where the blood would be 
collected and then to forward the samples to the Department of Medical Genetics 
where the blood constituents were separated and stored until use. The 10ml EDTA 
blood sample was used for DNA extraction, while the lithium heparin sample was 
used to obtain red cells, plasma and lymphocyte preparations. Blood samples 
obtained within the department were processed within 2 hours of being taken, 
however the time elapsing between donation and receipt for samples sent via 
normal mailing was in the order of between 2 and 5 days on average.
The method of sample collection was approved by the local Ethics Committee of 
Yorkhili Hospital, Glasgow. In summary there were 262 controls, 40 individuals with 
NTD, 85 mothers with NTD pregnancies, 35 fathers of affected pregnancies and 
36 other family members.
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CHAPTER 4. METHODS
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4.1 Chemicals and reagents
All Chemicals used were purchased from the Sigma Chemical Company unless 
otherwise specified in the text.
4.2 Blood samples for purine analysis
4.2.1 Separation of Constituents
The whole blood samples in the anticoagulant tubes were inspected for clotting, 
and mixed thoroughly by repeated inversion prior to being balanced and spun by 
an I EC Centra GP8 centrifuge at 900 x g for 10 minutes at room temperature. The 
upper straw coloured plasma layer was carefully aspirated using a 3ml plastic 
pasteur pipette into a labelled polystyrene LP3 tube (Sarstedt) (capacity -2.5mls) 
and stoppered. The samples were stored at -20°C, pending analysis.
The intermediate layer containing plasma and buffy coat was removed to just 
below the beginning of the red cell layer and discarded.
The remaining red cell fraction was stored frozen using a suitable cryoprotective 
agent, in this case cold buffered citrate-glycerol, which prevents red cell lysis on 
freezing. This solution consisted of 200mls of glycerol (BDH) mixed with 300mls of 
a solution consisting of 3.25% Tripotassium citrate (BDH), 0.6% Dipotassium 
hydrogen phosphate (K2HPO4) (BDH), and 0.47% of Potassium dihydrogen 
phosphate (KH2PO4) (BDH) and was stored at 4°C until use. An equal volume of 
this solution was added to the remaining red cells, mixed thoroughly by repeated 
inversion and allowed to stand for a few minutes to ensure the complete diffusion 
of the glycerol into the cells. The samples were stored at -20°C until use.
4.2.2 Retrieval and Handling
Plasma, white cell and red cell samples were allowed to thaw at room temperature. 
The tubes were mixed by re-inversion to ensure complete homogeneity before use. 
This procedure was repeated after the analysis when the samples were returned 
to -20°G storage.
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4.3 Amniotic fluid cells
4.3.1 Cell culture
4.3.2 Trypsinisation
Samples obtained from at risk and control pregnancies were spun in a MSE 
centrifuge at 200 x g for 10 minutes. Most of the supernatant was removed and 
forwarded for subsequent biochemical analysis , while the cell pellet was 
resuspended in the remainder (1-1.5 mis), prior to being dispensed into 3 Nunc 
tissue culture tubes (110 x 16mm) using a sterile cannula attached to a 2ml 
syringe. To each tube was added 2mls of culture media consisting of Hams F10 
supplemented with 2% Fetal Calf serum (Gibco); 4% Ultroser serum substitute and 
1% Penicillin/Streptomycin solution (10000 lU/ml Penicillin and 10000 UG/ml 
Streptomycin). The presence of cells was checked by observation under an 
inverted microscope and the tubes incubated at 37°C. After 7days, the tubes were 
examined for evidence of cell settlement. If sufficient active growth was observed, 
cultures were fed twice a week until judged suitable for harvesting.
Poor cell growth over the tube’s surface required that subculturing by means of a 
trypinisation step be introduced into the procedure. II
The trypsin/EDTA solution consisted of SOOmIs distilled water, 0.9 % phosphate 
buffered saline (PBS) (BDH) , 0.4g EDTA (Versene) (disodium salt, dihydrate) and 
2g of Trypsin dispensed into 20 ml Universal containers and stored at -20°C. The
solution was filter sterilised by a 0.2pm Acrodisk 32 filter prior to use.
Removal of the media was followed by addition of 1ml of the trypsin/versene 
solution, which was immediately discarded and replaced by a further 2 drops, and 
incubated at 37°C for 5 minutes, at which time the cells have detached from the 
surface of the tube. 2mls of fresh media is added and the tubes returned to the 
incubator until ready for harvest.
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4.3.3 Pelleting and storage
Amniotic fluid cells were pelleted when sufficiently confluent. The existing media 
was poured off from the flask, replaced by I.SmIs of Trypsin/EDTA solution, and 
the flask swirled gently to facilitate coverage of all the cells, after which this was
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poured off. A further 0.5m!s of fresh Trypsin/EDTA solution was added and the 
cells incubated for Smins at a temperature of 37°C. Detachment of the cells from 
the walls of the flask was facilitated by a gentie tap of the flask on a hard surface 
and confirmed by observation using a binocular microscope. Using a long, 
siliconised, glass Pasteur pipette, the cells were transferred to a 20ml polystyrene 
Universal container containing 10mls of Hams F10 medium supplemented with 
20% fetal calf serum. After thorough mixing by inversion, the container was 
centrifuged in an MSE centrifuge at 400 x g for 10 minutes, the supernatant was 
removed and the pellets washed with lOmIs of phosphate buffered saline , prior to 
a further centrifugation for 10 minutes at 400 x g . This was repeated twice more, 
before the remaining buffer was discarded, the pellet reconstituted and transferred 
to a large Eppendorff tube for centrifugation at 7,500 x g in a Microcentaur 
microcentrifuge for 5 minutes. The remaining pellet was air dried, and snap frozen 
in liquid nitrogen before storage at -70°C.
4.3.4 Retrieval and handling
After thawing at room temperature, the pellet was reconstituted with an appropriate 
amount of distilled water. The relative volume, was determined by the size of pellet 
obtained, but was typically between 60 and 120p.l. After gently vortexing to ensure 
complete homogeneity, the cells were sonicated at 4pm for 10 seconds on an 
MSE Soniprep 150 sonicator and the resulting lysate spun for 10 minutes at 7,500 
x g  in a Microcentaur microcentrifuge. The supernatant was kept on ice until use. 
The minimum volume of 60pi was determined by the limitation of the sonicator 
which, due to the type of probe used, would not adequately disrupt the cell 
preparation in a lesser volume.
After analysis, the remainder of the cell supernatants were returned to long term 
storage at -20°C.
4.4 Chorionic villus cells
4.4.1 Preparation
The entire aspirate was transferred to a glass petri dish and a small amount of 
RPMI 1640 media (Gibco) poured in to clarify the tissue from the accompanying 
blood. The GV was cut from the surrounding tissue using scissors, and with
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siliconised glassware, was transferred to a clean petri dish containing fresh media 
where it was sorted to remove blood clots and fragments of maternal decidua from 
the villi. The most adequate method of performing this was found to be with 2 
Microlance 19g2 gauge needles, allowing small pieces of the villi to be teased 
apart. After removal of this tissue to another petri dish and a further wash with 
RPMI 1640, a more detailed sort was performed under a phase microscope, if the 
samples proved to be of adequate size, they were divided into two equal parts, and 
an aliquot containing a minimum of 10-20mg tissue was pelleted and used 
immediately for biochemical analysis. The remainder of the tissue was cultured as 
described below.
Control CV was prepared identically and the material snap frozen in liquid nitrogen 
and stored at -70°C for up to 7 days before analysis.
4.4.2 Collagenase Dissociation and Culture
Approximately lOmg of the CV tissue was transferred to a culture tube containing 
4mi sterile, Trypsin/EDTA and incubated for 1 hour at 37°C, ensuring that the tube 
was mixed after each 30 minute period. After centrifugation at 400 x g for 5 
minutes on an MSE centrifuge, the supernatant was discarded and the pellet 
resuspended in 1ml of 3% collagenase culture medium (CCM) (1:1 RPMI and 
Hams F10 medium; 3% Ultroser serum substitute and 3% Penicillin/Streptomycin, 
filter sterilised through a 0.22 pm filter); and 1ml collagenase (20mg collagenase in 
10ml CCM, filtered and stored in 1ml aliquots at -20°C). This was mixed thoroughly 
and incubated at 37®C for 2 hours, again mixing the tube after each 30 minute 
period. The cells were spun down for 5 minutes at ISOOrpm and washed in 1ml of 
fresh CCM. This step was repeated and the cells transferred to a Nunc 25cm 
culture flask with 5ml of Tube media ( consisting of Hams F10 with Hepes buffer 
and L-glutamine (Gibco); 20% Fetal calf serum and 1% Penicillin/Streptomycin) 
and incubated at 37°C , with refeeding every 3-4 days until confluence was 
reached.
The method for pelleting, storage, reconstitution and handling of CV was identical 
to that described previously for Amniotic Fluid cells (Section 4.3.3).
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4.5 hibroblast cells
Fibroblast cells were prepared and cultured by a method identical to that employed 
for CV cells. The only salient difference was that due to the nature of fibroblast 
tissue, it was necessary to chop the large pieces into much smaller ones. This was 
done using a small sterile plastic petri dish and sterile scissors.
4.6 Lymphocyte cells
4.6.1 Collection and Preparation.
Approximately lOmIs of whole blood was collected from control patients and study 
cases in lithium heparin tubes as described previously and stored for not more than 
2 days at 4°C before processing. A volume of 4m!s Lymphoprep solution 
(Nycomed) was placed in a 15ml plastic tube and to this was added 5mls of whole 
blood. After centrifugation at 400 x g for 40mins, the constituents had separated 
into 3 fractions; the plasma, the white cells (buffy coat) and the red cell 
components. The plasma component was removed and discarded, while the white 
cells , which lay at the centre of the interface, were removed to a second 15ml 
plastic tube. Preparation of the remaining red cells was as described in section
3.1.1. , before storage of these aliquots at -20°C. The buffy coat containing the 
white cell fraction was washed with 12mis of RPMI medium containing 1% 
Penicillin/Streptomycin antibiotic and centrifuged at 400 x g for 20mins. The 
supernatant was disposed of into 10% Chloros and the cell pellet resuspended in
,
a further lOmis of RPMI medium, with a further centrifugation at 400 x g for 20 
minutes. Contamination of the cell pellet by significant amounts of red cells, was 
minimised by addition of 1ml of red cell lysis mix (155mM NH4CI (BDH); lOmM 
KHCO3 (BDH) and lOm M  EDTA (pH 8.0)), and allowed to stand for 20 minutes.
Since a. volume of approximately lOmIs of whole blood was processed as 2 
separate cell preparations, these were combined in a large Eppendorf microtube 
and centrifuged at 7,500 x g for 10 minutes before a further wash with Im i of 
RPMI buffer and a further centrifugation step to pellet the washed cells . The pellet 
was then snap frozen in solid CO2 , prior to storage at -70°G until use.
Control lymphocyte preparations used in the evaluation of the various assay 
parameters were obtained from the Scottish Blood Transfusion Service, as 2 
batches of ‘buffy coat’. Arrival was 4 weeks between each batch, preparation was
'
as described above for heparlnised blood, with the exception that the final cell 
pellets were dispensed into 100pi aliquots, transferred to small Eppendorf tubes, 
spun at 7,500 x g and the supernatant discarded, and the pellet stored at -70°C 
until use.
4.7 DNA extraction
DNA was extracted from fresh whole blood samples collected in di-sodium EDTA 
for both the purine and pteridine studies.
A maximum of lOmIs of whole blood was transferred to a 50ml polyethene tube 
and 2 volumes of cold lysis mix added. The lysis mix consisted of 0.32 M sucrose, 
lOmM Tris, 5mM MgCb, 1% Triton X-100, and adjusted to pH 7.5 before storage at 
4°C. Separation was achieved by spinning the solution at 4°C for Smins at 1000 x g 
in a Sorvall RT 6000D refrigerated centrifuge. Supernatant was poured off into a 
beaker of 5% Chloros, with particular care taken for those blood samples which 
have been frozen prior to extraction. After addition of 2mls of nucleic acid mix 
(0.4M NaCI; lOmM Tris; 2mM EDTA; pH 8.2); 200pl 10%SDS and lOOpi of a 
lOmg/ml preparation of Proteinase K, the mixture was vortexed briefly to 
resuspend the pellet. Incubation in a 37°C waterbath overnight was followed by 
addition of 700pl of a saturated NaCI solution with a vigorous shaking prior to a 
further centrifugation for 15 minutes at 200 x g at room temperature.
Using a disposable Pasteur pipette the supernatant was transferred to a 5ml 
centrifuge tube containing 600pl of a phenol/chloroform solution (water saturated 
phenol) (BDH) with 1M Tris to give pH 7.5 containing 0.1% B-hydroxyquinoline 
mixed with an equal volume of chloroform (BDH) and allowed to settle) before 
mixing by gentle inversion for at least 1 minute to ensure complete mixing. 
Centrifugation for 15minutes for 1200rpm at room temperature, allowed the 
removal of the supernatant from the aqueous layer into a universal container. After 
addition of 2 volumes of ethanol, the DNA fibres were spooled out using a flame 
sealed glass Pasteur pipette, and allowed to dry thoroughly in air. The dried DNA 
was dissolved in a 1ml screwtop container containing TE buffer (lOmM Tris; ImM 
EDTA; pH to 7.5), using approximately 500jul of buffer for a typical 10ml blood 
sample yield of DNA, and left at room temperature overnight. The DNA was stored 
at -70°C until use.
All solutions with the exception of the phenol / chloroform solution were autociaved 
prior to use.
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4.7.1 Oligonucleotide primer preparation
Two stock preparations of oligonucleotide primers were constructed for analysis of 
the 677C-»T mutation, corresponding to the base sequences
1) 5’-AGAAGGAGAAGGTTGTCTGCGGGA-3’ (exonic)
2) 5’-AGGACGGTGCGGTGAGAGTG-3’ (intronic)
The primers were synthesised on an ABi Model 391 Oligosynthesiser using a 
Cruachem 0.2pM column and stored at 4°C until deprotection.
4.7.1.1 Primer deprotection
Deprotection of the primers consisted of drawing 1ml of Ammonium hydroxide into 
a 1ml polypropylene syringe before connection to one end of the column. An empty 
syringe was attached to the other end and the column washed with back and 
forward flushing approximately 3 times to remove the primer preparations for the 
column bed. This was repeated at 30 minute intervals over a period of 3 hours, 
always ensuring that the column is left in contact with the solution. A 
decolourisation of the column bed from yellow to white was an assurance of the 
success of the removal procedure. The ammonium hydroxide solution containing 
the primer was withdrawn and expelled into a small round bottomed screw-top 
tube (Nunc), and the volume made up to 2.5 mis with more ammonium hydroxide 
flushed through the column. The tubes were then incubated at 55°C overnight and 
stored at -70'’G until extraction of the oligonucleotide is performed.
4.7.1.2 Ethanol precipitation of the primer
A volume of 0.45mls of the ammonium hydroxide / primer solution was aliquotted 
into a large Eppendorf tube and to this was added 50pl of 3M sodium acetate and 
1ml of 95% ethanol (BDH). After gentle agitation of the mix for approximately 30 
seconds, it was incubated at -40^C for 2 hours prior to centrifugation at 10,000 x g 
for 10 minutes at 4°C. The supernatant was removed and the pellet washed with 
85% ethanol before a further centrifugation at 7,500 x g for 2 minutes. The ethanol 
supernatant was removed and the pellet allowed to air dry before being 
resuspended in 200p.l of TE buffer.
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The resulting stock was measured at and the required dilution was
calculated to give an appropriate concentration for the PCR assay as follows:-
Example of the calculation for primer stock dilution
Gram formula weight = number of base pairs x 300 (average weight of each base) 
= 2 4 x3 0 0  = 7200 g / l  
(If 1M = 7200g/l, then 1pM = 7.2pg/ml)
Spectrophotometric measurement of primer at 260nm = 0.241
Therefore, 0.241 x 33 x 100 = 795.3 pg/ml
where; 33 is the extinction coefficient of DNA in pg/ml ( 1 OD^®° = 33pg/ml)
100 is the dilution factor in the cuvette (5pl into SOOpI distilled water).
The molaritv of the stock primer is then = 110.4 umol7.2pg/ml
This is then diluted in distilled water to give a final stock preparation of 5pM, and 
stored at -20'"C until use.
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4.8 Purine enzyme assays
4.8.1 Sample Preparation
Since the activities of the enzymes under study for any specific tissue have to be 
compared, it was necessary to relate these to a common factor for the specific 
tissue under examination. Prior to the commencement of any of the purine enzyme 
assays, the concentration of either haemoglobin or total protein as appropriate was 
measured.
4.8.2 Haemoglobin Estimation
Haemoglobin concentration was measured by modification of the method 
described by van Kampen and Ziljstra (1961).
The activity of the red cell enzymes was expressed as a measure of the amount of 
haemoglobin present in the prepared haemolysate. This method measures 
haemoglobin concentration by the reaction of ferricyanide-cyanide on blood, which 
converts haemoglobin to cyanmethaemoglobin. The resulting optical density, 
determined at 540nm, is directly proportional to the concentration of 
cyanmethaemoglobin present.
The ferricyanide-cyanide reagent (colloquially known as Drabkins solution), 
contained 200mg potassium ferricyanide ( K3pe(CN)6  ) (BDH); 50mg potassium 
cyanide (KCN) (BDH) and 140mg potassium di-hydrogen phosphate (KH2PO4) 
(BDH) dissolved in 1 litre of distilled water. This solution is stable for several 
months when stored at 4°C.
4.8.2.1 Preparation of haemolysates
Using a plastic disposable pipette, approximately 2 drops of the citrate-glycerol red 
cell sample was added to 8 drops of distilled water in a large Eppendorf reaction 
tube, and vortexed thoroughly for 5 seconds. The resulting haemolysate was spun 
in a Microcentaur centrifuge at 7,500 x g for 10 minutes at room temperature to 
remove the stroma, and placed on ice.
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The concentration of haemoglobin was calculated as follows;
= grams / lOOmIs (g/%)^ 5 4 0
^ C N
where;
dilution factor = + 1.000 ^
I
A volume of 5pi of the haemolysate was added to 1ml of the Drabkins solution in a 
1ml Sarstedt disposable plastic spectrophotometer cuvette, and mixed carefully
..avoiding the introduction of bubbles with a 1ml capacity Gilson pipette. The tubes 
were left at room temperature for 5 minutes to allow complete conversion of the 
haemoglobin to cyanmethaemoglobin, and read on a Pye Unicam 8800 UV/VIS 
double beam spectrophotometer at 0D^'^°. The spectrophotometer was zeroed 
using 1ml of Drabkins solution alone as a sample blank, prior to measurement.
4.8.2.2 Calculation
-S
d X OD^"^ x  M X 10"^^
Îi
i0.005
OD '^*^ = Optical density of solution at 540nm.
_  540^  CN “  millimolar coefficient of absorptivity for cyanmethaemoglobin.
M = molecular weight of haemoglobin = 16,520.
All estimations were performed in duplicate and the average of the readings for 
each sample used to calculate the final result.
The resulting preparations were further diluted to obtain working red cell samples 
for the radiolabelled assays with haemoglobin levels in the region of 1-2g% for 
HGPRT and APRT analysis, and 0.5-1 g% for ADA analysis. For the spectro­
photometric analysis of PNP a concentration of 0.5 - 1.0 g% haemoglobin was also 
used. Values were converted to units of mg/5 pi to correspond to the sample 
volume used in the radiolabelled assay calculation .
Î
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4.8.3 Total Protein Estimation
This method was modified from that described by Lowry et al (1951).
In this widely used technique, the protein in the sample is pre-treated with an 
alkaline copper solution, before addition of a phenolic reagent. The colour 
produced results from the reduction of the phosphotungstic and phosphomoiybdic 
acids to molybdenum blue and tungsten blue by the copper-peptide bond complex, 
the tyrosine and tryptophan moieties and to a lesser extent the cysteine and 
histidine groups of the protein.
Three solutions were combined into a working reagent for the assay. These 
consisted of 2% NagCOs (BDH) in 0.1 M NaOH (solution A); 1% CUSO4 (BDH) in 
distilled water (solution B1) and 2% Na K Tartrate (BDH) in distilled water. These 
were combined in the ratio of 98 : 1 : 1 of solutions A, B1 and B2 respectively, 
mixed and 800pl of this working reagent was added to each tube.
A solution of 5G0pg/ml bovine serum albumin (BSA) was prepared which was
diluted down to 400,300,200,100,50 and OpI in distilled water, to construct a 
standard curve. Dilutions of the sample material were judged to be appropriate at
doubling dilutions of x20, x40 and x80 in distilled water.
A volume of 80pl of either the standard or sample dilution was added to the 
appropriate tube and vortexed thoroughly before being left at room temperature for 
10 minutes. After addition of 80pl of a 1:1 dilution of Folins Reagent (BDH) and 
distilled water, the reaction tubes were placed in the dark at room temperature for 
45 minutes to enable the reaction to reach completion.
Optical densities of standards and samples were read from a Pye Unicam 8800 
UV/VIS double beam spectrophotometer and sample concentration calculated from 
the resulting standard curve using Genesis curve fitting software. (Genesis: 
Windows software for microplate based assays, Labsystems (UK) Limited). Values 
obtained for the protein concentration in pg/ml were adjusted to units of mg/5pl to 
correspond to the sample volume used in the radiolabelled assay activity 
calculation.
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4.8.4 Radiolabelled Assays
The enzyme activities were determined by a modification of the method described 
by Galjaard (1980).
4.8.4.1 Hypoxanthine-Guanine Phoshoribosyl Transferase (HGPRT)
HGPRT in the presence of 5’-phosphorybosyl pyrophosphate (PRPP), acts upon 
the radiolabelled substrate [8 -'"‘C] hypoxanthine, to produce the products inosine 
and inosinic acid (IMP). These radiolabelled products were then separated by thin 
layer chromatography, and subsequently measured and calculated to determine 
the activity of the enzyme.
4.8.4.1.(i) Liquid Scintillation Counting
One of the best methods of measuring a particular moiety is to use the radioactive 
form of the substance under investigation. A small quantity of the radioactive form 
(tracer) is usually mixed with a much larger amount of its non-radioactive 
counterpart, and the behaviour of the two is then assumed to be identical. The 
tracer can be easily detected and measured by its radioactivity and can readily 
provide information about the behaviour of the non-radioactive form. The 
effectiveness of radioactive tracers necessitates a sensitive method of detection, 
and to this end scintillation counting, specifically liquid scintillation counting 
provides this.
Scintillation counting is based on the principle that a charged particle emitted from 
the source material (either as an alpha or beta ), is absorbed by a fluorescent 
material, the ‘scintillator’ (or 'fluor'), which convert the kinetic energy of an 
incoming charged particle to photons which are re-emitted and detected by a 
photomultiplier tube, converted to electrical energy and analysed.
Scintillation counters are of two main types, the solid scintillation counter and liquid 
scintillation counter. In the liquid scintillation counter, the penetration of p-particies 
is so short that they cannot pass through the walls of the sample container and so 
must be brought into close relationship with a suitable solvent which acts as a 
scintillator. Since some of the most important and convenient radioisotopes in 
biochemistry emit p-particles of low energy, such as and ^H, only liquid 
scintillation counting is suitable.
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4.8.4.1.(il) Method
The HGPRT assay was performed in 200pl volume Eppendorff tube and consisted 
of 10fxl 1.0M/I Tris-HGI buffer (pH 7.4) containing 5.0mM/LI PRPP and 12.5mM 
MgClz: 5pl of 19.1mM hypoxanthine (dissolved in acidified distilled water and pH 
adjusted to between 4.0-4.4 with NaOH) and 5pl of 0.9Q9mM [8 - '^’C] hypoxanthine 
(specific activity 54mCi/mmol (Amersham)). This was maintained on ice at all times. 
Following careful vortexing for 10 seconds, 5pi of the sample lysate was added to 
the reaction mixture and vortexed. A thin layer of paraffin oil was applied to the 
surface of the mixture and the tube returned to ice until all sample preparation was 
complete, incubation was at 37°C for either 1 hour for red cells, or 2  hours for other 
tissues. The reaction was terminated by addition of 5pi of ice cold 20% 
trichloroacetic acid (TCA), and the resulting denatured proteins removed by 
centrifugation at 10,000 x g in a MSE Microcentaur microcentrifuge. Reaction 
products and unused substrate were separated by ascending chromatography on 
polyethylimine-F cellulose (PEI-F) (BDH) by spotting 2pi sample supernatant over 
6 pl of a carrier solution consisting of a 1:1:1 mix of 5mg/ml hypoxanthine : inosine 
:IMP, in 5% Na2HP0 4  (BDH) as solvent for 1 . 5 - 2  hours. The completed 
chromatograms were dried gently in a warm air stream and the spots identified in a 
light box under short wave ultra-violet light, before being cut out and the 
radioactivity quantified by heterogeneous liquid scintillation counting in a Wallac 
1407 counter with Ecoscint A scintillation fluid (National Diagnostics).
4.8.4.1 .(iii) Calculation of results
Results were calculated using the formula:-
CPM (product -  blank) loo 1 , , ^  X —  X -------------------------- = nmoles /hr/mgCPM (total counts) T Hb or protein / 5pi
where:- CPM = Counts per minute 
T = Time (hrs)
1 0 0  = substrate concentration (nmole/l)
Hb = Haemoglobin content of sample in mg.
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4.8.4.2 Adenine Phosphoribosyl Transferase (APRT)
APRT in the presence of PRPP, acts upon the radiolabelled substrate [8- '^*C] 
adenine, to produce the products adenosine, and AMP. These radiolabelled 
products are detected by thin layer chromatography, and subsequently measured 
and calculated to determine the activity of the enzyme.
4.8.4.2.(i) Method
The method for APRT was a modification of that described previously for HGPRT 
(Section 4.8.4.1.(ii)), The assay was performed in 200pl volume Eppendorff tube 
and consisted of 10pl 1.0M/I Tris-HCI buffer (pH 7.4) containing 5.0Mm/l PRPP and 
12.5mM MgCb: 5pl of 19.1mM adenine (dissolved in acidified distilled water and 
pH adjusted to between 4.0-4.4 with NaOH) and 5pl of 0.909mM [8- '^*C] adenine 
(specific activity 54mCi/mmol (Amersham)) and maintained on ice at all times. 
Following careful vortexing for 10 seconds, 5pl of the sample lysate was added to 
the reaction mixture and vortexed. A thin layer of paraffin oil (BDH) applied to the 
surface of the mixture and the tube returned to ice until all sample preparation was 
complete. Incubation was at 37°C for either 1 hour for red cells, or 2 hours for other 
tissues. The reaction was terminated by addition of 5pl of ice cold 20% TCA (BDH), 
and the resulting denatured proteins removed by centrifugation at 10,000 x g in a 
microcentrifuge. Reaction products and unused substrate were separated by 
spotting 2pi supernatant over 6pl of a carrier solution consisting of a 1:1:1 mix of 
5mg/ml adenine : adenosine : AMP before ascending chromatography in 5% 
NaHP0 4  as solvent for 1 . 5 - 2  hours. The subsequent chromatograms were dried 
gently in a warm air stream and the spots identified in a light box under short wave 
ultra-violet light, before being cut out and the radioactivity quantified by 
heterogeneous liquid scintillation counting in a Wallac 1407 counter with Ecoscint 
A scintillation fluid.
4.8.4.2.(ii) Calculation of results
Calculation of results was as described for HGPRT (Section 4.8.4.1 .(iii)).
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4.8.4.S Adenosine Deaminase (ADA)
ADA acts upon the radiolabelled substrate adenosine, to produce the
product, inosine. The radiolabelled product is detected by thin layer 
chromatography, and subsequently measured and calculated to determine the 
activity of the enzyme.
4.8.4.3.(i) Method
The method for adenosine deaminase was a modification of that described for 
HGPRT. The assay was performed in 200pl volume Eppendorff tube and consisted 
of 10pl 0.25M/I Tris-HCI buffer (pH 7.4); 5pl of 0.875 unlabelled Adenosine and 5pl 
of 0.91 mM [S- '^^C] adenosine (specific activity 46 mCi/mmol (Amersham)). This 
was maintained on ice at all times. Following careful vortexing for 10 seconds, 5pl 
of the sample lysate was added to the reaction mixture and vortexed. A thin layer 
of paraffin oil was applied to the surface of the mixture and the tube returned to ice 
until all sample preparation was complete. Incubation was at 37°C for either 1 hour 
for red cells, or 2 hours for other tissues. The reaction was terminated by addition 
of 5pl of ice cold 20% trichloroacetic acid, and the resulting denatured proteins 
removed by centrifugation at in a microcentrifuge. Reaction products and unused 
substrate were separated by spotting 2pi supernatant over 6pl of a carrier solution 
consisting of a 1:1 mix of 5mg/ml adenosine : inosine, before ascending 
chromatography on PEI-F cellulose in 5% Na2HP0 4  as solvent for 1 . 5 - 2  hours. 
The subsequent chromatograms were dried gently in a warm air stream and the 
spots identified in a light box under short wave ultra-violet light, before being cut 
out and the radioactivity quantified by heterogeneous liquid scintillation counting in 
a Wallac Rackbeta 1407 counter with Ecoscint A scintillation fluid (National 
Diagnostics).
4.8.4.3.(ii) Calculation of results
Results were calculated using the formula:-
CPM(product -  blank) substrate cone 1 1
CPM (total counts) 1 T Hb or protein / 5//1
= nmoles / hr/mg protein.
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where:-
CPM = Counts per minute 
Substrate concentration = 9 nmol/l
T = Time (hrs)
Hb = Haemoglobin (mg)
4.8.5 Spectrophometric assays
The Beer-Lambert law states that the concentration of a substance is directly 
proportional to the amount of radiant energy absorbed or inversely proportional to 
the logarithm of the transmitted radiant energy. This can be described by the 
formula:
A = abc
where A is the absorbance; a is the absorptivity; b is the light path and c is the 
concentration of the substance of interest. The absorptivity is a proportionality 
constant related to the chemical nature of the substance, and is called ‘molar
absorptivity’ ( denoted as S ) when the concentration is expressed in moles per litre
and the light path in centimetres. Molar absorptivity is constant for a given 
compound at a given wavelength under specified conditions of solvent. pH and 
temperature and is a means of relating concentration and absorbance for any 
substance.
Thus, the equation becomes 
A = Bbc
Absorbance measurements for these studies were performed using a Pye-Unicam 
8800/03 UV/Visible Spectrophotometer. The instrument has the facility to perform 
a power-on self diagnostic, where both the optics and peripherals are tested prior 
to use, and as the name suggests is capable of measuring in both the ultra violet 
and visible spectra by virtue of having both a quartz-halogen and deuterium arc 
source. Glass and plastic disposable cuvettes can be used at wavelengths above 
320nm, but due to their absorbance characteristics below this wavelength, were 
replaced by optically identical quartz cuvettes when samples were measured at 
ultra-violet wavelengths.
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4.8.5.1 Purine Nucleoside Phosphorylase (PNP)
PNP acts upon the substrate inosine to produce hypoxanthine. The auxiiliary 
enzyme, xanthine oxidase converts this via xanthine to uric acid. The uric add 
concentration is measured spectrophotometricaliy to determine the activity of the 
enzyme.
4.8.5.1.(i) Method
A reaction volume of 0.5ml of inosine (1.5mM) in 0.05M sodium phosphate buffer 
(pH 7.5) and 6.25pl xanthine oxidase (0.72units/mg protein), was mixed thoroughly 
in a 0.5ml micro quartz cuvette using a 200pl Gilson pipette. This was placed into 
the thermostatted cuvette carrier compartment, of a Pye Unicam 8820 double 
beam UV / VIS spectrophotometer, the carrier having been pre-heated to a 
temperature of 37°C. To a second optically matched cuvette was added 0.5ml of 
0.05M sodium phosphate buffer and 6.25|liI xanthine oxidase. After thorough 
mixing, this cuvette was placed in the reference beam carrier of the 
spectrophotometer to act as the reagent blank. The cuvettes were allowed to 
Incubate for 3-4 minutes before addition of 6.25pl of haemolysate to each, again 
ensuring complete homogeneity by careful mixing. Accumulation of uric acid was 
measured by an increase in the absorbance at 293nm. All measurements were 
performed in a heating block connected to a water bath controlled thermostatically 
and the result displayed as a change in optical density (AOD) on an integral 
thermal printer.
4.8.5.1 .(ii) Calculation of Results
The results for the PNP assay were calculated using the following formula:-
AOD/m in ^  ^ ^  x 60 = pmoles / hr / gHb or proteinHb V,
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where
Vc = final volume in cuvette.
4.8.6 High Performance Chromatographic Assays
determined by the chosen pH.
lon-pair chromatography uses the technique of “ion-suppression”, where an organic 
ionic substance is added to the mobile phase and forms an ion-pair with a sample
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8 = millimolar extinction coefficient of uric acid (12.6 ).
Hb = quantity of haemoglobin in original haemolysate (g %) 
Vh = volume of haemolysate.
100 = conversion factor from mis to lOOmIs for Hb.
-
High Performance Liquid Chromatography (HPLC) is a chromatographic technique 
which yields highly efficient separations within a short period of time, in which the 
sample mixture is distributed between 2 phases In the chromatographic bed. One 
phase is stationary, consisting either of a solid porous surface active material in 
small particle form, or a thin film of liquid coated on a solid support or column, while 
the other phase is mobile and consists of a liquid which distributes itself throughout 
this stationary phase. The various components to be separated must have different 
distribution coefficients in the chromatographic system if the mixture is to be 
separated efficiently.
Reversed phase (RP) chromatography is the term used to describe the state in 
which the stationary phase is less polar than the mobile phase. Chemically bonded 
octadecylsilane (ODS) an alkane, with 18 carbon atoms is the most frequently used 
stationary phase. In normal phase adsorption chromatography, water interacts 
strongly with the active centres of silica and alumina bases of the stationary phase, 
so that absorption of sample molecules become highly restricted and as a 
consequence are rapidly eluted from the column. In RP the opposite applies, in that 
water cannot interact with the non-polar (hydrophobic) alkyl groups. Hence it is the 
weakest RP mobile phase, giving the slowest sample elution rate, since samples 
will tend to bind to the solid phase in preference to water. The more water in the
I
I
e luen t, the longer the retention time.
Ionic samples may be separated by reversed-phase chromatography provided they 
contain only weak acids or only weak bases present in undissociated form as
f
lon-pair chromatography uses the technique of "ion-suppression”, where an organic 
ionic substance is added to the mobile phase and forms an ion-pair with a sample 
component of the opposite charge. This salt has the chromatographic behaviour of 
a non-ionic molecule. The advantages of ion-pair chromatography for separating 
ionic molecules are that RP systems can be used for separation; mixtures of acids, 
bases and amphoteric molecules can be separated and the selectivity of the 
system may be influenced by the choice of the counter ion.
4.8.6.1 Phosphoribosyl pyrophosphate synthetase (PRPP-S)
The assay of PRPP-S was based on a modification of the method described by 
Sakum aefa/ (1991).
The enzyme PRPP-S catalyses the synthesis of PRPP from R5P and ATP in the 
presence of inorganic phosphate and magnesium. AMP is then reconverted back 
to ADP by adenylate kinase. The reaction sequence is as follows:
R5P + A TP ->  P R P P  + AM P  
A M P + ATP ^  2ADP
Where the concentration of ATP present is in excess of AMP.
The ADP produced is followed by measuring the increase in the absorbance of 
ADP after separation of the ADP from ATP and AMP by an ion-pair reversed-phase 
HPLC, and is a direct measure of the reaction catalysed by PRPP-S.
All reagents were of the highest purity available, and the water used was purified to 
18MQ.cm by a Millipore Milli-Q RG Ultrapure Water System.
4.8.6.1.(i) Sample Preparation
The red cell samples prepared and stored as previously described were thawed at
room temperature, and 1.0ml of the mixed homogenate added to a 1.5ml plastic
Eppendorf tube. This was spun at 10,000 X g for 10 minutes in a microcentrifuge,
pre-cooled to 4°C. After discarding all but a small amount of the supernatant
(required to overcome the viscosity of the preparation), the remaining red cells
were sonicated x2 at 2pm for 5 seconds and diluted with 5 volumes of a charcoal-
dextran T70 solution consisting of 10g/L charcoal: 1g/L Dextran T70 in cold distilled
water. After a 10 second vortex and a 10 minute equilibration period on ice, the
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Haemoglobin was estimated by the method of van Kampen and Ziljstra (1961) as 
previously described in Section 4.8.2.
4.8.6.1.(ii) Enzyme Assay
A reaction mix was prepared consisting of lOOmIs of a 40mM sodium phosphate 
buffer (pH 7.4) to which was added I.OmM R5P; 1.4mM ATP; 6mM MgCL and 
1 .OMm reduced glutathione. The pH of the buffer was rechecked and readjusted to 
7.4 if necessary, before use, either immediately or after storage at 4°C for not 
more than 5 days.
Immediately prior to use, the appropriate volume of reaction mix required for the 
number of samples to be processed was measured out and to this was added 1.8 
lU/ml of adenylate kinase (AK; Myokinase) (Boehringer). Plastic 2.5ml LP2 tubes 
were labelled accordingly and using a Gilson pipette, 2.Omis of this reagent was 
added to each. All tubes were pre-incubated at 37°C for Sminutes before addition 
of lOOpI of the sample. All tubes were then returned to the 37°C water bath. 
Volumes of O.Smls were removed after 10 minutes and after 30 minutes incubation 
and transferred to Eppendorf tubes containing 0.5mls of 0.6M Perchloric acid. 
After a 10 second vortex mix and equilibration for a further 10 minutes at room 
temperature, ail tubes were centrifuged at 10,000 x g in a microcentrifuge for 10 
minutes before removal of 0.2mls of the mix into 0.4M sodium phosphate 
neutralising buffer (pH 7.4). A final vortex followed by centrifugation at 10,000 x g 
was sufficient to remove all particulate matter. The sample was stored at 4°C until 
determination of ADP levels by HPLC.
4.8.6.1.(iii) HPLC
A volume of 50pl was syringed into the injection port of an HPLC apparatus ( a
modular LKB system ) consisted of a model 2152 controller, a model 2150 single
pump and a Uvicord SD detection system with a flow cell. The gradient was
generated and maintained by the controller via a switching valve which determined 
the appropriate concentrations of the two buffers throughout the run. The UV 
detector was set at 254 nm on 0.05 AUFS and the signal output was displayed on 
a 2210 potentiometric chart recorder running at a speed of 2mm/minute.
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All separations were performed at ambient temperature on a Resource RPC 3 
reversed phase column (100 x 6.4 mm: Pharmacia Biotech) with 15pm bead size 
and a Waters guard column. The mobile phase consisted of 2 separate buffers; 
Buffer A which comprised 0.03M/L potassium di-hydrogen phosphate / ammonium 
chloride (pH 3.9) containing 300pM/L of the ion-pair reagent, 
Tetrabutylammoniumhydrogen sulphate (TBAHS) and Buffer B which was 0.1 M/L 
potassium di-hydrogen phosphate / ammonium chloride (pH 3.4) containing 50 
mM/L TBAHS and 30% Methanol.
The buffers were degassed in-line using a Whatman Aqueous In-Line Filter / 
Degasser (IFD) which traps gas and prevents it entering the flow system.
The flow rate used was 1.0 ml/minute and to maintain adequate separation the 
gradient was 0-60%B for 20 minutes for the run followed by 60-0%B for 10 
minutes as an re-equilibration step.
Prior to each batch of samples, 3 in-house standards comprising 140pM/L, 70pM/L 
and 35 pM/L ADP were run in order that the concentration of the samples could be 
calculated by reference to the size of standard peaks obtained.
Since the deleterious effects of the use of ion-paired reagents have been well 
documented, the column was cleaned at the end of the days run using the 
protocol specified on the data sheet for the column for contaminations which 
dissolve at acidic pH. This involved reversing the direction of the column flow and 
running 2 solutions; 1M/L HCL (Solution A) and 90% acetonitrile (Solution B) in the 
gradient Of 0-100% B for 30 minutes followed by 100-0%B for 30 minutes at a flow 
rate of 1.0 ml/minute.
When not in use overnight or for any prolonged length of time, the system was left 
running with 50% ethanol at a low flow rate of 0.01ml / minute, to maintain column 
integrity and to prevent salt build up on pump seals and other components of the 
system.
Prior to the analysis of the samples the HPLC system was assessed for its 
suitability of application for determining the adenosine nucleotides. The column 
parameters were quantified using a reversed phase test mix (Sigma 251 SA ) to 
establish the retention parameters and the efficiency of the column. Periodic 
testing of the retention and efficiency properties was performed to assess the 
quality of the sample results obtained. The reversed phase test mixture used, 
consisted of six components in varying concentrations: uracil (0.005mg/ml), phenol 
(0.7mg/ml), benzaldehyde (0.05mg/ml), N,N-diethyl-m-toluamide (1 mg/ml), and
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toluidine and ethybenzene (4mg/ml each) dissolved in a 65% acetonitrile - 35% 
water and was stored at 4°C until use.. The components were resolved on the 
column by injection of 10pl of the test mixture at a sensitivity of 0.5 AUFS at 254nm 
wavelength, and the retention time of each component calculated.
4.9 Enzymes of the Folate pathway
4.9.1 PCR Method for thermoiabile MTHFR Alleles
This method is a modification of that described by Frosst et al (1995).
A mutation which alters a highly conserved amino-acid in the homozygous and 
heterozygous state correlates with the presence of reduced enzyme activity and 
thermolability in lymphocyte extracts. This mutation (C to T substitution) at 
nucleotide 677 converts an alanine residue to valine and creates a HinH site. This 
can be cleaved to give 175bp and 23bp fragments in the mutation, compared with 
a 198bp fragment in the wild type allele.
4.9.1.1 PCR Method
The primers used In the analysis of the thermoiabile allele were as described in 
Sec, tion 4.7.1.
To facilitate consistency of the reagents, a working solution was prepared to 
accommodate the appropriate number of samples (plus 1 extra ) and a total of 
2.5pl primer 1; 2.5pl primer 2; 2.5pl of Taq buffer (supplied with the Taq 
polymerase enzyme) (Boehringer) and 2.5pl of deoxy nucleic triphosphates (dntp’s) 
was prepared for each sample to be assayed. An Eppendorf tube was labelled for 
every sample to assayed, and lOpI of this working solution was added to each with 
thorough mixing, followed by 13pl of distilled water and 1pl of the appropriate 
individual DNA. After overlaying the mixture with mineral oil using a disposable 
plastic pipette (just enough to cover the preparation, ~1-2 drops), the samples were 
loaded into a Perkin Elmer 480 DNA Thermal Cycler, and a ‘soak’ file run to bring 
the temperature of the tubes up to 90°C. This step also prevents premature 
reaction at room temperature, prior to the addition Ip l of Taq polymerase (1 Unit) 
as soon as this initial temperature is reached. The PCR was then run until
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completion of the pre-set program for 34 cycles (usually around 2.5 hours) utilising 
the following protocol
=> Heating to 95°C for 5 minutes 
=> 34 cycles of 95°C for 30 seconds 
55°C for 30 seconds 
72°C for 45 seconds 
=> 72°C for 10 minutes
=> 4°C until removal from PCR instrumentation.
On completion of the PCR, the tubes were removed from the heating block and 
either the Hinfl digest performed immediately, or they were stored at 4'^C overnight 
until the digest could be performed.
4.9.1.2 Hinn Digest
The Hinf^ enzyme (Boehringer) was removed from -20°C storage, allowed to thaw 
and pulsed on a microcentrifuge to ensure that all the preparation was at the 
bottom of the tube. A small Eppendorf tube was labelled for each sample and to 
this was added 1.5pl HinH buffer (previously thawed from -20°C); lOpI of the 
appropriate sample PCR; 1pl HinH enzyme and 2.5pl distilled water. This reaction 
mix was incubated overnight at 37°C. Using tris-acetate buffer, a 2% agarose 
solution was prepared and boiled until molten. To this was added 4pl ethidium 
bromide, and the solution mixed thoroughly prior to pouring into a gel mould 
containing a 2 x 10 tooth combs. The gel was allowed to solidify and moved to a 
4°C environment for 30-60 minutes prior to use. A volume of 2pi of loading mix 
consisting 50% glycerol and 50% bromophenol blue dye of was added to each 
digest tube, which was then mixed. The gel comb was removed from the gel, which 
was placed in the mini-gel tank, followed by Tris-acetate tank buffer. Addition of 
samples and molecular weight ladder was added under the buffer and the 
apparatus run at 125V for 2 hours or until the upper series of samples had run 
almost to the lower comb. The gel was removed from the tank and visualised under 
UV light with a photographic record retained for comparison.
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4.9.2 Lymphocyte MTHFR Assay
Lymphocyte preparations were made as described previously in Section 4.6.1 
(Lymphocyte cells: Collection and preparation.)
The lymphocyte cell pellets were removed from -20°C storage and allowed to thaw 
at room temperature. After addition of lOOpI distilled water, the preparation was 
thoroughly vortexed prior to sonication twice for 5 seconds at 2pm amplitude and a 
further centrifugation for 5 minutes at 7,500 x g . The supernatant was assayed for 
total protein using the method described in Section 4.8.3, and the protein 
concentration adjusted to 2mg/mi with distilled water for use in the assay.
Addition of 30pl of sample (or distilled water for the blanks) to each of two screwtop 
microtubes was followed by the incubation of one tube in a block heater for 5 
minutes at 46°C while the other remained at room temperature. On completion of 
this step, both tubes were placed on ice for the remainder of the subsequent 
reagent additions.
To each tube was added 579.6pl of 0.217M potassium phosphate buffer (pH 6.8) 
containing 10.5M L (+) ascorbic acid (Fisons)( the addition of which was made just 
prior to use); 50pl of 16.ImM EDTA (pH 7.0); 5.4pl [Methyl -’’'’C] methylene 
tetrahydrofolate (50pCi/ml) (Amersham); 5pL of 7.56mM flavine adenine 
dinucleotide (FAD) and 5Qpl of either treated or untreated sample or distilled water 
for the blank. This gave a final volume in the Eppendorff tube of 690pl. All tubes 
were mixed thoroughly and placed on ice until the same stage of preparation, at 
which time IQpl of 7mM menadione was added to all tubes. The tubes were 
vortexed thoroughly and incubated in a waterbath at 37°C for 1.5 hours, after which 
time they were again removed to ice. Derivatisation of the reaction product was 
accomplished by a mixture of 10pi of 1.0M formaldehyde; 200pl of 50pM 
Dimedone in 50% ethanol and lOOpI of 3.0M potassium acetate solution (pH 4.5 
with acetic acid), combined with heating at 95°C on a solid heating block for 15 
minutes. After cooling on Ice for 10 minutes, the mixture was removed with a 1.0ml 
Gilson pipette to 3.Omis of toluene (BDH) in a 15ml screwtop tube. Refluxing the 
tube with toluene from the upper phase of the preparation ensured the complete 
transfer of the derivative. This toluene preparation was vortexed for 15 seconds 
and centrifuged for 10 minutes at 900 x g in an lEC Centra GP8, with 2.Omis of the 
upper phase removed into a 20ml plastic scintillation vial containing 5.Omis of 
Ecoscint A scintillation fluid. The remainder of the upper and lower phases were
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also treated similarly in a second vial. All vials were counted on a Wallac 1407 
liquid scintillation counter for 2 minutes and the activity calculated as follows.
D P M (p ro d u c t-b la n k ) 20x10 1 1010 3 1
DPM (totabounts) ^ Ï T  50 2 P
where ; DPM = Disintegrations per minute
20 X 10'® M = Label concentration in 1.0ml final volume 
T = Time (hours)
P = Total protein (mg/ml)
1010 = final volume of stopped reaction (pi)
50 = sample volume (pi)
3/2 = Toluene fraction removed
I
FAD was prepared as a 7.56mM stock solution and dispensed into lOOpI aliquots.
Stored at ~20°C until use and thawed at room temp. Menadione was prepared as a 
7mM stock solution and dispensed into 200pl aliquots and stored at -20°C until 
use and thawed in the 
dark at room temperature until use. Aliquots were kept out of the light at all times 
during assay preparation.
.. ’-s’;4.10 Red cell folate and plasma vitamin B12 Estimation
The nutritional status of individuals participating in the study was assessed by the 
measurement of Folate and vitamin B12 using an ICN Simultrac-SNB Radioassay 
kit. This method simultaneously determines levels of folate and B12 by competitive 
protein binding, where the unlabelled folate or B12 competes with its labelled
ff
species for the limited number of available binding sites on the specific binder.
Therefore the level of radioactivity is inversely related to the concentration of in the 
patient sample. Both species are determined in a single assay tube since the two 
tracers [®^Co] for vitamin B12 and I] for folate produce energies at levels which 
can be easily separated by a two channel gamma scintillation counter.
 ^Aï
Î:Ï#
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compromised by this modification.
4.10.2 Radiolabelled assay
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II4.10.1 Sample and reagent Preparation
Plasma and red cells samples previously separated and stored as described in the 
procedure in Section 4.2 were thawed and mixed thoroughly by vortexing. The 
plasma samples were used neat in the assay. Red cell samples were diluted by 
adding lOOpI to 2ml of freshly prepared 0,2% ascorbic acid solution (w/v). This 1 in 
21 dilution was mixed thoroughly and left to stand at room temperature in the dark 
for 1.5 hours prior to assay. The haematocrit of the packed red cell samples was 
estimated using a Coulter ZM particle analyser, and the haemoglobin concentration 
was estimated by the cyanmethaemoglobin method described in Section 4.8.2. The 
results were noted for use in the later calculation of folate concentration. The 
reagent kit is stored at 4°C and brought to room temperature prior to use.
The tracer solution containing both of the isotopes was prepared by the addition of 
all of the contents of the dithiothreitol (DTT) reagent to the tracer solution. In order 
to maximise the number of samples analysed by the kit, the recommended 
volumes were scaled down by a factor of 2, after a small pilot study had confirmed
- ;that the quality of the results obtained and the method itself were not
All patient samples and standards for the radio-assay were assayed in duplicate, in 
batches of 120 tubes according to the following design:
'
Tubes 1,2 :- Total Counts
Tubes 3,4 :- Standard A (blank)
Tubes 5-16 :- Standards A-F (These corresponded to concentrations of 0-2000
pg/ml for Vitamin B12 and 0-20mg/ml for folic acid)
Tubes 17,18 ;- Normal range control
Tubes 19-118 :- Patient samples 
Tubes 119-120 :- Normal range control
A volume of lOOpI of each standard, control, patient red cell or plasma sample was 
added to the appropriate polythene tubes (Sarstedt), followed by lOOpI of the 
tracer to all tubes. The total counts were capped and no further reagent additions
were made. All tubes were vortexed thoroughly and left to stand at room 
temperature in the dark for 15 minutes, before the addition of lOOfxl of the 
extracting reagent, followed by vortexing and a further incubation at room 
temperature in the dark for 10 minutes. The bottle of Simultrac-SNB blank reagent 
was thoroughly mixed and 500^L added to tubes 3 and 4 only.
The bottle of Simultrac-SNB binding solution was shaken vigorously and 50Qp.l 
added to the remainder of the tubes. After vortexing, incubation was at room 
temperature in the dark for 60 minutes from the time of the last addition of the 
binder.
All tubes were capped and centrifuged at 1000 x g for 10 minutes at room 
temperature and the supernatant decanted, assisted by gentle tapping onto 
absorbent paper to remove any remaining drops. The pellets were counted in a 
Packard Cobra 5010 gamma scintillation counter using proprietary software to 
perform a dual RIA, 4 parameter Log-Logistic plotting of the standard curve and 
calculation of the patient sample folic acid and vitamin B12 concentrations after 
automatic blank subtraction using the values from tubes 3 and 4.
To ensure that the assay meets its required specifications, the trace binding of the 
0 standard (Bo) was calculated for each assay batch, by dividing the average of 
tubes 5 and 6 by the average total counts. Any assay falling to attain a Bo of 
greater than 35% was repeated.
4.10.3 Calculation
It is not routinely necessary to correct for plasma folate since this value is very 
small compared to that of red cell folate, however occasionally elevated plasma 
folate levels will occur. In this assay, if the plasma folate concentration was greater 
than 10% of the calculated red cell folate concentration a plasma correction was 
made to the red cell result.
An example of the red cell folate calculation was as follows
Plasma folate concentration = 32ng/ml 
Red cell haemolysate folate concentration = 3ng/ml
Haematocrit = 30%
Red cell haemolysate dilution factor = 21
Uncorrected red cell folate concentration _ 3 ^0 n ^^_ x_ _ ^  = 210ng/ml
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Since 32 n g/m I is greater than 10% of 210ng/ml, the red cell folate concentration 
must be corrected as follows:-
corrected ng/ml of red cell folate = (3.ng/ml x 2l) (32ng/ml (1 0.3))
0.30
= 135ng/ml
While the example quoted uses the haematocrit of the red cell sample to calculate 
the folate levels, assessment of the haemoglobin content of the sample as an 
alternative was also made.
In obtaining whole blood by postal methods for control and patient evaluation of red 
cell folate status, it is inevitable that a proportion of the samples may be 
haemolysed on receipt. The haemolysis renders the folate analysis questionable 
since the calculation requires that red cell integrity be maintained in assessment of 
the haematocrit by particle counting methods. In an attempt to avoid this the 
haemoglobin content was analysed and the value also assessed in the red cell 
folate calculation.
The accurate usage of the folate/ B12 dual labelled kit is highly dependent on the 
ability of the specified gamma scintillation counter to discriminate between 
disintegrations of the f  and [^^Co] Isotopes. The counting windows must be set 
such that there is minimal interference from the [’'^ ®l] in the f^Co] channel and 
vice-versa (i.e. spillover).
Assessment of spillover between the two channels was performed using and 
[®^Co] calibration standards. These were obtained from the West of Scotland 
Radionuclide Dispensary (Western Infirmary, Glasgow), as 0.2 and 0.02 
Megabecquerels (MBq) in 5ml volumes respectively, and diluted with distilled 
water to give working standards of -20,000 counts per minute for both, based on a 
recommended counting efficiency of 20% for [^ ^^ 1] and 50-60% for [^^Co]
The method to determine the spillover was as follows:-
1) in the [^ ^®l] channel of the gamma counter, count [^ ^^ 1] source = A; count 
[^^Co] source = B;
2) In the [®^Co] channel of the gamma counter, count [^^Co] source = C; count
100
Calculate spillover by [®^Co] in the [''^ 1^] channel by — x 100Lf
DCalculate spillover by [^ ^®l] in the [^^Co] channel by “ “ x 100A
Should spillover exceed 3% for either channel, the window setting for the channel 
must be narrowed or a mathematical method of correction applied.
4.11 Statistical Methods
All statistical calculations were performed on a Dell Dimension XPS P60 
microcomputer using “SPSS for Windows" statistical software package.
4.11.1 Medians and Centiles
The median is defined as the value of that observation which, when the 
observations are arranged into ascending or descending order of magnitude, 
divides them into two equal sized groups. As a descriptive method, the median 
maintains the advantage of being unaffected by extreme observations. The median 
may be determined from a frequency distribution where the data has been divided 
into classes of equal width, using the formula;-
Median = (5) '
where X = upper boundary of median class
X = lower boundary of median class 
F = upper frequency of median class 
f = lower frequency of median class 
P = median frequency i.e. (n+1)/2
Centiles other than the median value (i.e. the 50th centile) may be derived form the 
same set of data. The p th centile can be found by calculation of the (n - p) /100  th 
value.
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4:11.2 Mean, Standard deviation and Coefficient of Variation
The mean (or ‘arithmetic mean', X ) is a measure of central value for a series of 
ungrouped data and is defined as the total of the observations divided by the 
number of observations. It is calculated by the following formula:-
X
n
Z  X
n=1
n
where x = individual observations
n = number of measurements
The standard deviation (sd) is a measure of the dispersion or variability of 
observations around the central value and is described by the formula:-
sd JIp
The coefficient of variation (cv), is a method whereby the relative amount of 
variation of a set of values in a distribution may be calculated. This is independent 
of the absolute values and is expressed as a percentage by the following formula:-
sdcv = x 100%
X
where sd = standard deviation 
X = mean
To avoid the influence of outlying values for normally distributed data, the standard 
deviation can be estimated as the difference between the 90 '^' and 10^  ^ centiles 
divided by 2.56, and for Iogio normally distributed data from from the difference 
between the logio(90‘  ^centile) and logio(10th centile) divided bt 2.56.
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4.11.3 Gaussian Distribution
The Gaussian or normal distribution is defined as a symmetrical ‘bell shaped’ area 
with the formula:
X -  X
sd
s d V M
• e
where X = mean
sd = standard deviation
4.11.4 Probability Plots
Prior to using the mean and standard deviation for comparative statistics, it is 
important to know whether the data can reasonably be regarded as being sampled 
from an underlying Gaussian distribution. Even a sampling from a population 
whose shape departs from the Gaussian distribution, may still provide the basis for 
statistical analysis, providing the data is transformed. One method of data 
transformation is the use of the logarithmic value of the observed values rather 
than the actual values themselves. The probability plot provides a graphical 
method of examining departures from normality in both the non-transformed and 
transformed data.
For a given data set, all values are sorted into ascending order and each value 
assigned its centile value and from these the standard deviation may be derived 
from the normal distribution tables which give areas under the normal distribution . 
A graph is subsequently plotted with theses standard deviations (x-axis) against 
the actual values or the log transformed values (y-axis). A continuous line of the 
appropriate Gaussian or log Gaussian distribution, derived from the mean and 
standard deviation is plotted and the graph inspected for departures from the 
expected distribution.
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4.11.5 Kolmogorov ” Smirnov (KS) Test
The KS test is a non-parametric test of the cumulative distribution of a set of 
values, and is used to determine whether the an observed frequency distribution 
deviates from the expected one. The KS value , D, is the absolute value of the 
largest difference between the observed cumulative distribution and the theoretical 
cumulative distribution. Each value once converted to a standard deviation is read 
against the statistical tables and the cumulative area under the curve derived. A 
comparison with the predicted cumulative frequency distribution then allows the 
individual difference to be calculated for each value. The maximum difference, 
□max. is compared to the critical value from the statistical tables and the probability 
(p) derived for the appropriate sample size.
4.11.6 Log Transformation of data.
The term ’normal range’ has certain assumptions implicit within it, notably that 
results obtained for a test conform to the ‘bell-shaped’ statistical distribution or 
‘Gaussian distribution’. There is no reason to assume that a particular analyte will 
exhibit this distribution, and so for those which do not conform , a number of 
methods are available for mathematically processing raw data in order to more 
closely match the Gaussian distribution. Since the Gaussian or normal distribution 
is central to the concept of statistical inference, where even a sampling from a 
population whose shape departs from this may still provide the basis for statistical 
analysis. With a normal distribution there are fewer restrictions in the application of 
statistical methods, hence it is sometimes extremely valuable to make adjustment 
of these raw values to accommodate this, and yield derived data which 
approximates that of the classical normal distribution. One of these is the use of 
logarithmic transformation of the observed values rather than the values 
themselves.
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4.11.7 Correlation
The product - moment correlation coefficient ( r ), (also known as Pearson’s 
coefficient of correlation), describes the relationship between two mutually 
dependent variables, x and y  and is described by the formula:
Z ( x - x ) ( y - ÿ )
. s ( y - ÿ f )
The correlation coefficient, r , may have a range of values from 0 to ±  1, with 
positive and negative r values representing positive and negative correlation 
respectively. If plotted on a scatter diagram, the points begin to deviate from a 
perfect straight line as the correlation coefficient departs from +1 or -1. Values of 
close to 0 indicate virtually no association between the variables, while the values 
closer to ±1 , describe the magnitude of the association. To determine the 
statistical significance of the correlation, the r value may be compared at n-2 
degrees of freedom, to the appropriate statistical tables, the probability of 
significance obtained for the data-set under observation.
4.11.8 Students t-test
The parametric or Students t-test is used to compare two different populations, 
each with a known mean and standard deviation. Since this is a parametric test of 
significance, this test can only be used on populations which have been shown to 
be normally distributed. The t-test may be calculated using a number of varying 
formulae, depending on whether the data is paired or unpaired. The formula used 
in this instance is as follows:-
^ ^   |xl "  X2 I________________________________
J d in i *sd i )+ (n2*sd2 ))  ^(n2  +n2 ^ ^ ))")/( 1 /n i + 1 / n2 )
where :- ( n2  + n2  ~ 2 ) = degrees of freedom.
sdi and sd2 = the standard deviations from each population.
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4.11.10 Odds Ratio
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The null hypothesis states that there is no difference in the underlying populations 
for the two samples. The calculated t values were compared against the t-test 
statistical table using the appropriate degrees of freedom and the probability values 
(p) associated with the found value of t derived. On the basis of the probability, i.e. 
p<0.05, the difference of the two means is significant, and the null hypothesis 
rejected.
4.11.9 Chi-square ( x  ) significance test
The test Is used to compare differences between 2 independent proportions,
with the test statistic based on a measure of the overall differences between
-observed and expected frequencies displayed in a tabular form. If the observed 
and expected frequencies in each cell are equal, the value of x^ will be zero, and 
the greater the relative differences between the observed and expected 
frequencies, the greater the value of x^ ■ Both the observed and expected data 
must be numerically equal, and this requires adjustment of the data on the 
expected side of the table prior to calculation of the % statistic. After calculation of 
the value of ^  a statistical table of distributions may be consulted to determine the 
significance of the comparison at the 5 or 1% levels, with the appropriate degrees 
of freedom. The significance can then be used to accept or reject the null 
hypothesis. The formula used to calculate x^ is as follows:
. f
where: O = Observed numbers 
E = Expected numbers
if a factor is associated with the particular di sease or t ra it , then it should appear 
more commonly in the cases than in the controls. An estimate of the relative risk 
may be obtained, providing the cases and controls are random samples from their 
corresponding populations and the incidence of the particular event under study in 
the population is small. This approximation of the relative risk is called the “odds
a
ratio” (OR) and is calculated by dividing the ‘odds’ of a case exhibiting the trait by 
the ‘odds’ of a control exhibiting the trait. The odds of the event occuring is related 
to its probability, but the odds are defined as the number of individuals who 
experience the event, divided by the number of individuals not experiencing the 
event.
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CHAPTER 5. RESULTS
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5.1 Reference ranges
Enzyme activities estimated in a randomly selected group from the normal 
population, are not identical and will fall within a defined range of values, which 
may described by the term ‘normal range'. The use of the word ‘normal’ in this 
context may be misleading and the term ‘reference range’ should be used. A 
comparison of enzyme values between individuals of a given population depends 
on the use of a common unit of measurement. For example, in analyses where 
erythrocytes are used, the activity of the enzyme may be related to the 
concentration of haemoglobin within the haemolysate. In tissues, such as CV, 
amniotic fluid cells, and fibroblasts, comparisons may be made by expressing the 
activity against the protein concentration of the homogenised sample. Statistical 
evaluation of the parameters of the distribution of reference values is Important to 
ensure that appropriate statistical tests are used for comparisons between patient 
samples and controls
5.2 Purine study
5.2.1 Control Reference Ranges
The results of the KS test on the distribution of values obtained for each enzyme in 
the various tissues are shown in Table 5 - 1 .  The results show that for all 
enzymes in each of the tissue types studied logio transformation of values are 
gave a reasonable fit to Gaussian distributions. If untransformed values are 
considered, HGPRT and APRT in adult red cell samples show a significant 
departure (I.e. p<0.05) from a normal Gaussian distribution indicated that these 
enzyme activities were skewed to higher values. In order that that valid statistical 
comparisions of the red cell HGPRT and APRT activities could be made with the 
enzyme activities in the other tissue types, logio transformation was applied to all 
data, and the transformed values used for parametric testing. The graphical 
representation of the effect of this transformation for HGPRT and APRT on red 
cells controls can be seen in Figures 5 - 1 and 5 - 2 ,  with the corresponding 
probability plots in Figures 5 - 3 and 5 - 4.
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Figure 5 -1
Frequency distributions of adult red cell control (a) non-transformed HGPRT 
activity and (b) logio transformed HGPRT activity.
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Figure 5 - 2
Frequency distributions of adult red cell control (a) non-transformed APRT activity 
and (b) logio transformed APRT activity.
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Figure 5 - 3
Probability plots of (a) non-transformed and (b) Log io transformed HGPRT activity 
for adult red cells. The continuous lines are defined by means and standard 
deviations from the Gaussian distributions of each population.
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Figure 5 - 4
Probability plots of (a) non-transformed and (b) Log io transformed APRT activity 
for adult red cell controls. The continuous lines are defined by means and standard 
deviations from the Gaussian distributions of each population.
114
1I
%I
%
S
1
‘
Î I
The enzymes ADA, PNP and PRPP-S exhibited normal distribution statistics when 
values were logio transformed in all the tissues under examination, as did HGPRT 
and APRT for amniotic fluid cells, cultured and uncultured CV, fibroblasts, fetal 
red blood cells and cord blood red cells.
The construction of the reference ranges was based on the normally distributed 
data, for ease of comparison of the means and standard deviations of the control 
and patient populations under study. The subsequent data obtained is presented in 
Tables 5 - 2 to 5 - 8. Upper and lower limits of the reference range for each 
enzyme in each tissue can be set using the mean and standard deviation. For 
example, the mean ± 2 standard deviations indicate the 95% confidence limits for 
the given population.
Table 5 - 2
Adult red cell control reference range for HGPRT, APRT, ADA and PNP in 
nmoles / h r /  mgHb , and the HGPRT / APRT ratio. Logio transformed values were 
used to define the reference ranges, while the brackets indicate the antilogarithmic 
conversion back to concentration units, (n = number of samples in distribution).
HGPRT APRT HGPRT/
APRT
Ratio
ADA PNP
Median 92.7 14.1 6.7 55.5 2887
Logio Mean 1.973 1.166 0.807 1.732 3.471
(93.9) (14.7) (6.4) (53.9) (2958)
Logic sd 0.077 0.142 0.163 0.143 0.130
Range 
(M e a n  ± 2 s d )
65.9 - 133.9 7.6-28.2 3.0-13.6 27.9- 104.2 1625-5383
n 106 106 106 83 85
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Tab le 5 - 3
Uncultured CV control reference ranges for HGPRT and APRT, in nmoles / hr / mg 
protein and the HGPRT / APRT ratio. Logio transformed values were used to 
defiine the reference ranges, while the brackets indicate the antilogarithmic 
conversion back to concentration units, (n = number of samples in distribution).
HGPRT APRT HGPRT/APRT 
Ratio
Median 63.1 48.0 1.26
Logic Mean 1.751 1.638 0.110
(56.4) (43.5) (1.29)
Logic sd 0.239 0.257 0.235
Range
(Mean±2scO
18.7-169.4 13.3-141.9 0.44-3.8
n 54 48 48
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Table 5 - 4
Cultured CV control reference range for HGPRT and APRT in nmoles / h r/ mg 
protein and the HGPRT / APRT ratio. Logic transformed values were used to 
define the reference ranges, while the brackets indicate the antilogarithmic 
conversion back to concentration units, (n = number of samples in distribution).
HGPRT APRT HGPRT / APRT 
Ratio
ADA
Median 34.5 50.7 0.68 480.5
Logic Mean 1.538 1.690 -0.201 2.66
(34.5) (48.9) (0.63) (457.0)
Logic sd 0.399 0.348 0.289 0.180
Range
(M ean±2sd)
5.5-216.8 9.9 - 242.6 0 .17-2 .4 199.5 - 1047
n 57 53 51 37
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Table 5 - 5
Amniotic fluid cell control reference range for HGPRT and APRT, in nmoles / hr / 
mg protein, and the HGPRT / APRT ratio. Logic transformed values were used to 
define the reference ranges, while the brackets indicate the antilogarithmic 
conversion back to concentration units, (n = number of samples in distribution).
HGPRT APRT HGPRT /APRT 
Ratio
Median 164.9 139.1 1.190
Logic Mean 2.207 2.157 0.050
(161.1) (143.5) (1.12)
Logic sd 0.204 0.230 0.309
Range 
(Mean ± 2sd)
62.9-412.1 49.8-413.9 0.46 - 2.75
n 45 45 45
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HGPRT APRT HG PRT/APRT 
Ratio
Median 52.4 60.8 0.760
Logic Mean 1.631 1.719 -0.087
(42.7) (52.3) (0.818)
Logic sd 0.385 0.428 0.349
Range
(M ean±2sd)
7.3-251.8 8.6 - 443.6 0.16-4.1
n 18 18 18
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Table 5 - 6
Fibroblast cell control reference ranges for HGPRT and APRT in nmoles / hr / mg 
protein, and the HGPRT / APRT ratio. Logic transformed values were used to 
define the reference ranges, while the brackets indicate the antilogarithmic 
conversion back to concentration units, (n = number of samples in distribution).
S
:
I
I
:
Tab le 5 - 7
Fetal red cell control reference ranges for HGPRT and APRT in nmoles / hr / mg 
Hb, and the HGPRT / APRT ratio. Logic transformed values were used to define 
the reference ranges, while the brackets indicate the antilogarithmic conversion 
back to concentration units, (n = number of samples in distribution).
HGPRT APRT HGPRT / APRT 
Ratio
Median 71.9 31.7 2.4
Logic Mean 1.867 1.462 0.400
(73.6) (28.9) (2.51)
Logic sd 0.078 0.150 0.138
Range
(M ean±2sd)
51.4- 105.4 14.5-57.8 1.3-4.7
n 22 23 22
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Table 5 - 8
Cord blood red cell control reference ranges for purine enzymes in nmoles / hr/ 
mg Hb, and the HGPRT / APRT ratio . Logic transformed values were used to 
define the reference ranges, while the brackets indicate the antilogarithmic 
conversion back to concentration units, (n = number of samples in distribution).
HGPRT APRT HG PRT/APRT 
Ratio
Median 94.9 28.9 3.467
Logio Mean 1.970 1.424 0.548
(93.3) (26.5) (3.53)
Logic sd 0.085 0.208 0.184
Range 
(Mean ±  2sd)
63.1 - 138 17.7-69.2 1.5 - 8.2
n 39 39 39
The HGPRT / APRT ratio was estimated in all tissues and the distributions of the 
ratio in both the control and patient samples assessed as a potential discriminator 
between these populations. The median HGPRT / APRT ratio increased in the 
following order; Cultured CV (0.68) > Fibroblasts (0.76) > Amniotic fluid cells 
(1.19) > Uncultured CV (1.26) > Fetal red cells (2.40) > Cord red cells (3.47) > 
Adult red cells(6.70), indicating a difference in the specific requirements for purine 
moieties within different tissues with red cells giving higher HGPRT and lower 
APRT activities than other tissues.
The spread of the distributions in each tissue can be seen in the graphical 
representations of the populations in Figures 5 - 5  to 5 -1 1 .
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Figure 5 - 5
Distributions of HGPRT and APRT activity, and HGPRT / APRT ratio in adult red 
cells for individual control samples summarised in Table 5 - 2.
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Distributions of HGPRT and APRT activity, and HGPRT / APRT ratio in uncultured 
CV for individual control samples summarised in Table 5 -3 .
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Distributions of HGPRT and APRT activity, and HGPRT / APRT ratio in cultured 
CV distributions for individual control samples summarised in Table 5 -4 .
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Figure 5 - 8
Distributions of HGPRT and APRT activity and HGPRT / APRT ratio in amniotic 
fluid cells for individual control samples summarised in Table 5 - 5.
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Distributions of HGPRT and APRT activity and HGPRT / APRT ratio in fibroblast 
cell for individual control samples summarised in Table 5 - 6.
126
120
g  100
O)E
JZ
IoEc
>
o<
HGPRT APRT HGPRT/APRT
g
ccI—(T
CL<
OC
CLü
X
(n=22) (n=23) (n=22)
Figure 5 -1 0
Distributions of HGPRT and APRT activity and HGPRT / APRT ratio in fetal red 
cells for individual control samples summarised in Table 5 -7 .
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Figure 5 - 11
Distributions of HGPRT and APRT activity and HGPRT / APRT ratio in cord red 
cells from individual control samples summarised in Table 5 - 8.
In examining the relationships of the enzymes in each tissue studied, it was 
observed that for the adult red cells, a significant correlation (p<0.004) existed 
between ADA and PNP enzyme activities. No significant correlation (p>0.05) 
existed between the other enzymes in adult red cells, however significant 
correlation ( p<0.G5) was observed in cord erythrocytes for HGPRT and APRT. For 
the other tissues, significant correlation was observed in cultured CV (p<0.02), 
uncultured CV (p<0.01) and fibroblasts (p<0.01) between HGPRT and APRT, while 
for amniotic fluid cells and fetal erythrocytes, no significant correlation was found 
for HGPRT and APRT. (Table 5 -  9).
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5.2.2 Quality Control
In order to assess and compare the results obtained from any test it is essential 
that all assay parameters are controlled both within and between different batches 
of samples under investigation. Prior to the beginning of investigation of control 
ranges, or any other test/ control comparisons, 3 separate erythrocyte quality 
control samples were run in 3 assays and the mean and standard deviation of the 
HGPRT and APRT activities used as interim QC values in order to assess the 
reliability of the subsequent assay batches, until a more reliable estimate of the QC 
sample could be obtained.
Using 18 values , the working QC sample had a mean of 87.6 + 11.9 nmoles/ hr 
/ mg protein for HGPRT and 12.5 ± 2.9 nmoles/ hr / mg protein for APRT and a 
combined HGPRT / APRT ratio of 7.0 . These gave coefficients of variation (cv) for 
HGPRT and APRT assays of 13.6% and 23.2% respectively. During the period of 
patient sample analysis, internal QC results were compared individually to this 
working mean and the results within it were accepted or rejected on the basis of a 
± 2sd confidence limit. At the end of the study, a reappraisal of the internal QC for 
70 results from HGPRT and APRT assays with common samples showed that the 
inter-assay mean for HGPRT was 87.8 ± 12.8 nmoles/ h r/ mg protein, 16.1 ± 4.2 
nmoles/ h r/ mg protein for APRT and gave an HGPRT / APRT ratio of 5.9 ± 2.1 . 
Figure 5 - 1 2  shows the Levy - Jennings plot for both the HGPRT and APRT values 
over the course of the evaluation. While a small number of HGPRT values fall 
outwith the ±2  sd limits, the majority fall within the limits of the assay. With APRT 
a considerable number of results were above the mean and occasionally over the 
+2sd level. This may be explained by the initial working mean and standard 
deviations for APRT , being too low, possibly due to the small number of 
observations on which the means and sd’s were based. This is borne out by 
comparing the mean of 16.1 nmoles/hr/mg protein obtained from 70 values, with 
that of 12,5 ± 2.9 nmoles/ hr / mg protein obtained during the initial estimation. 
When the final mean and sd were applied retrospectively to the Levy-Jennings plot 
of the data it was clear that these new values were more appropriate, particularly 
for the APRT assay.
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Figure 5 - 1 2
Levy-Jennings plot of red cell internal quality control sample for HGPRT and APRT 
values, over the course of the control range evaluation. Means and sds are 
retrospectively applied from the final data of 70 values.
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was specified in 2 cases (Table 5 -10).
Enzyme activities (either HGPRT alone or HGPRT/APRT ratio) were assessed
5.2.3 Lesch-Nyhan Syndrome 
5.2.3.1 Pre-natal Diagnosis
During the period of the study, a total of 23 pregnancies were investigated in 15 
women known or suspected through family history to be carriers for the Lesch- 
Nyhan Syndrome. Three successive pregnancies were investigated in two patients, 
and two in each of four other obligate carriers, while nine other women had 
prenatal investigation in only one pregnancy. In 8 of these cases, CV was 
obtained from the first trimester of pregnancy and 3 from the second trimester while
amniotic fluid samples were obtained second trimester from 10 cases. No gestation
against the reference ranges derived in Tables 5 - 3 (uncultured CV), 5 - 4
(cultured CV) and 5 - 5 (amniotic fluid cells) as appropriate. Nineteen of these 
pregnancies gave normal enzyme activities, of which 13 had normal outcome ■
verified by the referring clinician; SFS, LHN, JHR, JJN(a), JJN(b), PMD, DSN(a),
Î
I
,
DSN(b), GWS(b), GWS(c), NFN(a), NFN(b) and K-SN. Two pregnancies miscarried 
(GTR, MOH) and four (underlined in table) had abnormal enzyme results (JRL(a),
JRL(b) and GWS(a), AGN(a)). The remaining 4 cases (DSN (c), AGN(b), CRE, and 
STA) all female, gave normal enzyme results with the outcome yet to be 
confirmed.
HGPRT activities in the affected pregnancies, ranged from 0.06 - 13.9% of the 
mean of the appropriate reference range, showing that in this series of affected 
cases, there was significant residual HGPRT activity. No post-mortem tissues were 
available for confirmatory assays from either of the terminations of patient JRL or 
from pateint AGN(a) , but cultured fibroblasts assayed from the index case gave a 
residual HGPRT activity of 9.9 per cent of normal fibroblast levels. The HGPRT/
APRT ratio in patients JRL(b) and AGN(a) showed a 31.5 and 112 fold decrease
■respectively, compared with the mean control ratios. Patient GWS(a) opted for a 
termination of pregnancy after enzyme results revealed a HGPRT activity of 9.0 % 
of normal. Post-mortem fibroblast tissue form this pregnancy was obtained, and 
gave an HGPRT activity of 13.8% , confirming the prenatal diagnosis results.
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Tab le 5 - 1 0
Prenatal diagnoses for the Lesch-Nyhan Syndrome. Underlined cases denote 
affected males. Key:- AFC = amniotic fluid cells; CV (U) = uncultured CV; CV (C) = 
cultured CV; Fibre = fibroblasts; Cord = cord red cells
Case Fetal Gest. Sample 
Kary. (wK-S) Type
HGPRT APRT HGPRT/APRT Outcome
(nmols/hr/mg protein or Hb) Ratio
SFS 46XX 17
LHN 46XX 11
GV(U)
c v  (C)
94.0
32.6
ND
116.6 0.28
normal female 
normal female
JHR 7 CV (U) 
cv (C)
61.8
247.5
ND
348 0.71 normal female
JJN(a) 46XX 16 AFC
JJN(b) 46XY 16 AFC
87.7
116.0
ND
110.1 1.05
normal female 
normal male
PMD 46XX 16 AFC 145.0 52 2.80 normal female
MOH 46 XY 11 CV(U)
JRLfal 46XY 10 CV (U
CV (C
JRLfbf 46XY 8
DSN(a) 46XY 
DSN(b) 46XY
DSN(c) 46XX
GTR 46XY
GWSfal 46XY 
GWS(b) 46XY 
GWS(c) 46XX
17
25
12
10
14
11
NFN(a) 46XX 14
CV(U
CV(C
AFC 
CV (U 
CV (C 
cv (C
CV(U 
CV (C
cv (U 
FIBRO.' 
CV(U 
CV (C 
CV (U 
CV (C 
CORD.
AFC
49.0
4.7
4.8
2.1
2.9
103.9
70.1
120.1
73.6
54.8
76.8
5.1
5.9
51.6
113.8 
35.4 
117.3
73.8
103.7
ND
ND
ND
ND
142.6
ND
38.5
95.9
105.8
ND
ND
ND
ND
39.1
134.1
30.1 
ND 
14
90.7
0.02
1.82
1.25
0.69
1.32
0.85
1.18
5.30
1.14
miscarriage
affected male
affected male
normal male
normal male 
? normal female
miscarriage
affected male 
normal male
normal female 
normal female
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Tab le 5 - 1 0  (continued)
Prenatal diagnoses for the Lesch-Nyhan Syndrome.
Key:- AFC = amniotic fluid cells; CV (U) = uncultured CV; CV (C) = cultured CV; 
Fibre = fibroblasts; Cord = cord red cells
Case Fetal
Kary.
Gest.
(wK-S)
Sample
Type
HGPRT
(nmols/hr/mg
APRT 
protein or Hb)
HGPRT/APRT
Ratio
Outcome
NFN(b) 46XX 15 AFC 210.4 107.5 2.00 normal female
AGN/al 46XY 16 AFC 1.0 184.3 0.01 affected male
AGN(b) 46XX 16 AFC 124.8 84.0 1.49 7 normal female
CRE 46XX 17 AFC 115.5 51.2 2.2 ? normal female
K-SN 46XY 16 AFC 152.7 84.1 1,81
Cord 115.1 15.0 7.4 normal male
STA 46XX - CV(C) 26.2 31.8 0.82 ? normal female
5.2.3.2 Post-natal and Adult Diagnosis
Table 5 - 1 1  shows the comparison obtained for the HGPRT, APRT,HG PR1^PRT 
APA^PNP data in red cells from postnatal diagnostic analyses involving 3 male 
Lesch-Nyhan index cases, 5 obligate carriers and 33 other relatives, compared to 
the control population, after logio transformation.
The Lesch-Nyhan index cases displayed significantly altered levels of HGPRT (t- 
test: p<0.001), APRT (p<0.001), HGPRT/APRT ratio (p<0.001), ADA (p<0.001) and 
PNP (p<0.05). Enzyme activities for HGPRT ranged from 0.95 - 4.9% of normal. 
These residual levels emphasise the fact that in this condition a complete 
deficiency of the enzyme is not always evident and that residual levels of HGPRT 
are often found. APRT levels were found to be above the upper levels of the 
reference ranges for all three index cases. ADA activity for the index case JMD 
were observed to be 168% of the upper limit if normal while the remaining two 
cases ( MBE and KHY) gave activities in the upper normal range. For PNP, cases 
MBE and KHY gave activities of between 170 and 175% above the upper limit of
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normal, while JMD had activities in the upper part of the normal range. Statistical 
comparisons of the HGPRT, APRT and ADA and PNP activities between the 
control and obligate carriers using a t-test, showed only HGPRT in these cases to 
be significantly different (p<0.02) from the reference range mean, while for the 
other family members, both HGPRT and APRT were found to be significantly 
different (p<0.01 and p<0.05 respectively). Despite the significantly reduced 
activities of HGPRT in these groups, the degree of overlap between the reference 
and control ranges, prevent this from being diagnostically useful. However this 
data was based on a small number of only 5 samples, further data may clarify this. 
Activities for ADA and PNP in both of these groups was found not to be 
significantly different from normal (p>0.05). Since only 5 obligate carrier cases 
were again available for this comparison, a larger data-set may be required to show 
whether the activities of these salvage pathway enzymes are altered in LNS. While 
all Lesch-Nyhan affected cases were distinguishable by HGPRT activity alone, the 
elevated APRT levels found in these patients allowed the HGPRT/APRT ratio to be 
used to better differentiate between the affected and control populations.
Figures 5 - 1 3  to 5 - 1 7  show the graphical distributions of these populations.
i
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Controls Index Cases Obi. Carriers Others 
(n=106) (n=3) (n=5) (n=35)
Figure 5 - 1 3
Distribution of red cell HGPRT activity for Lesch-Nyhan index cases, obligate 
carriers and other family members
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Figure 5-14
Distribution of red cell APRT activity for Lesch-Nyhan index cases, obligate 
carriers and other family members
137
2<
(T
CLOX
•ÿ,;
Controls Index Cases Obi. Carriers Others 
(n=106) (n=3) (n=5) (n=35)
Figure 5 - 1 5
Distribution of red cell HGPRT / APRT ratio for Lesch-Nyhan cases, obligate 
carriers and other family members.
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Others
Figure 5-16
Distribution of red cell ADA for Lesch-Nyhan cases, obligate carriers and other 
family members.
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Figure 5-17
Distribution of red cell PNP for Lesch-Nyhan cases, obligate carriers 
and other family members.
5.2.4 Gout Study
HGPRT, APRT and PRPP-S activities in the series of all controls and gout patients 
is summarised in Table 5 -12.
This data was subsequently broken down and analysed by sex to determine 
whether any differences could be discerned between males and females in both 
the control and patient populations. This data is summarised in Table 5 - 1 3 ,  but 
does not include 5 samples which appear in Table 12 due to lack of information 
regarding the gender for these patients. Application of the KS test to the range of 
enzyme activities found in the 54 patients analysed, indicated a reasonable fit to 
loQio Gaussian distributions for HGPRT, APRT, HGPRT/APRT ratio and PRPP-S 
with p values of 0.83, 0.27, 0.81 and 0.91 respectively. No significant differences 
were found for the KS test when applied to the data after separation with regard to 
gender. Comparison of the means of the control and patient ranges (Table 5 - 1 2 )  
for each enzyme (t-test) showed a significant difference for HGPRT (p<0.002) and 
HGPRT / APRT ratio (p<0.003), while APRT and PRPP-S showed no significant 
difference. The reference ranges for the control and patient groups show a marked
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degree of overlap, which indicates that these red cell enzymes cannot be used with 
any confidence in distinguishing these populations.
When the data was broken down by gender, the statistical difference for HGPRT 
found in the total population was associated with males only (p<0.05), with no 
corresponding significant difference in APRT or PRPP-S activities. For female gout 
patients, only APRT was found to be statistically significantly different (p<0.05). 
While the HGPRT activity for females was not found to be significantly altered 
(p=0.068), it contributed to a significant difference for the HGPRT / APRT ratio in 
this population. These gender differences may be due in part to the number of 
values used in the calculations ( 45 for males and 9 for females) and more data are 
required to verify this result (Table 5 -1 3 ) .
Uric acid data on these patients was not Included in this evaluation since most of 
the subjects under study were on medication for hyperuricacidemia at the time of 
sampling.
From the entire series of 54 gout patients, two male individuals FFR and TGR 
gave results of around 50% of the mean of the red cell HGPRT control range. 
Although these patients gave HGPRT activities of 49.3 and 42.7 nmoles / hr / mg 
Hb, respectively (i.e. below the lower limit of the HGPRT reference range), their 
HGPRT / APRT ratios of 4.7 and 6.4 were within the normal range. Of the series 
of 54 patients with gout, these two had polyarticular gout, whereas the remaining 
52 presented with gout of an idiopathic nature. These results suggest that HGPRT 
activity alone may be useful in classifying these patients whereas the 
HGPRT/APRT ratio is not. The distributions of HGPRT and APRT associated with 
these populations are presented in Figures 18 and 19, while Appendix B shows 
the entire dataset for these patients.
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Figure 5 - 1 8
Distribution of HGPRT activity in nmoles/ hr/ mg Hb for controls and gout patients, 
where 1 ™ Controls (Male), 2 = Controls (Female), 3 = Gout (Male), 4 = Gout 
(Female). The symbol o  Indicates the position of the two polyarticular patients 
FFR and TGR .
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Figure 5 -19
Distribution of APRT activity in nmoles/ hr/ mg Hb for controls and gout patients, 
where 1 ~ Controls (Male), 2 ”  Controls (Female), 3 = Gout (Male), 4 = Gout 
(Female)
One factor which was not tested in this study, was the effect of the medication 
which most of the patients were on at the time of the blood donation (data not 
shown). The pharmacological regimes varied from individual to individual and 
included a wide spectrum of drugs, the most common being allopurinol, related to 
the specific symptoms of each patient. Due to this fact, it is unclear whether the 
data obtained here in terms of the purine enzyme activities for these individuals is 
modified by the specific medication being taken.
The enzyme PRPP-S was analysed in all gout patients and compared with a 
subset of the same adult red cell control population used for HGPRT and APRT 
estimations to determine if PRPP-S superactivity could be implicated as a cause of 
gout in these patients. Examples of the chromatograms obtained from the HPLC 
run of the standards and samples used to calculate PRPP-S levels in the control 
and patient populations are shown in Figures 5 - 20 and 5 -21, and the range of 
enzyme activities in patients and controls in tables 5 -1 2  and 5 -  13.
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36|aM ADP 70|iM ADP 140[a,M ADP
Figure 5-20
HPLC chromatograms and buffer gradients of 35, 70 and 140^M ADP standards.
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Figure 5 -21
HPLC chromatograms and buffer gradients of AMP, ADP, ATP production by 
PRPP-S, after 10 minutes and 30 minutes incubation of the red cell sample.
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As with HGPRT and APRT, logio transformed data was used and this gave a 
reasonable fit to a Gaussian distribution. No statistical significance was observed 
for PRPP-S activity (p>0,05), either using the entire patient group or when 
individual male and female groups were analysed, indicating that the cause of the 
condition was unlikely to be due to PRPP-S superactivity.
Patient MHD, a 2 year old male who presented with elevated uric acid and 
dyskinetic cerebral palsy, was investigated regarding a possible diagnosis of 
Lesch-Nyhan syndrome by HGPRT and APRT analysis. There was no evidence of 
an HGPRT deficiency with red cell HGPRT and APRT activities of 114.9 and 16.6 
nmoles /  hr /mg Hb respectively, translating to an HGPRT / APRT ratio of 6.9. 
However, when PRPP-S was investigated, the enzyme activity was 1.26 pmoles / 
hr / mg Hb, which was 3.7 times the mean of the red cell reference range 
suggesting PRPP-S superactivity. Unfortunately, due to non-compliance, no further 
blood samples could be obtained and further attempts to investigate this patient 
were unsuccessful. The results obtained for this study suggest that while HGPRT 
may be useful in determining certain types of gout, PRPP-S superactivity should 
be considered as a cause in those cases where the diagnosis is less obvious. The 
graphical representation of the distributions of PRPP-S activities is shown in Figure 
5 -2 2
>-f-g0.8 
g
Dl
£  0.4
All Female Male Control Population All Female Male Patient MDH Gout population
Figure 5 - 2 2
Distribution of PRPP-S activity in pmoles /  hr/ mg Hb for controls, gout patients 
and a diagnostic case (Patient MHD).
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6.2.5 ADA and PNP
5.2.5.1 Controls and Patients
The results of the assessment of enzyme activity in individuals at risk for ADA and 
PNP disorders are shown in Tables 5 - 1 4  and 5 - 1 5  with the graphical 
representations of the distributions shown in Figures 5 - 2 3  and 5 - 24. Of the 
patients initially presenting for ADA assessment; 17 had long standing fungal or 
viral infections (GST, JGN, RHS(a) and (b), ASD, CBN, JLW, AWR, RML, SGD, 
DRE, JSH, SBN, ABN, KMT, UIL, MMC; DGN) ; 2 had ataxia telangectasia (GFS, 
RCS); 1 had Graft versus Host disease (DME (a) and (b)); 6  individuals from 4 
families had a history of ADA deficiency ( TGG, JRS, RMN, JTD, SRN, MMH); 3 
individuals from one fam ily initially suspected of ADA deficency, were subsequently 
found to have PNP deficiency ( DOD, LCD, KOD(a) and (b)) and 1 patient had an 
uncertain diagnosis (SBN). For those initially presenting for PNP investigation, 5 
had recurrent infections (LID, CFR, CCY, CCR, CRE); 5 had ataxia (LFY, NPE, 
SBT, DRD, GST); 2 had unexplained diplegia (LDN, IMD); lhad athetosis (AMN); 1 
patient with cerebral palsy. Also, 3 members of a family with PNP deficiency were 
investigated (PFK, FFK, IFK) as were 4 members of the fam ily who initially 
presented with ADA deficiency (MIL, ELB, MOL, KO (c) and (d)). The red cell and 
CV reference ranges were constructed using the same samples as those used in 
the evaluation of normal ranges for the Lesch-Nyhan study. Where possible, ADA 
and PNP analyses were performed in tandem on any samples obtained for 
investigation of a suspected immunodeficiency disorder. Of the patients referred 
for ADA investigation (Table 5 - 14), 3 (TGG, JTD, MMC) had a complete 
deficiency of ADA activity confirming a diagnosis of severe combined 
immunodeficiency disease. Child TGG presented at 14 months with recurring 
chest infections, neutropenia, failure to thrive and hepatosplenomegaly. 
Investigations showed a complete deficiency of ADA activity with normal levels of 
PNP, and the child subsequently died aged 2 years. The sister of this index case, 
JTD , born at 36 weeks gestation, initially showed good APGAR scores, but when 
tested was shown to have a complete deficiency of red cell ADA activity with 
normal levels of PNP. The pedigree of fam ily GG is shown in Figure 5 -  25. All 
other patients had ADA activities above the lower end of the appropriate reference 
range (Tables 5 - 2 ,  5 - 3 ,  5 - 4 ) ,  while several had ADA activities greater than +2
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SDs beyond the mean. There was one prenatal diagnosis at 15 weeks gestation 
based on an analysis of ADA activity in cultured amniotic fluid cells. The use of 
intra-assay AF cell controls confirmed that an ADA deficiency could be excluded in 
the fetus. There was no evidence of ADA carrier status in any of the patients 
tested.
Table 5-14
Summary of affected and at-risk individuals referred for ADA investigation. 
Activities for red cells are expressed as nmoles / hr / mg Hb, and nmoles / hr / mg 
protein for Amniotic fluid cells, CV and fibroblasts. Affected cases are underlined. 
Key:- RBC = Red cells; AFC = Amniotic fluid cells; FIBRO. = Fibroblast cells.
NAME SEX AGE. CELL TYPE ADA PNP COMMENTS
TGG M 14 months RBC 0 4085 ADA deficient
J IB F < 1 month RBC 0 2292 ADA deficient
JRS M 31 yrs RBC 65.0 1995 Normal ADA/P NP
RMN F 21 yrs RBC 61.6 2340 Normal ADA/P NP
GST M 8 yrs RBC 72.5 2292 Normal ADA/P NP
JGN M 7 months RBC 101.6 3957 Normal ADA/P NP
SRN F AFC 282 - PND: Normal activity In fetus
RHS(a) M < 1 month RBC 82.9 Normal
RHS(b) M 3 months RBC 103.8 3048 Normal
ASD F 18 months RBC 122.6 2402 High Normal ADA
CBN F 2 yrs RBC 134.9 - High Normal
JLW F 1 month RBC 59.9 2141 Normal
AWR F 9 months RBC 81.6 3517 Normal
RML M 8 yrs RBC 64.8 4629 Normal
GFS M 12 yrs RBC 106.6 4356 High Normal ADA
8GD F - RBC 117.2 2526 High Normal ADA
ORE M 3 yrs RBC 47.3 2104 Normal
RCS M 5 yrs RBC 105.2 3867 High Normal
JSH F 6 months RBC 52.2 2337 Normal
SBN F 3 months RBC 69.9 - Normal
ABN F 2 months RBC 66.4 3174 Normal
KMT F < 1 month RBC 82.8 4154 Normal
MMH F 22 yrs RBC 46.0 - Normal
UlL M 4 months RBC 97.3 2734 Normal
DME(a) M 2 months RBC 117.3 - High Normal
DME(b) M 4 months FIBRO. 668.9 - High Normal
MMC M - RBC 0 4612 ADA deficient
DGN F 9 yrs RBC 66.0 2444 Normal
SBN F - RBC 106.8 - High Normal
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Table 5 -15
Summary of affected and at-risk Individuals referred for PNP Investigation. 
Activities for red ceiis are expressed as nmoies / hr / mg Hb, and nmoies /  hr / mg 
protein for Amniotic fluid cells, CV and fibroblasts.
Key:- RBC = Red cells; CCV = cultured chorionic villi; FIBRO = Fibroblast cells.
NAME SEX AGE CELL TYPE ADA PNP COMMENTS
Family CD
KOD (a) F 27 yrs Red Cells 40.9 1739 PNP carrier
KOD fb) F low k s CCV 381.2 0 PNP deficiency
KOD (c) F ^«.st \Oujki: CCV 284.4 743 Normal PNP/ADA
KOD (d) F CCV - 2804 Normal PNP
DOD M - RBC 66.8 1803 PNP carrier
LOP F 3 yrs RBC 257.1 0 PNP deficiency
MIL M 3 months RBC 1495 PNP carrier
ELB F 39 yrs RBC - 3727 Normal PNP
MOL M 30 yrs RBC - 1626 PNP carrier
Family FK
PFK M - FIBRO 546 6.5 PNP deficiency
FFK F 42 yrs RBC - 1316 PNP carrier
IFK M 39 yrs RBC - 1319 PNP carrier
Others
LDN F 2 months RBC - 2000 Normal PNP
LID F 5 yrs RBC “ 2046 Normal PNP
CFR F 1 month RBC - 2606 Normal PNP
AMN M 1 month RBC - 3300 Normal PNP
LFY F 5 yrs RBC - 2471 Normal PNP
NPE F 2yrs RBC - 2028 Normal PNP
IMD M 4 yrs RBC - 3450 Normal PNP
ZPY F 2 yrs RBC - 1486 ?PNP carrier
COY M 2 yrs RBC 4088 Normal PNP
CCR M 3 yrs RBC 3277 Normal PNP
SBT M 2 yrs RBC 3567 Normal PNP
CRE M < 1 month RBC 91.4 4800 Normal PNP
DRD F 1 yr RBC 2100 Normal PNP
GST M 1 yr RBC 3500 Normal PNP
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Figure 5 - 2 3
Distributions of red cell ADA activity in control and patient samples.
Activity in nmoles / hr / mg Hb. The annotations, JTD and TGG indicate those 
patients found to have a complete deficiency of ADA.
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Figure 5 - 24
Distributions of red cell PNP activity in control and at-risk samples. Activity in 
nmoles /h r / mg Hb.
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Figure 5 - 25
Pedigree for Family GG
Key: 13 = untested male; ®  female; ®  = affected female; ^  = affected
male (deceased). The arrow denotes the proband.
Of the patients referred for PNP investigation (Table 5 - 1 5 )  around half of the 
cases originated from two families in which PNP deficiency was later identified.
Family OD
The pedigree of Family OD is shown in Figure 5 -  26. Child LOD presented with 
neutropenia, lymphopenia and an absence of cell cluster designation markers, CD4 
and CDS. ADA activity was very high at 257.1 nmoles / hr /mgHb, but there was a 'complete deficiency of PNP. Blood samples from the mother and the father of this 
child (KOD(a) and DOD) tested within the red cell reference range for ADA, but 
were found to have levels of 59% and 61% of the mean of the PNP controls, 
placing them in the extreme lower end of the red cell reference range, and 
confirming their obligate carrier status. Further testing of red cell PNP activity in two 
siblings of the affected child (MIL and MOL) gave activities of 51% and 53 % 
respectively, and these levels are consistent with carrier status. Prenatal diagnosis 
was carried out on CV in 3 further pregnancies for the mother (KOD (b), KOD (c), 
and KOD (d)). The first of these showed a complete deficiency of PNP indicating
■an affected fetus and the parents opted for termination. In the second pregnancy,
PNP activity was found to be low at 743nmoles / hr / mg protein (equivalent to 25% 
of the control mean). This was interpreted as possible carrier levels thus excluding 
a deficiency of PNP activity and the pregnancy proceeded to term. The third 
pregnancy exhibited normal PNP activity and also proceeded to term. The ADA 
results where performed on these samples, showed normal levels. No further 
samples could be obtained in these prenatal diagnostic cases to allow follow up 
and confirmation of the diagnosis, however karyotype analysis showed them to be 
male. Patient ELB, an aunt of the index case had normal red cell PNP activity.
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Figure 5 - 2 6
Pedigree for family OD.
Key:- 13 = untested male; ®  = untested female; O = normal female; ©  = carrier
female (arrow denotes proband); O  = normal male; E  = carrier male; ^  = 
termination (male);
Family FK
The pedigree of fam ily FK is shown in Figure 5 -  27. In fam ily FK a diagnosis of 
PNP deficiency immunodeficiency disease was suspected only after the index case 
(PFK) was deceased. A fibroblast cell line had been stored in liquid nitrogen. Blood 
from the parents gave red cell PNP activities in the carrier range, and the cell line 
was reconstituted for investigation of PNP activity in the index case.
Due to the lack of fibroblast control material, no formal reference range for PNP in 
cultured cells was available. Therefore, intra-assay fibroblast controls were used to 
verify whether the patient sample was deficient for ADA and PNP activities. The 
cell line from subject PFK gave a result of 6.5 nmoles / hr / mg protein for PNP 
activity and 646 nmoles / hr /mg protein for ADA activity with the corresponding 
control values of 353.8, 179.1 and 286.6 for PNP and 623, 543 and 903 for ADA, 
confirming a diagnosis of PNP deficiency.
All other patients investigated for PNP deficiency had levels within the normal 
reference (Table 5 - 2 )  except for 1 case (ZPY), where carrier levels were found.
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Figure 5 - 2 7
Pedigree for family FK.
Key:-; 0 = carrier female ; E = carrier male; M  = affected male
5.3 Pteridine study
5.3.1 Results of molecular analysis of the 677C->T mutation
The resulting 198 and 175 base pair fragments obtained from the PCR and digest 
of the MTHFR gene were exam ined for all control and at risk individuals for the 
677C->T mutation. Figure 5 - 28 shows the relative positions of each band for each 
group studied, while Table 5-16  gives the genotype frequencies for each study 
group.
The results indicate that within the study population of NTD affected individuals, 
the frequency of the MTHFR thermolabile (+/+) allele (10.0%) is not significantly 
different from that of the controls (11.8%). However, the mothers of affected 
individuals had a significantly higher frequency of the +/+ genotype (15.3%) than 
the controls (p<0.01), suggesting that possession of this MTHFR genotype in the 
maternal environment may be a risk factor in the development of some NTDs. 
Neither the fathers (8.3%), nor other family members (11.1%) had significantly 
different frequencies of the MTHFR +/+ genotype compared to the controls. 
Relative to  the controls, the odds ratio for the presence of the +/+ genotype was 
higher only in the mothers group (OR 1.3). Similar results are obtaind when the 
all<ste frequencies in each study group are compared. The relative proportions of 
the MTHFR + and MTHFR - a l ld is  in the controls, NTD affected, mothers, fathers 
and other groups were: 0.36, 0.44, 0.31, 0.28 respectively. Only in the mothers
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group was there a statistical significant increase (% p<0 .0 1 ) in the frequency of the 
MTHFR allele.
198 bp 
175 bp
SI 82 S3 S4 S5
Figure 5 - 2 8
Ethidum bromide stained 2% agarose gel showing PCR products corresponding to 
the fragments of MTHFR gene after Hinf1 digestion (198 and 175 base pair). 
Lanes S1-S5 correspond to subject samples, while +/+, -/- and +/- are 
homozygous thermolabile, homozygous normal and heterozygote control samples 
respectively.
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Tab le 5 - 1 6
Genotype frequencies for the MTHFR allele in the study population. Values in 
brackets indicate the relative percentages of each genotype.
MTHFR
Genotype n
Homozygous
Normal
(-/-)
Heterozygous
(+/-)
Homozygous
Thermolabile
(+/+)
Odds
Ratio
(OR)
(+) Allele 
frequency
Controls 262 126 (48.1) 105 (40.0) 31 (11.8)
NTD Affected 40 15(37.5) 21 (52.5) 4 (10.0) 0.9 0.36
Mothers of NTD 
pregnancies
85 24 (28.2) 48 (56.4) 13 (15.3) 1.3 0.44
Fathers of NTD 
pregnancies
35 16 (44.4) 16 (47.2) 3 (8.3) 0.7 0.31
Other family 
members
36 20 (55.5) 12(33.3) 4 (11.1) 0.9 0.28
5.3.2 Lymphocyte MTHFR activities
Observation of raw values showed that the MTHFR activities were positively 
skewed to higher values. Log^o transformation gave a reasonable fit to Gaussian 
distributions as confirmed by KS testing (data not shown), with the subsequent 
means, sds and reference ranges defined from this logio transformed data. The 
lymphocyte MTHFR activities and % residual activity after heating for the various 
populations are summarised in Table 5 - 1 7 ,  while graphical representations of the 
% residual activities are shown in Figures 5 - 2 9  to 5 -31 .
From Table 5 -1 7  it can be seen that there is a marked reduction in MTHFR activity 
associated with the thermolabile allele (+) . However the extent of the reduction in 
MTHFR activity in the individual patient study groups must be interpreted with
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caution as the number of individuals in each +/+ group is small. Inspection of the 
combined (overall) data suggests that specific activity In heterozygous (+/-) 
individuals is around 75% of the homozygous normal (-/-) levels, and in the 
homozygous thermolabile (+/+) group, 55% of -/- levels suggests that one 
thermolabile allele has approximately half the activity of one normal (-) allele.
If the data are considered within each of the individual study groups compared to 
the normal -/- control levels, the lowest MTHFR activities were found associated 
with the +/+ NTD affected group (21%). The + / - NTD cases had a mean activity 
of 52% of controls while the normal -/- NTD cases had 75% of -/- MTHFR activity. 
The MTHFR total activity in both the +/+ and +/- individuals in the affected group 
were significantly different from the -A control group (t test: p<0.005 and p<0.02 
respectively). A similar trend was found when the activities in each of the maternal 
MTHFR genotypic groups were compared with the -A control activity. These varied 
from 25.6% for the +/+ mothers (p<0.001) , through 53% for the +A mothers 
(p=0.001), to 54% for the -A mothers. The +/+ fathers had 38.5% of normal -A 
activity and the +/+ other relatives, 40.2%. The significantly higher proportion of 
homozygosity for the +/+ MTHFR allele amongst the mothers of NTD children (OR 
1.3, Table 5 -16)  and the significantly reduced activity associated with this allele In 
both mothers and affected individuals support the hypothesis that at least some 
cases of NTD may be due to a reduced utilisation of folate caused by a low activity 
enzyme variant.
Heating serum samples at 46°C for Sminutes before measurement of MTHFR 
activities showed little diference in the extent of the reduc tion in activity between 
each genotypic group. Overall , -A individuals retained 38.4% of the starting 
activity, +A individuals 37.8% and +/+ individuals 34.0%. Therefore under the 
conditions used In the study, the MTHFR + allele does not appear to be 
significantly more heat labile than the normal - allele.
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Figure 5 -29
Residual MTHFR activity after heating for 5 minutes at 46° C for individuals with 
homozygous normal genotype. MTHFR activity in pmoles formaldehyde / hr/ g 
protein
Key:- #  = Total MTHFR activity O = Residual MTHFR after heating
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Figure 5 - 30
Residual MTHFR activity after heating for 5 minutes at 46° C for individuals with 
heterozygous genotype. MTHFR activity in pmoles formaldehyde / h r / g protein. 
The annotated data in brackets indicates outlying values.
Key:- #  -  Total MTHFR activity O = Residual MTHFR after heating
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Figure 5 - 31
Residual MTHFR activity after heating for 5 minutes at 46° C for individuals with 
homozygous thermolabile genotype. MTHFR activity in pmoles formaldehyde/ h r/ 
g protein
Key:- #  = Total MTHFR activity O = Residual MTHFR after heating
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5.3.3 Enzymatic analysis of Lymphocyte MTHFR
The method used in the evaluation of the lymphocyte MTHFR activity (Section 
4.9.2) was a modification of that described by Engbersen et al (1995). Prior to its 
application in the analysis of samples from the MTHFR study, a number of assay 
parameters were assessed and optimised where necessary. In addition, to the 
estimation of the MTHFR activity in lymphocytes, the plasma component of the 
whole blood sample obtained was also examined for MTHFR activity.
5.3.3.1 Optimisation of the MTHFR assay
5.3.3.1 .(i) Concentration of f'^C] Methylenetetrahydrofolate substrate
The original radiolabelled substrate concentration was assessed to suit the 
conditions of the modified assay protocol. A volume of 5.4|itl was calculated to give 
around 600,000 counts in the final assay mix and a Km of at least 18pm/l as 
specified in the original method. Results for the Lineweaver-Burk equation showed 
that the Michaelis constant (Km), defined as the activity of an enzyme at half 
maximal velocity, was 26.5pm/l. (Figures 5 - 3 2  and 5 - 33).
Evidence of significant hydrolysis of the radiolabelled substrate caused by a 
working menadione concentration of 3.5mM, prompted further evaluation of the 
optimum concentration of menadione require to maintain a suitable level of activity 
of the MTHFR assay. Ï
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Figure 5 - 32
Velocity (V) versus substrate concentration [S] plot for the 
Methylenetetrahydrofolate radiolabelled substrate.
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Figure 5 - 33
Lineweaver-Burk plot for data based on the reciprocal velocity (v) and substrate 
concentration ([s]) data from Figure 31 for [ '^^C] Methylenetetrahdrofolate 
radiolabelled substrate. The Michaelis constant (Km) extrapolated from the graph 
was 0.3906 which was calculated to be 25.6 |amoles/l.
5.3.3.1.(111 Menadione Concentration
Assessment of the optimal menadione concentration required for use in the 
modified lymphocyte MTHFR assay, indicates that the maximum enzymic activity 
occurs at a final assay concentration of 0.01 mM (10|xm), giving a 40% turnover of 
product compared to the initial substrate. However, since this value is very close to 
inflection point of the curve, a higher concentration, of 0.1 mM (corresponding to an 
original stock concentration of 7m M) , was used in the assay .
Figure 5 - 3 4  shows that this modification still gives a significant difference 
between the blank and the sample levels of activity for this lymphocyte control. This 
is in marked contrast with the menadione concentration of 3.5mM specified in the 
original method.
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The re-assessed menadione concentration of 0.1 mM was used in a routine MTHFR 
assay to evaluate the enzyme activity of the lymphocyte control under the 
thermolabile conditions specified in Section 4.9.2. The results show that MTHFR 
residual activity for separate aliquots of the lymphocyte control gave a total activity 
of 39.6 fxm formaldehyde / hr / mg protein respectively corresponding to 6 6 % 
residual activity after heating.
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Figure 5 - 3 4
Graph for the lymphocyte control sample and the sample blank over a range of 
menadione concentrations. Key:- #  = sample; o  = blank.
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5.3.3.1, Protein concentration of sample
The concentration of total protein in the sample used for MTHFR enzyme assay is 
of importance, since the least protein required for measurable and reproducable 
activity compared to the blank, the more sample is available for subsequent 
analysis. This also has Implications for the optimal sample volume. The method 
described by Rosenblatt et al (1977) specified an optimal protein concentration of 
between 0.3 - 0.6 mg/ml, albeit in a fibroblast sample. Using dilutions of the 
original lymphocyte control preparation, results suggest that a sample consisting of 
a total protein concentration of 6.4mg/ml diluted down to 0.2mg/ml in distilled 
water, gave a good signal to noise ratio at about 2.1 mg/ml, appropriate to a x3 
dilution factor respectively. Concentration of protein at these levels was considered 
appropriate, as a compromise of maximal dilution and maximal product produced to 
give an adequate signal for scintillation counting (i.e around 35,000 dpm ). (Figure 
5 - 35).
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Figure 5 - 35
Disintigrations per minute of lymphocyte control sample product for varying 
dilutions of the total protein concentration.
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5.3.3.1.(iv) Sample volume
From previous experiments it is apparent that lymphocytes can be used in 
estimation of MTHFR estimation. While Engbersen at al (1995) suggest a volume 
of sample of 250jil and an incubation time of 20 minutes. Due to the nature of the 
blood collection process in this study and the inherent delays in receipt and 
separation of the sample constituents, yields of lymphocytes tend to be somewhat 
reduced compared to those obtained from fresh blood. Consequently, the protein 
concentration and hence the volume of sample used is a primary concern in 
assessment of this assay. A sample volume of 250|il as specified in the original 
report, is greater than would be wished for this assay given the lymphocyte 
purification protocols. Figure 5 - 3 6  shows the effect of a decrease in the volume 
of sample to a proposed working volume of 50]il while increasing the incubation 
time to 1.5hours. This provides adequate turnover of the MTHFR enzyme, while at 
the same time maintaining a low background count for the blank.
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Figure 5 - 3 6
Comparison of sample volume for use in the lymphocyte MTHFR assay during 5 
hour incubation.
Key:- O - lOOpI sample ; A - 50^1 sample; # - lO^il sample ;
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5.3.3.1.(v) Thermal stability
Thermal stability is a crucial element in the evaluation of the lymphocyte MTHFR 
enzyme assay. The original method by Engbersen et al (1995) stipulates a 
sample pre-incubation of 5 minutes at a temperature of 46°C for a residual activity 
of 40% for the control population. There is however no specification as to whether 
this was for sample alone or in pre-incubation with the auxilliary reagents. This 
aspect of the protocol was evaluated over a range of temperatures involving 
sample In a total reaction volume (minus FAD and menadione, which were 
considered too labile) and with sample alone. There appears to be no difference in 
the resulting residual enzyme activities, with both protocols indicating that pre- 
incubation for 5 minutes at 46°C was suitable for the prospective enzyme assay 
(Figure 5 - 37 ) .  For ease of assay preparation, pre-incubation of the sample prior 
to addition of the auxilliary reagents was the preferred option.
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Figure 5 - 3 7
Thermal stability of MTHFR after pre-incubation with and without other assay 
reagents. Key:- #  - sample pre-incubation with other reagents; o  - sample pre- 
incubation with no other reagents.
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5.3.3.1.(vi) Quality Control
The pooled lymphocyte preparation was assayed 6  times in 2 batches of the 
MTHFR enzyme aniysis, to give a preliminary consensus value with which to 
assess the quality control of each assay. This pooled sample gave results of 29.3 
± 2.45 with a coefficient of variation of 7.3%. The residual activity after heating 
was 53.4 ± 6.7 % with a coefficent of variation of 12.4%.
5.3.3.1.(vii) Comparison of plasma and lymphocyte enzyme activities
The original assay method specifies lymphocytes as the preferred material for the 
measurement of MTHFR enzyme activities. An evaluation of MTHFR assay using 
plasma was performed with the object of assessing the potential of this as an 
alternative to using the lymphocyte method, which is both labour intensive and 
provides only a small amount of material for analysis. The results indicate that over 
a 24 hour incubation period , plasma activities were very much reduced compared 
with those of lymphocyte. There appears to be a significant amount of 
spontaneous hydrolysis of the label as evidenced by the blank, where the 
radioactive product is equal or, in some cases greater than that seen in the tubes 
containing the plasma samples (Figure 5 - 38).
Further investigation suggested that the high dpm in the blank was due to the 
menadione in a concentration of 3.5mM, as specified in the method by Engbersen 
et al (1995) which was responsible for the hydrolysis of the label, since absence 
of menadione in the assay gave no appreciable radioactivity in the product 
compared to that of the sample blank. Removal of the FAD cofactor still gave 
increased levels of radioactivity in the product, which supports the conclusion that 
the menadione appears to be the causitive factor (Figure 5 - 39).
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Figure 5 - 38
Comparison of MTHFR activity for lymphocyte and plasma samples over 30 hour 
incubation time. Key:- ■ - lymphocytes; •  - plasma; o - blank
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Figure 5 - 39
Comparison of radioactive product produced In a 24 hour incubation for plasma 
MTHFR, with and without FAD and Menadione.
Key:- * - plasma blank ; □ - plasma (no FAD ) ; # - plasma ; x - plasma (no 
menadione)
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The results for estimation of plasma MTHFR seem to suggest that due to the very 
low levels of expression in plasma compared to those in lymphocyte preparations, 
that plasma can not be used In determination of MTHFR activities with any degree 
of accuracy using this assay method, and that lymphocyte preparations should be 
used in MTHFR estimations.
5.3.4 Nutritional status
The nutritional status of individuals in the populations under study was assessed 
using red cell folate, and plasma vitamin B12 . While the method for analysis of red 
cell stipulated the use of the haematocrit in the calculation of the final value, this 
was not a viable option since due to transportation and storage problems, a 
number of samples were haemolysed on receipt. In light of this, the haemoglobin 
content of the sample was also evaluated as a comparitive index in red cell folate 
assessment. A comparision of haematocrit and haemoglobin gave a correlation 
coefficient of 0.79, indicating that haemoglobin would be a good substitute for 
haematocrit in the calculation of red cell folate.
The red cell folate and plasma vitamin B12 results were assessed with relation to 
the genotype of each population. Examination of the distribution data using the 
Kolmogorov-Sm irnoff statistical test showed a non-Gaussian distribution for red cell 
measurements in the +/- controls (p<0.01), mothers (p<0.05) and other family 
members (p<0.04). Normal distributions were obtained for red cell folate and 
plasma vitamin B12 in all genotypic groups after logio transformation and this was 
used in the statistical assessments of results and establishment of the reference 
ranges.
Inspection of the combined red cell folate data in Table 5 - 18 (overall), shows that 
red cell folate levels are reduced (81%) in +/+ individuals compared with -/- 
controls. When the data within each of the respective study groups is compared to 
the -/- controls, +/+ affected, mothers and fathers show reduced folate 
concentrations of 75%, 68% and 70% respectively. The corresponding +/- 
individuals in these groups showed the same or marginally increased red cell folate 
levels ranging from 98% to 120% of the mean -A control group. It should be noted 
however, that these differences may be due in part to the low numbers of +/+ 
samples obtained and must be interpreted with caution.
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Examination of the plasma B12 data for each of the study groups (Table 5 -  18), 
indicated higher plasma B12 concentrations in +/+ individuals in all of the study 
groups , with increases of 32%, 64%, 69% and 89% for the mothers, affected, 
others and fathers respectively. The +/~ in these groups failed to show the 
correspondingly high values for plasma B12, where, with the exception of the 
affected individuals, who had reduced B12 levels, all groups showed modest 
increases of between 15% and 24% compared to the -/- controls.
There was no significant difference in the red cell folate levels between any of the
patient groups with the +/+ thermolabile genotype and the controls, however 
plasma vitamin B12 levels were consistently higher in all +/+ groups, with levels in 
the affected, group significantly so ( p<0.05 ).
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CHAPTER 6. DISCUSSION
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6.1 General Discussion
in this study, the metabolic pathways of purine and pteridine synthesis and 
catabolism, and the devastating disorders associated with them, have by necessity, 
been treated as separate processes. However, the links between these two 
pathways are evident in many diverse cellular reactions such as the role played by 
tetrahydrofolate as 5’ 10- methenyl and 10 f ormy Itetra hy d rof o I ate as the cofactor 
for enzymes in the de novo synthesis of the purines, and conversion of 5- 
methÿenetetrahydrcpfolate to methionine as a source of S-adenosyl methionine 
(SAM) in the méthylation of proteins, DNA, phospholipids and DOPA. Perturbations 
in the metabolism of folate may also have widespread and related effects in the 
synthesis of the purine ring structure.
This study has examined a spectrum of genetic disorders associated with purine 
and pteridine metabolism and attempted to evaluate the diagnostic approaches 
used in their diagnosis. These disorders cover a number of inheritance patterns 
including X-linked (LNS and gout), autosomal (ADA and PNP) and multifactorial 
(folate resistant NTD's) and their investigation has required various biochemical 
and molecular techniques used including radiolabelled enzyme assay, kinetic 
enzyme assay, HPLC, radioimmunoassay and PGR.
For purine metabolic disorders, the target of the analysis has been specific enzyme 
defects which are not affected by environmental factors. For investigation of NTDs, 
which have a multifactorial aetiology, a single candidate gene, MTHFR, was 
chosen. Here, environmental factors (i.e. folate levels) are implicated resulting in a 
more difficult interpretation of results, through the need to rationalise nutritional 
status with the functional level of enzyme activity.
6.2 Purine metabolism
6.2.1 Distribution of purine enzyme activity in various tissues.
Analyte levels measured in selected (control) individuals cannot be assumed to be 
“normally” distributed. Uniess distributions can be shown to be Gaussian in nature, 
statistical comparisons between different groups must be based on non-parametric 
analysis. Analyte levels from substances found to be asymetrically distributed in
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the healthy population may be treated in the same manner as symetrically 
distributed data If a suitable mathematical conversion or transformation can 
be made to bring them into an underlying Gaussian form. In this study, KS testing 
confirmed that logio transformation of all ranges gave a normal Gaussian 
distribution.
Examination of the results obtained from the HGPRT, APRT, ADA, PNP and 
PRPP-S in the present study, indicated that results tended to be skewed to higher 
values. Logio transformation was carried out on all data which resulted in a 
reasonable fit to Gaussian distribution. The probability plots for HGPRT and APRT 
in adult red cells (Figures 5 - 3  and 5 - 4) illustrate the effect that logio trans­
formation has on the individual data, and shows the value of applying the KS test 
to data, before statistical comparisons are carried out. Remarkably, little attention 
appears to have been paid to the distribution of purine enzyme activities in other 
studies. Burgemeister and Gutensohn (1989) reported data from a large study 
examining controls ranges for a number of enzymes including HGPRT, ADA and 
PNP in homogenates of chorionic villi from induced abortions. They examined 
enzyme activities in homogenates obtained from both uncultured and cultured 
sources. They found wide ranges for these enzymes in the all tissues, and also 
reported that HGPRT and PNP activities did not correspond to the normal 
distribution. This study confirms that trend, and extends the findings to other 
enzymes and other tissues. One interesting finding in these CV homogenates was 
the significant correlation of activities between HGPRT and ADA (0.001 >p<0.05) , 
and HGPRT and PNP (P<0,001), while ADA and PNP showed no significant 
correlation (p>0.05).These workers found that villi taken from various sites of the 
same placenta, showed markedly different enzyme activities, particularly with 
HGPRT. They postulated that this may have contributed to the wide ranges of 
activities found. Accurate description of enzyme reference ranges, derived from 
the parameters of the distribution, are important for the correct interpretation of 
individual results. While many of the purine metabolic disorders examined in this 
study are associated with zero enzyme activity and are therfore readily 
distinguishable from normal, some cases have been described where substantial 
residual activity associated with an affected individual have been found. In the 
present study, analysis of HGPRT for both pre-natal and post-natal diagnoses, 
have found affected cases with residual activities ranging from 0.6% -13.9%  in CV 
and amniotic fluid cells (Table 5 - 1 0 )  and 0.95% - 4.9% in red cells (Table 5-11) .
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In these cases, an accurately defined lower limit of normal may allow an affected 
individual with significant residual enzyme activity to be distinguished from an 
unaffected individual with activity at the lower end of the normal range.
More critical analysis of normal and carrier reference ranges for autosomal 
recessive conditions may also allow a clearer distinction to be made between 
heterozygotes and homozygous normal individuals.
6.2.1.1 Assay performance and quality control
The control ranges obtained for all tissues (Tables 5 - 2  to 5 - 8 ) clearly show that 
better precision can be achieved for HGPRT and APRT in erythrocytes, at 19.4% 
and 39.5% respectively, than in any other tissue investigated, with the poorest 
precision being obtained in cultured CV for HGPRT and in fibroblasts for APRT. 
The coefficients of variation for these assays in the respective tissues are relatively 
high, reflecting the manual nature of the assays. In addition, while the HGPRT and 
APRT coefficients in red cells were based on the analysis of 106 samples, the 
other ranges were based on fewer samples, with fibroblast coefficents being 
calculated on only 18 samples. Quality control is an essential part of all analytical 
assessments. The purpose of quality control is to assess the analytical data 
obtained to ensure the reliability of each measurement performed and therefore to 
clarify any clinical decision making process.
Inter-assay controls provide verification of batch to batch reliability with regard to 
the higher coefficients of variation which can be obtained in manual compared to 
automated assays, particularly where reagents, such as substrates are prepared 
fresh for each analysis. In this study, the internal QC sample used was obtained 
from an individual with no family history of metabolic disorders and analysed in 
each batch of the HGPRT and APRT assay. The Levy-Jennings graph in Figure 5 - 
1 2  shows benefit of good quality control procedures where the batch to batch 
variations of the assays can be tracked and any problems rectified immediately. 
This was of particular relevance to the HGPRT assay, where the substrate could 
only be maintained in solution below a pH about 4.4, with any precipitation of the 
substrate having adverse effects on the assay kinetics, leading to erroneous 
results. Thus the QC values reflect any assay variability both of the short and long 
term variablity of this reagent, in addition to a well defined reference range , intra­
assay controls are also vital in ascertaining the reliability of results. Where
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possible, in addition to an internal QC, red cell samples from both normal and 
affected individuals also used In the assay provide valuable infomatlon of the 
performance of the assay, in both the normal ranges and in the area of enzyme 
activity associated with enzyme deficiency.
Ideally, tissues from both normal and affected cases should be analysed along 
side the sample being tested for the condition. For assays involving CV, fibroblasts 
or amniotic fluid cells, samples from pregnancies with normal karyotype and no 
histroy of metabolic disorders can harvested and pelleted from the same batch of 
cultures, to minimise procedural differences in the preparation of the at-risk 
sample. In practice, particularly when fresh CV from the affected individuals is 
used direct in the assay, the small size of the sample leaves very little remaining for 
further analyses. Consequently, CV should be cultured not only for confirmatory 
purposes, but also, in the case of affected preganancies, as a ready source of 
control material for future assays.
With diagnostic samples where red cells are the tissue of choice, samples from 
affected individuals may be successfully stored after cryopreservation in buffered 
citrate glycerol (Section 4.2.1) and used as intra-assay controls In subsequent 
assays.
6 .2.1.2 Substrate
As previously indicated in Section 4.8.4.1 (ii), the radiolabelled assay system used 
for the analysis of the purine enzymes in this study, utilised a radioactive substrate 
tracer to provide a detectable signal for the assessment for enzyme activity. In 
each assay procedure, the tracer was mixed with a higher concentration of the 
unlabelled substrate to provide the optimum substrate concentration to fulfil the 
kinetic requirements of the assay. When assaying HGPRT, the unlabelled 
hypoxanthine is added as a 19.1mM stock solution dissolved in distilled water. 
Since the disssociation constant (pKa) of hypoxanthine is 2.0 (Joule and Smith 
1972), it was necessary to acidify it to around pH 2.0 in order to dissolve it entirely 
within the stock solution. However, since the pH of the Tris-HCI buffer system for 
the enzyme assay was 7.4, it was essential to bring the pH of the stock substrate 
solution as close as possible to this pH in order that the Tris-HCI may buffer it 
sufficiently during the assay. Experimentation showed that at this concentration, 
the maximal pH which could be obtained before the hypoxanthine came out of 
solution was pH 4.2 - 4.4. This proved to be a time consuming and precise
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requirement of the assay preparation, since a pH above this value, resulted in 
precipitation of the hypoxanthine with the risk that a lower than optimal substrate 
concentration might be used in the assay yielding inaccurate results. With the 
substrate for the other enzyme analysis. Adenine, the preparation of substrate was 
staightforward, since the pKa for this substance was 4.2 (Joule and Smith 1972), 
and as such it displayed better solubility at higher pH values.
6.2.1.3 Red cell sample preparations
A potential drawback in using lysed red cells for the diagnosis of LNS by HGPRT 
assay, has been highlighted by Fairbanks et al (1987). They proposed that the 
assessment of purine (and pyrimidine ) enzyme activities may be misleading when 
using lysed red cells and that intact red cells may provide a better indication of the 
functional capacity of the enzyme in vivo, in addition to showing a closer correlation 
with the clinical phenotype. They studied 8  patients exhibiting virtually undetectable 
HGPRT activity in lysed red cells. Only 2 patients failed to convert some 
hypoxanthine into [8 - '^^C] IMP when the HGPRT activity was assessed using intact 
red cells. These patients were subsequently shown to have LNS while the 
remaining 6  who presented with gout and/or renal failure or LNS without self- 
mutilation converted up to 25% hypoxanthine into IMP. In addition,
these workers reported that when investigating two patients who appeared to be 
homozygous for a complete absence of ADA activity in red cell lysates, intact red 
cell studies indicated a 60% normal conversion of the substrate.
Since Fairbanks et al (1987) also demonstrated lower residual levels of HGPRT 
(<0.1 nmoles / hr / mg Hb) than was evident in 2 out of the 3 patients presented 
here, it may be that both the use of intact red cell preparations and an ultra­
sensitive detection system such as HPLC are required to obtain this level of 
correlation with enzyme activity and phenotype, and that TLC as a separation 
mechanism is not sensitive enough. While it is clear from the results presented in 
this current study, that lysed red cell preparations can distinguish between those 
patients affected with purine enzyme deficiencies and controls, further work 
remains to be done to determine whether intact red cells can clarify the relationship 
between the clinical phenotype and the level of this red cell enzyme activity.
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6.2.2 Pre-natal and Post-natal Diagnosis
6.2.2.1 Technical observations
%
'
The enzyme m icromethod described here for the prenatal diagnosis of HGPRT and 
APRT in Lesch-Nyhan Syndrome, provides a rapid means of identifying affected 
fetuses without the requirement for detailed mutation analysis. For the most part, 
the turnover time of the assay is within 1 working day from receipt of sample to
reporting of the results to the clinician. In this study, a microassay using thin-layer 
chromatography as a separation step to determine the amount of nucleotide
I
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turnover was used, however other more precise diagnostic systems such as 
HPLC, may be used here, by determining the concentration of intermediate or 
aberrant nucleotides. (Morris and Simmonds 1985; Simmonds et al 1991;
Simmonds et al 1997; Duran et al 1997) . While HPLC undoubtedly provides a 
rapid and sensitive method for the separation of the various purine species, its 
drawback is that its expense and complexity which limits its use to specialised 
laboratories and centres, where metabolic profiles are used to obtain a diagnosis.
The m icroassay method described here, involving TLC as a separation step is 
simple, cost effective and much less labour intensive, and although limited in its 
application, still provides the means of detecting specific enzyme deficiencies in 
purine disorders such as LNS.
■6.2.2.2 Index cases
Detection of specific inborn errors of metabolism in the index case is an absolute 
requiremant if prenatal diagnosis in any future pregnancy is to be undertaken.
Where the defect can be detected in red cells, this would be the tissue of choice as 
it provides the opportunity for rapid diagnosis, however other cell types such as 
skin fibroblasts may also be used. The storage of these tissues also provides a 
source of long term reference material, irrespective of the survival of the patient, 
upon which subsequent biochemical or molecular testing can be performed, a fact 
which may be of great benefit in the elucidation of the defect in other family 
members.
In the specific prenatal diagnostic cases for LNS cited here, where low levels of 
residual activity are found, the security of the result is greatly enhanced by the 
information available from the levels of enzyme activity expected in an index case.
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One caveat however is that enzyme activities may vary from tissue to tissue and 
even from each family due to the heterogeneous nature of LNS.
6.2.2.3 Chorionic villi
and CV tissue. At least two other studies have reported HGPRT and APRT 
activities in amniotic fluid cells and CV tissue (Zoref-Shani et al 1989; Page and 
Broock 1990). These data are shown with comparison to the results from the 
present study in Table 6 - 1 .  During prenatal diagnosis in in 3 fetuses at risk for
CV sampling has become an increasingly important means of prenatal diagnosis 
of LNS. In theory, material may be obtained as early as the eighth week of 
gestation onwards, (although in practice, sampling is more often performed around 
the tenth week), and can be used uncultured, therefore obtaining results earlier 
than by amniocentesis. The primary disadvantage of CV sampling is the increased 
risk of contamination by maternal cells, the small size of sample and cells with a
:;A-
more limited life span in culture than amniotic fluid cells. The results obtained In this 
study for the control ranges of HGPRT and APRT are similar to a number of 
studies where prenatal diagnosis of LNS was assessed using amniotic fluid cells
J
LNS, Zoref-Shani et al (1989) reported residual HGPRT activities 5.4% of normal 
in cultured amniocytes, 16% and 9-10% in CV and cultured CV extracts 
respectively, 6.7% - 16 % in skin fibroblasts and APRT/HGPRT ratios 4 - 1 0  fold 
higher than the normal ratio. This compares with the 0.06%-13.9% residual 
HGPRT activity found in the affected pregnancies from the present study. The 
HGPRT / APRT ratio used here provides a reciprocal figure to that of Zoref-Shani 
et al (1989) but in either case the differentiation between the control and affected 
cases is clear.
Page and Broock (1990) have drawn attention to a possible analytical problem 
with the measurement of HGPRT activity in frozen and in cultured chorionic villi. In 
these types of cells, rapid catabolism of the products of the HGPRT reaction may 
cause normal cells to appear HGPRT-deflcient and these investigators advocate 
the use of a 5' nucleotidase inhibitor (a,p-methyleneadenosine diphosphate; 
AOPCP) in assays to block the removal of the HGPRT reaction products. These 
workers stressed the important differences in composition of CV compared to 
amniotic fluid when assessing these tissues for use in prenatal diagnosis, a
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difference reflected in the levels of activity for the three studies indicated in Table
6 - 1.
CV is optimally suited to the transport of small molecules whereas the fetal 
amniocytes are adapted to perform rapid cell division. Consequently the observed 
enzyme levels may change as the CV cells grow and divide in culture. The rate of 
nucleotide catabolism is relatively higher in CV than in cultured amniotic fluid cells, 
and may outstrip the synthetic capacity of the cells and cause normal cells to 
appear HGPRT deficient.
In the present study, none of the CV samples from at-risk pregnancies was 
frozen before HGPRT analysis and little difference was evident between cultured 
and uncultured CV controls, although APRT specific activities were higher in the 
cultured CV. However within the series of at-risk pregnancies, both enzymes 
consistently gave higher activities in cultured cells than in uncultured material. The 
low levels of HGPRT activity found in three pregnancies examined, can be 
interpreted as due to the presence of an affected fetus and not attributed to the 
increased catabolism of the HGPRT reaction products, as similar residual activities 
were found in non-placental tissues from the probands (two cases) and the abortus 
(one case). In the affected pregnancies, the highest residual activity was found to 
be 12.3% of normal, while in the unaffected pregnancies, the lowest HGPRT 
activity was 52 % of normal, suggesting minimal loss of HGPRT reaction products 
in CV due to intracellular catabolism. From these data it appears that provided CV 
material is not frozen, the use of AOPCP in the assay is unnecessary.
A number of workers have reported on the experience of using CV for first trimester 
diagnosis of inherited metabolic defects . Besley et al (1991) collected data from a 
total of 339 diagnoses from 4 centres in the UK, and while none of the centres 
quoted data specifically for purine metabolic disorders, the data provide useful 
insights into the advantages and disadvantages of using CV as a first trimester 
prenatal diagnostic tissue and highlighted the problems of using small or poor 
quality CV samples for enzyme analysis as a cause of equivocal results. In 
subsequent work, Besley (1992) recommended that samples of between 10 and 50 
mg wet weight are optimal amounts for biochemical assays.
For prenatal diagnosis of the purine enzyme disorders in this study, only fresh CV 
samples of lOmg or greater were analysed directly, with cultures also being set up 
and analysed after confluence for confirmation of the direct result. Samples of less 
than this amount were considered unsuitable and were cultured prior to the
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analysis. Fortunately, most CV samples obtained for prenatal dagnosis were 
adequate to allow analysis both fresh and after culture.
Where sufficient material for analysis of cultured and uncultured CV can be 
obtained , and where cells from an index case are available, enzyme analysis in 
CV a reliable method for prenatal diagnosis of purine metabolic disorders.
Table 6 -1
Comparison of HGPRT and APRT enzyme activies for amniotic fluid cells, cultured 
and uncultured CV, in 3 studies. Activities are in nmoles / hr / mg protein. The 
ranges in brackets indicates results obtained using logio transformed data 
converted back to concentration units.
Amniotic
Fluid
Cultured
CV
Uncultured
CV
Zoref-Shani HGPRT 1 5 4 .6 ±  42.2 52 1 0 3 .8 +  60,4
(1989) (n=8) (n=1) (n=5)
APRT 406.6 ±  77.0 103 202.4 +  114.0
(n=8) (n=1) (n=5)
APRT/HGPRT ratio 2.7 ±  0.68 2.0 2.04 +  0.37
(n=8) (n=1) (n=5)
Page and Broock HGPRT 1 0 6 +  48.6 5 9 .7 +  56 1 4 .1 +  5.1
(1990) (n=8) (n=6) (n=4)
APRT 250.0 ±  155.0 78.2 +  63.0 2 .5 +  3.4
(n=8) (n=6) (n-6)
HGPRT/APRT n/a n/a n/a
Ratio
This study HGPRT 161.1 34.5 56.4
(Range) (62 .9 -412 .9 ) (5 .5 -216 ,8 ) (18 .7 -169 .4 )
(n=45) (n=57) (n=54)
APRT 143.5 48.9 43.5
(Range) (4 9 .8 -4 1 3 .9 ) (9 .9 -243 .6 ) 13.3 -141.9)
(n=45) (n=53) (n=48)
HGPRT/ APRT 1.12 0.63 1.29
(Range) (0 .46 -2 .75 ) (0 .1 7 -2 .4 ) (0.44 - 3.8)
(n=45) (n=51) (n=48)
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This present study indicated that when carrying out prenatal diagnosis for LNS, 
amniotic fluid cells still have a useful place, and may even have some advantages 
over uncultured or cultured CV. Apart from the benefits that second trimester 
diagnosis is still available should the first trimester analysis fail to obtain a result, 
the reduced levels of HGPRT in affected pregnancies may be very close to the 
lower limits of the normal control ranges in cultured and uncultured CV and as 
such may cloud the distinctions between the affected and reference populations. 
Since the overall mean and therefore the lower limits of the reference ranges of 
HGPRT and APRT are markedly greater in amniotic fluid cells, there is a greater 
difference between normal levels of HGPRT and APRT and the residual levels 
found in individuals affected with LNS. It is for this reason that the HGPRT/APRT 
ratio in determining affected individuals for the normal population is used since this 
affords a more precise method of separating normal and affected individuals.
The confirmation of a prenatal diagnosis by the analysis of fetal material such as 
fibroblast tissue taken at post-mortem or cord blood at delivery is essential to 
assess the accuracy of the prenatal diagnostic results. Despite requests to 
referring clinicians, very few tissues for confirmatory analyses were obtained 
either after termination or delivery, with only two pregnancies ( WS (a) and WS (c) ) 
providing fibroblast and cord red cell samples respectively. Cell cultures from 
affected pregnancies also provide an important source of analytical controls for 
prenatal diagnosis in any future pregnancies.
6.2.2.4 Fetal blood sampling
While prenatal diagnosis of Lesch-Nyhan has, concentrated on the use of fetal 
tissues such as CV, amniocytes and fibroblasts, assessment of the HGPRT and 
APRT levels in fetal erythrocytes was made in this study to assess their suitability 
for PND (Table 5 - 7). Despite the fact that the technique of fetal blood sampling 
has been used for greater than 2 0  years, it is seldom used for the prenatal 
diagnosis of enzyme disorders. Fetal blood sampling is generally carried out late 
in gestation, due to the small size of the feto-placental unit and increased risks of 
sampling before 21 weeks gestation (Ghidini et al 1993). While maternal 
contamination of the sample may also be a contributing factor the lack of use of 
this procedure for prenatal diagnosis, this may become less important as 
experience of this technique becomes more widespread. The establishment in this
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study of fetal red cell reference ranges indicate that mean HGPRT, APRT and 
HGPRT/APRT of 71.9 and 31.7 nmoles/ hr/ mg Hb and 2.4 respectively, while 
lower than the adult values, would provide the basis for fetal red cells to be used in 
prenatal diagnosis. While CV and amniotic fluid cells would still be the tissue of 
choice for prenatal diagnosis of purine disorders, fetal sampling may provide a 
useful alternative, should these two approaches fail to provide a definitive result.
6.2.2.5 Carrier detection
A drawback in the use of biochemical methods for prenatal diagnosis of Lesch- 
Nyhan Syndrome, is their inability to predict the carrier status of a female fetus due 
to the effect of non-random X-inactivation. Lyonisation is the process of inactivation 
of one of the two X chromosomes in every female cell around 12 days for 
trophoblast tissues and 16 days for the embryo. Inactivation only occurs in somatic 
cells and is random as to whether the maternal or paternal X chromosome is 
inactivated. As only one X chromosome is active in the female, the product levels 
for most genes on the X chromosome are similar in females and males where the 
single X chromosome remains active. The difficulties of performing carrier 
detection by enzym ic methods in tissues such as red cells, due to X-inactivation 
have been well documented. Kelley (1968) attempted to diagnose heterozygote 
status by HGPRT analysis in red cells in 6  test subjects using guanine as a 
substrate, but found that HGPRT activities fell within ± 2 s d  of the mean of the 
control range. This work was substantiated by Nyhan et a! (1970) who in addition 
to finding normal HGPRT activities in the red cells of female heterozygotes, found 
no evidence of mosaicism in autoradiographs of hypoxanthine uptake in 
lymphocytes of these subjects. These workers postulated that X-inactivation in the 
marrow of obligate carriers is not random or that following random inactivation 
there was selection against the cells with the deficient HGPRT gene. The results 
shown in Table 5 - 1 1  confirm the findings that obligate carriers of LNS cannot be 
detected by HGPRT analysis in red cells, due to the overlap in the ranges between 
the carriers an the controls. This overlap is reflected not only in HGPRT but also in 
APRT, thereby rendering the HGPRT / APRT ratio unusable in differentiating 
these subjects from the controls. Some success however has been achieved using 
hair roots for carrier detection (Gartler et al 1971; Silvers et al 1972). Hair roots 
constitute a readily available enzyme source for the detection of heterozygotes in 
Lesch-Nyhan Syndrome. Hairs are taken from sevaral areas of the scalp, and the
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visible intact root put into an appropriate buffer. Lysates are prepared by 
repeatedly freezing and thawing at -20°C and room temperature and an aliqout of 
the preparation taken for enzyme activity. Hair roots provide a good material for X 
chromosome studies, as the probability of obtaining a follicle with only one of the 
X-linked alleles being expressed is high, due to the fact that the cells on the scalp 
are not distributed at random, but exhibit clonal growth. Thus a heterozygous 
female will exhibit enzyme levels in a bimodal distribution. Each mode of the 
distribution compaing with the control female and hemizygous affected male 
distributions.
Alford et al (1995) demonstrated that the use of molecular methods in the 
identification of female carriers provides families with accurate and reliable 
information regarding risk and family planning information. In a recent study where 
they reported their experience with prenatal diagnosis in 26 pregnancies, 14 were 
investigated by HGPRT assay only, four by HGPRT and molecular analysis and 
eight by mutation analysis alone. For those cases investigated biochemically, six 
affected pregnancies were identified and all had low but detectable HGPRT 
activities. APRT in these pregnancies was not measured. Techniques such as 
linkage analysis and quantitative PCR and densitometry, rely on the acquisition of 
DNA from the proband to identify the familial mutation, thus allowing effective 
carrier detection.
6.2.3 Gout Study
The aim of this part of the purine study was to investigate the HGPRT and APRT 
activities in patients who had presented at a Rheumatology clinic with chronic gout 
to assess whether these enzymes helped to identify the severe form of gout 
showing the X-linked pattern of inheritance. The clinical information suggested the 
familial nature of the disorder in a number of patients, however, no evidence of 
HGPRT deficiency at the residual levels of enzyme activity expected In partial 
deficiencies was found. The finding however of lower levels of HGPRT in two male 
patients presenting with polyarticular gout raises the question of the role played by 
low levels of HGPRT activity in the differentiation of the various presentations of 
gout. Lawry et al (1988) reported that of 106 men presenting with gout at one 
hospital, 1 1  had polyarticular involvement, and these cases tended to be less 
abrupt in onset, less severely painful and more likely to be associated with
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onset , a longer history and more previous attacks. The raised serum uric acid in 
these patients may not aid diagnosis since symptom-less hyperuricaemia may 
accompany other forms of arthritis. Although gout in older patients tends to be sub­
acute to chronic and often polyarticular in nature, it is important to note that in the 
present study population, the patients were the only ones to exhibit polyarticular 
symptoms. Since this older population of patients do not exhibit the X-linked form 
of gout to any discernable degree, it would be perhaps more rewarding to 
Investigate a population where the incidence is higher, for example in cases of 
juvenile gout.
Many of the current techniques for PRPP-S estimation are radiochemical 
techniques and are difficult to apply in clinical labs, while those based on enzyme- 
linked systems lack the required sensitivity. The original method of Sakuma et al 
(1991) translated well to the HPLC system used in this study, but gave higher 
results than those obtained here. Sakuma et al (1991) quoted PRPP-S values of
1 .2 S i 0.11 pmo 1/ min / gHb (n=28) for gout patients and 1.110 -  0.11 pmol / min / 
gHb for normal controls (n-27), while this study gave a mean of 0.307 p,mol / min / 
gHb (Range = 0.152 - 0.622) and 0.341 pmol / min / gHb (Range = 0.205 - 0.569) 
for gout patients (n = 54) and normal controls (n=18) respectively.
Patient MHD presented with increased uric acid and cerebral palsy (CP) and the 
request for HGPRT estimation was intended to exclude the diagnosis of LNS 
where a number of clinical symptoms are common. CP is caused by the non- 
progressive defects of lesions of the immature brain and is a persistent disorder of 
movement and posture, often complicated by neurological and mental problems 
and characterised by delayed motor development and choreoathetosis (Hull and 
Johnstone 1981).
The finding of elevated PRPP-S in this patient is an indication for further 
investigation, but no further samples could be obtained. Roessler et al (1993) and
a
I
Becker et al (1995) demonstrated the value of using point mutations of the genes 
PRS1 and PRS2 in the examination of the molecular pathology underlying PRPP- 
S superactivity, while a study by Bory et al (1995) showed the validity of using the 
altered concentrations of NAD, UDPG, GTP and IMP In red cells associated with a 
rise in uric acid and hypoxanthine levels as a biochemical characteristic of PRPP-S 
superactivity.
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6.2.4 ADA / PNP
Around 20% of patients with SCID have a deficiency of ADA activity (Hershfield et 
al 1997). Also, in 20% of ADA deficient patients, immune deficiency is initially less 
severe and as a result often present later in childhood or even may not be 
diagnosed until 15-40 years of age with chronic pulmonary insufficiency due to 
recurrent respiratory infections, or other manifestations of immune deficiency and 
dysregulation (Santisteban e ta l 1993). Enzyme analysis allows the distinction to be 
made between the ADA and non ADA types of SCID, and also between 
immunodeficiency syndromes associated with ADA and those with PNP. While 
some clinical indices, such as neurological involvement, give clues as to the type 
of immunodeficiency, the only certain method of determination, remains the 
demonstration of the specific enzyme defect, in the appropriate tissue.
In this study, it is clear that the ADA activities can differentiate between those 
individuals with ADA type of SCID and those with other forms of immunodeficiency. 
Patients TGG, MMC who presented with recurrent infections and patient JTD who 
was the sister of TGG, all had immunodefciencies of the ADA type as seen by the 
lack of any detectable ADA activity. It can be seen from the results obtained from 
the ADA study however, that the majority of those patients presenting with 
recurring infections and therefore possible immunodeficiencies gave ADA activities 
in the normal reference range, and therefore may have had SCID of the non ADA 
type. A number of patients gave ADA activities above 104.2 nmoles / hr / mgHb , 
the upper level of the normal reference range. Three of these (ASD, CBN, SGD) 
presented with recurrent infection and gave red cell ADA concentrations of 122.6, 
134.9 and 117.2; while patient DME (a) presented with Graft versus Host disease 
and gave red cell ADA activity of 117.3. It is not clear whether these high values 
simply represent outliers beyond the upper end of the normal range or whether 
they indicate disruption of the salvage pathway. One patient with a family history 
of PNP deficiency, and immunodeficiency (LCD) was observed to have ADA of
257.1 nmoles / hr / mg Hb. The results in Table 5 - 9  show correlation between 
ADA and PNP in adult red cells and suggests that a disruption in one of these 
enzymes affects the other. The results here suggest that both ADA and PNP may 
give valuable information in these cases.
While enzymatic analysis has traditionally been the most common method of
analysis of ADA and PNP deficiencies, more recently molecular methods have
become more widespread. The most common cause of mutations in the ADA gene
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are single base pair changes (around 75%), followed by splicing mutations then 
small and a few large deletions. One missense mutation identified in a healthy child 
with partial ADA deficiency, was later found 2 sisters with adult onset of 
immunodeficiency (Shovelin 1994). A report by Hershfeld et al (1997) on studies 
with 25 DNA samples carrying missense mutations suggests that patients with 2  
alleles providing <0.01% of wild type ADA activity have SCID, while those with 0.1- 
3% activity have a delayed or late onset SCID and those inheriting alleles that 
provide 5% or greater of wild type activity can be regarded as healthy idividuais, 
and this is consistent with the finding that there is good correlation between clinical 
severity and red cell dATP (or total deoxy-adenosine (dADO) nucleotide content) 
an index of overall capacity to eliminate ADA substrates.
Stone and Simmonds (1991) highlighted a problem of stability when analysing 
ADA. As ADA is reportedly unstable at -20'^C, they recommended that blood 
transportation should be at room temperature with storage at -70°C. These 
recommendations were made in light of the fact that at least 1 1  heathy individuals
'■with undetectable ADA in lysed red cells have been found, and was attributed to 
the instability of the erythrocyte enzyme on lysis since some ADA activity was
i
detected in the intact cells of obligate carriers. In this study, transport of red cells
•-
for ADA and PNP deficiency was at room temperature, while storage was at -20°C 
as unlysed cells in a suitable cryoprotective preservative. Both at-risk and control 
samples were subjected to identical transportation and storage conditions and 
while the controls gave levels in the normal range, the affected patients gave 
undetectable levels of ADA and were considered deficient individuals. It is possible 
however, that where levels of ADA and PNP activity fall at the lower limits of the 
normal range, suggesting possible carrier status, intact red cell analysis may be of 
use in clarifying these results. This raises the question of whether red cell ADA and
PNP analysis should be analysed in both lysed and intact red cell in order that the 
reference ranges for affected, heterozygotes and normal individuals are as 
stringent as possible. The solution (3-mercaptoethanol-EDTA has been used in 
previously reported methods of haemolysate preparation, as a stabilizing agent to 
prevent the oxidation of the enzyme disulphide bonds and thus maintain catalytic 
activity (Beutler 1984). It may be that addition of p-mercaptoethanol-EDTA to 
haemolysates, provides a comparable effect to that reported with intact red cell 
preparations. Further work is required on this question.
Tl
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6.3 Pteridines
6.3.1 MTHFR allele frequencies
Whitehead et a! (1995) postulated that folic acid supplementation does not act to 
correct a simple nutritional deficiency since most pregnant women carrying NTD 
affected fetuses have levels of folate above the deficient range. Instead they 
suggested that an increased folate concentration may prevent some cases of 
neural tube defects by overcoming a partial block in the conversion of 5,10 
methyltetrahydrofolate to 5,10 methYienetetrahydrofolate caused by reduced 
catalytic activity of the enzyme MTHFR. In a study of the thermolabile variant of 
MTHFR in the Irish population, they found only 13% of all NTDs could be attributed 
to this genetic variant while 50-75% of NTDs in the Irish population are folate 
related. While they considered that this was good evidence for a genetic role for 
MTHFR variants in the development of some NTDs, they speculated that other 
causitive factors in folate metabolism remain to be ellucidated. This is in keeping 
with other studies where a combination of the genotype frequencies of both the 
mother and child accounted for only 27.4% of the observed protective effects of 
folate (van der Put et al 1996).
Subsequent studies by other groups reported these investigations of MTHFR 
variants in NTD and control populations. This data was summarised by van der Put 
et al (1997) who carried out a meta-analysis which combined the observed 
frequencies of the 677C->T mutation in a prospective Dutch study with data 
reported from a series of 13 other studies. This analysis combined control data 
from both cardiovascular and NTD studies and compared the frequencies in 
relation to the NTD cases and their parents. (Table 6  - 2). The frequency of 11.8% 
obtained for the 677C->T variant of the Scottish control population in this study 
compares with a mean of 9.2% obtained for the combined studies which ranged 
from 2.3% (Papapetrou et al ) to 16.3% (de Franchis et al 1995). The frequency of 
the homozygous variant in the Scottish NTD affected population was 10.0% which 
was considerably lower than the mean for the meta-analysis of 16.4% and not 
significantly different from the control group. The meta-analysis suggested that 
homozygosity for this mutation was relevant not only in the affected patients but 
also in the mothers of affected pregnancies. The results of the present study in 
the Scottish population suggested that the maternal MTHFR genotype may be 
important, as the mothers of affected individuals homozygous for the variant allele
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showed a variant frequency significantlly different to the control group. The 
frequency of 15.3% for these homozygous mothers compared with the 14.5% 
observed in the pooled data. The claims by van der Put et al (1997) that the 
homozygosity is relevant in the fathers of affected individuals, as well as the 
mothers, is not borne out by the Scottish data where the fathers were found to 
have a low incidence of homozygosity of 8.3%. Other relatives of these affected 
individuals gave a frequency of 1 1 .1 %, which was comparable to that of 1 1 .8 % 
obtained for the control data. Van der Put et al (1997) quote odds ratios of 1.5-1. 8  
in patients and 1.6-1.9 in mothers, compared to 0.9 and 1.3 respectively in this 
study.
This would suggest that there is a population difference in the 677C ^T  mutation 
frequency between some European countries, and the Scottish population, and 
raises the possibility that other affected loci are involved, perhaps in conjunction 
with envi Tonmental factors in the development of an NTD.
A recent study by Shields et al (1999) using the trapsmission dysequilibrium test 
(TDT) presented data on 271 NTD cases in the Irish population, to support the 
contention that the +/+ allele was a significant genetic risk factor for NTD. They 
hypothesised that since the vast majority of +/+ mothers do not have NTD 
pregnancies, that the +/+ genotype is a risk factor with a very low penetrance and 
subsequently large numbers of individuals (and their parents) are needed to 
provide evidence that the +/+ genotype is indeed, a risk factor for NTDs. On the 
basis of the results obtained by Shields et al (1999), they hypothesised that the 
+/+ status of the developing embryo rather than the +/+ status of its mother was 
the critical genetic determining factor. Their data did not exclude the possibility, 
however that the maternal genotype may confer an addition risk to a +/+ embryo 
over and above the risk attributed to the genotype of the embyo itself, and that the 
maternal +/+ genotype m ight become a modest risk factor by further depressing 
maternal folate levels which are already below a nominal threshold, thus enhancing 
the already present risk of NTD in the fetus. The results obtained this study, where 
significantly higher frequency of the +/+ allele was found in mothers of affected 
cases, lend support to this contention.
;
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Table 6 - 2
Prevalence of thermolabile MTHFR due to 677C ->T mutation among Dutch and 
international controls, NTD patients and their parents. Data after van der Put et al 
(1997).
Control Groups Group size +/+ Frequency (n)
Dutch controls
Unpublished 833 8.9% (74)
Put e ta l (1995) 318 7.9% (25)
Verhoef et a! 99 7.1% (7)
Engtjertsen et al 23 4.3% (1)
Total Dutch Controls 1273 8.4% (107)
Reported International controls
Whitehead et al (1995) 99 6.1% (6)
Ou ef a/(1995) 109 4.6% (5)
Frosst of a/ (1995) 57 12.3% (7)
Franchis e ta /(1995) 289 16.3% (47)
Wilcken and Wang (1995) 225 10.7% (24)
Papapetrou et al (1996) 199 12.1% (24)
Papapetrou et al(^ 996) 44 2.3% (1)
Papapetrou et al (1996) 45 8.9% (4)
Kang et al 202 5.0% (10)
Total all Controls 2542 9.2% (235)
This study 262 11.8% (31)
Reported NTD cases
Put e ta l (1995) 55 12.7% (7)
Whitehead et al (1995) 82 17.6% (15)
Ou et a /(1995) 41 22.0 (9)
Papapetrou et al (1996) 41 12.2% (9)
Total all NTD cases 219 16.4% (36)
This study 40 10.0% (4)
Reported mothers
Put et a/ (1995) 70 15.7% (11)
Whitehead et al (1995) 32 18.8% (6)
Franchis et al (1995) 28 7.1% (2)
Papapetrou et al (1996) 36 13.9% (5)
Total ail mothers 166 14.5% (24)
This study 85 15.3% (13)
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Table 6 - 2  (con tinued)
Control Groups Group size +/+ Frequency (n)
Reported fathers
Put e ta l (1995) 60 10.0% (6)
Whitehead et a /(1995) 24 29.2% (7)
Papapetrou et al (1996) 26 15.4% (4)
Total fathers 110 15.4% (17)
This study 35 8.3% (3)
The differing frequencies obtained by ail these studies has raised questions about 
the validity of the selection criteria for controls on which MTHFR variant population 
frequencies are based. This study attempted to establish control ranges for the 
frequency of the MTHFR variant by genotype frequency and by MTHFR enzyme 
activity using control samples obtained from individuals in the same social class as 
the test individuals. The rationale was that by obtaining a blood sample from a 
friend or neighbour of the test subject there would be some matching of ethnicity, 
social class and a likelyhood that diet would be reasonably similar. This was only 
partially successful, and it became necessary to obtain blood samples from 
unselected members of the general population in order to provide adequate 
sample numbers. Posey et al (1996) raised a number of questions concerning the 
methodological aspects of studies investigating the 677C~>T mutation as a risk 
factor for NTDs. These concerns centred around the lack of an appropriate control 
group in the studies of Ou et a/(l99^„ van der Put et al (1995) and Whitehead et al 
(1995). The “convenience controls” used in these studies took no account of the 
race or ethnicity of the control populations or any account of differing social status 
and consequently any dietary anomalies. One approach to this problem was 
proposed by Papapetrou et al (1996) who advocated the use of within-family 
genetics studies of the variant MTHFR allele , which are not affected by population 
differences in the allele frequency. This approach is being used at present in a 
study of the effects of folate metabolism in the epidem iology of orofacial clefting in 
the Scottish population, where fam ily controls are used through the technique of 
transmission dysequilibrium (which uses the non-transmitted parental alleles to 
remove the element of genetic stratification between case / controls populations),
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and sib pair analysis as an alternative to the classical case / control methods of 
comparison (Dr. P. Mossey, Dundee: personal communication).
6.3.2 MTHFR enzyme activity
The hypothesis that the development of at least some causes of folate NTD are 
due to impaired utilisation of folate due to the presence of a defective enzyme, has 
been tested in various studies by investigating the frequency of the MTHFR 
677C->T variant as a risk factor in NTD patients and their parents. It follows 
therefore that if this is the underlying cause, the functional capacity of the enzyme 
to catalyze this key step in the pathway must be reduced and this should be 
demonstrable by measuring MTHFR activity in patients and controls. While the the 
majority of work on defining the relationship of the genotype to the enzyme 
activities of the thermolabile MTHFR allele has been reported using subjects with 
cardiovascular indications (Frosst et al 1995 ; Engbersen et al 1995), few studies 
have applied this to individuals with a family history of NTD. One such study, (van 
der Put et al 1995) reported that the thermolabile mutation was associated with 
decreased MTHFR activity, high homocysteine and high plasma folate 
concentrations, and concluded that the 677C->T mutation should be regarded as a 
genetic risk factor for spina bifida. However, since no specific data was available 
from the report on the MTHFR enzyme activités for each group of patients , it was 
impossible to assess that particular study in light of the results obtained here. The 
study by Frosst et al (1995) using patients with premature vascular disease, 
reported lymphocyte MTHFR activities of 22.9 ± 1 . 7  (Range 11.8-33.8); 15.0 ± 
0.8 (Range 10.2-18.8) and 6.9 ± 0.6 (Range 2.6 - 10.2) nmol formaldehyde / mg 
protein / hr for the homozygous normal, heterozygous and homozygous 
thermolabile genotypes respectively. After heating at 46°C for 5 minutes these 
samples gave a corresponding residual activity of 6 6 . 8  ±  1.5, 56.2 ±  2.8 and 21.8 
± 2.8 % respectively. In a comparison of control and hyperhomocysteinem ic 
vascular patients,
Engbersen et al (1995) reported similar results of 15.6 ± 4.7 nmol formaldehyde / 
mg protein / hr and residual activity of 55.3 ± 12.0 % for controls and 8.7 ± 2.1 
nmol formaldehyde /mg protein/hr and residual activity of 0-33% for the patients 
exhibiting the themolabile variant of MTHFR.
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The results of this NTD study indicated that when the mean overall MTHFR activity 
of each particular genotype was examined, this gave 8 .6 , 6 . 6  and 4.7 nmol 
formaldehyde /mg protein / hr for the homozygous normal, heterozygous and 
homozygous thermolabile alleles for the combined study groups. While these total 
activities were lower than those quoted by Frosst et al (1995) and Engbersen et al 
(1995), they compare favourably with those Kang et al (1991) who observed 
MTHFR specific activities in controls and patients with coronary artery disease of 
10.33 + 2.9 and 5.58 ±0.91 nmol formaldehyde / mg protein / hr respectively.
The expectation, based on the findings of other workers, of a residual MTHFR 
activity after heating at 46°C for 5 minutes, of -50%  for controls and <30% for 
those individuals exhibiting thermolabile allele was not borne out by the results of 
this study for the overall residual actitivities where 39.7, 37.7 and 38.8 % residual 
activity was found for the -/- , +/- and +/+ groups respectively. The result here 
suggests that when overall values for each genotype are considered, residual 
activity does not provide a indicator for discrimination of the genotypes. The 
explanation for these results is unclear at present. One obvious reason would be 
the failure of heating phase at 46°C to produce the residual activities expected, 
however this is not the case , since the internal QC results obtained (Section 
5.3.3.1.(vi) show that the expected residual activity of -50%  was achieved. The 
batch processing of samples may have provided a reason for the variation of 
results, particularly in the case of the higher residual activities of the thermolabile 
affected individuals, had they been asayed together. However, since all samples 
were assayed in the order with which they were received, this ensured that no bias 
was encountered in assaying large numbers of one particular group in one batch. 
This was particularly relevant to the 3 affected thermolabile patients who gave high 
residual activies despite being assayed in 3 distinct batches. Whether these 
diffences in thermolabile characteristics of the MTHFR enzyme is a factor specific 
to the Scottish population as is suggested by the allele frequency data, ramains to 
be elucidated.
The significantly reduced MTHFR activity found in +/+ affected cases in this study
(2 1 %), indicates that a potential association may exist between the genotype and
an impaired level of folate metabolism. However, as the frequency of the +/+
genotype in affected cases is not significantly different from the -/- controls. It
seems likely that other factors must be contributing to the etiology of NTDs in these
individuals, since it wiould be expected that a significantly greater number of these
affected individuals would be found if the +/+ genotype were a causal factor. A
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significantly reduced MTHFR activity in the +/+ mothers (25,6%) combined with a 
significant difference in the frequency of the +/+ genotype compared to the -/- 
controls, lends support the hypothesis that the maternal genotype may play some 
part in the occurance of NTDs. The mechanism by which this is acheived is as yet 
unclear, however the hypothesis that a reduced folate turnover caused by the 
presence of the +/+ genotype in the mother, places additional stress on a +/+ fetus 
which already has an impaired folate metabolism, may be a reasonable. While this 
may suggest a way in which the genetic factors of NTD formation may interact, 
there remains the crucial question of the environmental component to be 
considered, notably that of folate and vitamin B12.
6.3.3 Folate and vitamin B12
It is still unclear as to how folic acid affords the developing embryo protection from 
birth defects, and a number of suggestions have been put forward with regard to 
the mechanisms involved. It is possible that the level of folic acid available to the 
developing embryo compromises its ability to perform single-carbon transfer 
reactions, subsequently interfering with purine biosynthesis, or equally likely, that 
insufficient concentration of folic acid may adversely affect the normal functions of 
proteins or gene expression, essential to the closure of the neural tube. While 
there is overall reduction in red cell folate in +/+ individuals compared to the -/- 
controls of 81% this result is not significant, therefore it would appear on the basis 
of these results, that there is no evidence for implication of significantly reduced 
levels of red cell folate, in mothers of affected individuals or the affected 
individuals themselves, associated with the thermolabile MTHFR allele.
The relationship between circulating levels of folate in indiividuals and the aetiology 
of NTDs has been closely examined in a number of studies. A report by Molloy et 
al (1985) exam ined 32 samples from mothers with affected pregnancies found low 
concentrations of folic acid, vitamin C and vitamin B12, but no significant difference 
in serum folate and vitamin B12 concentrations between mothers of affected and 
controls. Unfortunately no red cell folate results were obtained in this study . They 
postulated that if maternal nutritional status plays a part in the aetiology of NTDs, 
this may be reflected in the low serum status of that particular nutrient before or 
during the pregnancy. Smithells et al (1976) found lower RBC folate in the first 
trimester in six mothers with affected pregnancies compared with the control group,
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while the study by Laurence et al (1981) showed the mean red cell folate 
concentration during the first trimester in women who had recurrent NTD 
pregnancies was lower, although not significantly so, compared to the controls. A 
systematic review of the literature by Wald et al (1996) showed that on average 
during the first trimester of pregnancy, serum folic acid was 0.6 mg/ml lower 
(p<0.01), red cell folate was 77ng/ml lower (p<0.001) and that serum vitamin B12 
was 38ng.ml lower ( p<Q.001) in NTD affected pregnancies compared to the 
controls. Yates et al (1987) found the mean concentration of red cell folate in 
mothers with affected pregnancies was significantly lower than the mean for the 
control groups, and that these levels showed a linear relationship with the number 
of NTD affected pregnancies where levels were lowest in women who had had 3 or 
4 NTD affected offspring. They concluded that since there was no significant 
difference in serum folate, B12 or trace elements e.g. magnesium, copper or zinc 
and dietary intakes of total folates were lower, although not significantly so, that 
these NTDs were not due entirely to a lower folate intake, and that a specific inborn 
error of metabolism may be implicated.
One major problem in assessing the effect of folate on the developing neural tube 
is that much of the works retrospective in nature and since none of these women 
were pregnant when the samples were taken (as in this study) the data may not 
represent a true picture of the state of folate metabolism during the formation of the 
neural tube where folate requirements may be substantially different, in order to 
cope with the increased demands of the fetus.
In addition to folate, these studies have reported that vitamin B12, and 
consequently the enzyme methionine synthase, as having a potential role in the 
determining susceptibility to NTDs. Reduced levels of vitamin B12 could 
compromise the function of methionine synthetase leading to to an increase in 
homocysteine which may have a deleterious effect on the developing neural tube. 
The results from this study differ from other workers, in that there appears to be no 
evidence of a reduction in vitamin B12 levels between the studied groups and the 
controls.However it is interesting to note that in both the mothers and fathers of 
affected individuals significant differences were observed in the B12 levels, these 
differences were higher and not lower as might be expected. The reasons for this 
are as yet unclear, however a re-evaluation of the assay method for both folate 
and vitamin B12 may shed light on this result.
Alterations of dietary habits to high or low folate intake are reflected initially in 
changing serum folate values. Day to day variations in serum folate may occur in a
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particular subject while on a reasonably similar diet over a period of time, and 
serum folate may fluctuate dramatically between deficiency and sufficiency ranges.
It was considered that since serum folate is an unreliable marker of nutritional 
status when a random sample is taken, in this study the value was used solely in 
the calculation of the erythrocyte folate which was considered to be a more useful 
index of nutritional status. Traditionally, serum and red cell folate was measured by 
m icrobiological assay but these were difficult to set up , maintain and notoriously 
slow in obtaining results. In recent years, these assay have been somewhat 
superseded by the competitive binding radio-assays such as the Simultrac method 
quoted in this study. The m icrobiological method remains the ‘gold standard’ 
method for folate analysis by most investigators ( Molloy and Scott 1997).
Molloy and Scott (1998) reported differing results for red cell folate values for the 
subjects with the homozygous thermolabile MTHFR variant when the 
m icrobiological method was compared to three other studies using the radioassay.
While the former study showed lower erythrocyte folates in the homozygous variant 
population compared to the controls and heterozygotes, the latter showed the 
converse. This has implications for this study’s folate results where the hypothesis 
that NTD affected and at risk individuals have lower erythrocyte folate levels due to 
the thermolabile allele was not observed. Current European studies into gene- 
nutrition interaction for orofacial clefting, have utilised the microbiological method
i
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for folate analysis as the method of choice (Welcome-Sparks study - Dr. P.Mossey, 
personal communication), and so it may be useful at a future date to re-assess the 
folate levels in this study using this microbiological method.
The relative folate deficiency may not be the main contributory factor in the 
aetiology of NTDs. Deficient red cell folate in association with normal serum values 
imply diminished uptake of folate into tissues, either due to Vitamin B12 deficiency 
or some other transport mechanism. Folic acid supplements taken periconceptuaHy 
can greatly reduce a womans risk of having child with an NTD, however, despite 
adequate amounts of folate in their diet, a significant number of women still have 
affected pregnancies, where this folic acid supplementation in some women fails to 
prevent the NTD. The data obtained from this study suggests that reduced levels of 
folate already present in some mothers, may be exacerbated by the demands of 
pregnancy, which combined with a genetic predisposition in both mothers and the 
fetus, to reduced activities of the folate processing enzymes, contribute to the 
malformation of the NTD. Supplementary folate in the diet, by overcoming a 
metabolic block may prevent NTD in the majority of pregnancies, whereas in those Î
i198
pregnancies where folate supplementation falls to prevent such an abnormality, 
other mechanisms, as yet unclear may be at work.
As Yates ef al ( 1987) so aptly pointed out:
"from the point of view of of preventing human 
malformations It may be necessary to look for causes which 
are In themselves, not abnormal at all but which are 
unfavourable In combination with one another. The maternal 
blood level of some chemical substance, hormone or 
vitamin, may be quite normal , according to ordinary clinical 
standards but below (or above) a value which Is critical from 
the point of view of a developing fetus with a given genetic 
constitution”
6.3.4 Folate and diet
The results from this and other studies have raised a number of questions by the 
scientific and health communities regarding the appropriate levels of folate intake
within different, populations, on both the amounts and methods of supplemen­
tation of folate (Wald 1994).
Surveys have shown that the wide distribution of folate intake within adult -
populations across Europe may partly reflect differences in dietary habits among 
European countries, where France, Spain and Portugal have a higher proportion 
of folate rich foods such as vegetables, fruits and whole grains compared to their 
northern counterparts (Kushi ef al 1995). This combined with methodological 
differences in collection of dietary information and the unreliability of estimating 
folate content in food has contributed to the variation in reported recommended 
dietary intake (RDI) (Black et al 1985).
Because of the critical timing of folic add supplementation, the general advice to 
women has been to take folic acid supplements from the time they decide to 
become pregnant. (Wald 1993) reported that data from the United States indicates 
that a large proportion (perhaps the majority) of pregnancies are unplanned, and 
so advising women planning a pregnancy to take extra folate supplements is 
unlikely to target the large numbers of preventable NTDs in the population. Based 
on a survey of British adults which showed the median intake of folate was 
200|ig/day, Wald theorised that even folate supplementation by a factor of 3 was
unlikely to attain the levels recommended for occurrent NTD prevention, and that
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1the only practical public health strategy was folic acid fortification of a limited 
range of commonly consumed or staple foods such as flour.
The ethical question of fortification of staple foods with folic acid has attracted a 
spectrum of views from both proponents and critics alike. Wald (1995) advocated 
this measure as a simple, safe and economical method of reducing the incidence 
of birth defects in the pregnant population, other workers have warned of the risks 
involved to the general population as a whole. Following a proposal by the US 
Food and Drug Administration, Gaull et at (1996) have questioned the wisdom of 
fortifying food given a variety of uncertainties. These reservations included, the 
multifactorial and polygenic nature of NTDs; the demographic nature and 
decreasing prevalence of NTDs; the lack of a dose-relationship between folate and 
NTDs and launching of a nutritional strategy without assurances that the health 
risks would not shift from one group to another, notably from developing embryos 
to adults with pernicious anaemia.
One powerful argument likely to sway opinion in favour of folic acid fortification has 
come from studies in the United States on the econom ic effect on health care costs 
with regard to birth defects, premature birth and coronary heart disease (Bendich et 
al 1997) . This study projected annual cost reductions in US hospitalisation 
charges, derived from data on the percentage of at-risk Americans with daily 
vitamin intake levels lower than those associated with a reduction in disease risk, 
and found that annual hospital charges for birth defects, low-weight premature 
births and coronary heart disease could be reduced by 40, 60 and 38% 
respectively. This equated to a Figure of nearly $20 billion dollars in hospital 
charges, avoidable by the daily use of folic acid and zinc containing multivitamins 
by all women of childbearing age and daily Vitamin E supplementation of 
individuals over 50 years of age.
6.4 Conclusions
i
It is clear from the study of the distribution of purine enzyme activities that the 
range of observable activities does not always fall within the limits of normal or 
Gaussian distributions and that data transformation is required to allow meaningful 
statistisicat analysis to be performed. In this instance the transformation technique 
chosen was that of conversion to a logio value although there are other methods of 
transformation which may also be suitable to obtain reference ranges for 
comparison of patient values. This should optimise the possibility of distinguishing
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normal and pathological values, although for many inborn errors where affected 
individuals have zero activity, interpretation of results is usually straight forward. 
However for some inborn errors of metabolism, e.g. Lesch-Nyhan syndrome, 
significant residual activity may be present and the approach used in this study 
allows the lower limit of normal to be clearly defined. This also helps in the 
interpretation of carrier levels, as reported for ADA and PNP individuals in this 
work.
For prenatal diagnosis of the purine disorders, CV is the tissue of choice, due to 
the fact that first trimester enzym ic analysis is a well established procedure both in 
the method of sampling and of obtaining reliable results for the analysis. Where CV 
tissue fails to give unequivocal results , perhaps due to small quantities of tissue or 
a failure of culture, amniotic fluid cell cultures are a suitable alternative. Amniotic 
fluid cells give considerably higher enzyme specific activities for the 3 purine 
enzymes studied here, thus enhancing the differentiation between the lower normal 
limits of the control range and residual activities of affected pregnancies. However, 
second trimester analysis is less desirable in light of the potentially distressing 
nature of a termination later into the pregnancy. The study has also shown that in 
extreme cases where the CV and amniocentesis failed to give an unequivocal 
result, these enzymes can be measured accurately in fetal blood, although 
obtaining a sample of this nature is restricted specialist centres.
It is important that confirmation of the prenatal diagnosis be made in tissue from 
the index case, whether in red cells for a liveborn infant or in the case of selective 
termination in fibroblast tissue, since only by this procedure can the accuracy of the 
diagnostic process be assessed. During the time of this study, it was clear from the 
very few postnatal samples obtained subsequent to a prenatal diagnosis that this 
message requires to be constantly reinforced.
The study confirms the work reported from other sources that while biochemical 
methods are appropriate for use in the prenatal and postnatal diagnosis of affected 
individuals, the lack of differentiation between the normal ranges and carrier 
females in Lesch-Nyhan syndrome dictates we must look toward molecular 
genetics techniques for a reliable assessment of carrier status.
The assessment of HGPRT appears to be unhelpful in the determination of the 
causes of idiopathic gout. However, low levels of HGPRT observed in cases of 
polyarticular gout may help in the differentiation of the types of gout presenting
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and aid in the long term management of the condition. The study has shown that 
enzymes other than those present in the salvage pathway may play a vital part in 
certain cases of gout and this should be borne in mind when a diagnosis is being 
made or request for enzyme analysis is being made.
Results for the analysis of ADA and PNP suggest when investigating the type of 
immunodeficiency present in a patient, it is of value to analyse both ADA and PNP 
in tandem where a diagnosis of immunodeficiency is suspected. Evidence is also 
presented that carrier detection by careful enzyme analysis is possible for ADA and 
PNP.
Clear evidence from other studies of a role for folate in the development of fetal 
neural tube defects, raises questions about the mechanism and biochemical 
pathway involvement of this co-factor. In this study a folate-dependent enzyme, 
MTHFR, was investigated to establish the importance of a common, genetically 
determined variant of the enzyme in the aetiology of NTDs. Comparison of the 
gene frequencies of the thermolabile MTHFR allele indicate that between the 
European data and that obtained in the Scottish study, an underlying population 
effect may exist, in that, the NTD affected patients for the latter do not exhibit a 
higher frequency of the 677C->T genotype than the control group. This suggests 
that factors other than this particular MTHFR mutation may be influencing the 
aetiology of this disorder in the NTD affected individuals, a contention supported 
by the increased frequncy of the 677C->T mutation, low MTHFR enzyme activities 
and low red cell folate levels compared to the controls in mothers who have had 
affected pregnancies. This raises the possibility, that a pre-existing reduced folate 
level and a reduced MTHFR processing capacity, perhaps exacerbated by the 
increased demands of the fetus during pregnancy, may be a potential risk factor 
in the development of some NTDs. in view of the contradictory findings between 
this and other reported studies, it is unlikely that this is the only factor associated 
with the formation of NTDs in humans, and it remains to be ellucidated whether 
other folate enzyme of transport defects contribute to this multifactorial disorder.
Î ,
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6.5 Future prospects
The association between the neurological dysfunction and the biochemical 
deficiencies in purine metabolism have been well documented, the mechanisms 
connecting the cause and effect are still unclear. There have been a number 
of hypotheses proposed as to the mechanisms involved as they relate to disorders 
such as Lesch-Nyhan Syndrome and gout, but these hypotheses are not mutually 
exclusive, and in some cases are consequences of one another. With the advent 
of the ever increasing computer power now available, the field of bio-mathematical 
analysis is proving a useful tool for screening these mechanisms and for detecting
patterns relating the biochemical abnormalities to the physiological and
neurological functions observed in patients. This analysis provides the opportunity 
of simulating experiments that would be impossible or perhaps unethical in animals 
or humans. Bio-mathematical modelling allows an analytical system to be set up in 
such a way that corresponds to the physiological or disease states and by
■manipulating the parameters of the model, insight can be gained into the 
importance of individual intermediates or analytes within the system, which can 
then be translated into biochemical and clinical terms. Curto e ta l (1998a; 1998b), 
using this modelling method have shown that the metabolic dysfunctions that lead 
to hyperuricaemia and gout can be ranked in order of importance as: changes in 
the effect of uric acid on its own excretion; changes in the inhibition of PRPP-s by 
adenylates and guanylates; changes in PRPP-S activity; changes in HGPRT 
activity and changes in the inhibition of AMPD by guanylates and phosphate. In 
addition, they reported that in Lesch-Nyhan Syndrome, the processes leading to
I!
the neurological dysfunctions are strongly affected by the guanylate pool depletion 
and that the ratio of flux of GPRT to HPRT is correlated ' with these 
perturbations.
As these methods of modelling become more sophisticated and the parameters of 
the dysfunction are better understood, a clearer understanding of the underlying 
mechanisms of this disorder may be obtained and may be applied to other
,metabolic systems.
Given that the mechanism for NTD risk reduction by folic acid supplementation
remains unknown and the maternal supplementation in the periconceptiona! period 
does not reduce the risk in susceptible individuals, there remains the possibility that 
there is deficiency in the transport or metabolism of folic acid as the cause of fetal
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abnormality. This study has exam ined only one aspect of the multifactorial nature 
of this disorder, namely the role played by the enzyme MTHFR in the aetiology of 
neural tube defects. Results here and elsewhere indicate that potential population 
differences on the risk association of MTHFR to neural tube defects and while the 
majority of the data suggests an association, it has been limited to studies where 
there is a relatively low risk population. Scotland and in particular the West of the 
country is considered to have one of the highest incidences of NTD in the world, 
and yet the data reported in this study indicates no significant risk factor of NTD 
with MTHFR. One possible reason may lie in the method of data reduction. Recent 
studies on disorders with similar aetiologies, such as orofacial cleft defects, 
suggest that in order to identify the genetic and enviromental factors which may 
underlie these disorders, several approaches may be necessary to analyse family 
and population based data. This rationale has its basis in the fact that 
aetiological factors in multifactorial disorders are diverse in their mode of 
contribution with monogenic factors being best Identified by segregation analyses 
such as linkage analysis, where as association studies can take into account 
environmental factors. The limitations of both of these approaches prompted 
Spielman et al (1993) to use the the transmission/dysequilibrium test (TDT) as an 
alternative to testing other genetic markers for linkage markers when a population 
difference has been found. The data obtained in this and future studies by the 
analysis of data by the TDT approach rather than the traditional and somewhat 
limited case-control study, may provide a better basis for the genotypic study of 
multifactorial disorders.
In order to accommodate DNA synthesis, large amounts of nucleotides are 
required by the rapidly dividing cells of the developing neural tube. If the supply of 
the nucleotides to these cells is reduced, the rate of cellular replication will be 
slowed and the development of the neural tube retarded. Folate receptors which 
are less efficient at binding and transporting 5-methyltetrahydrofolate into the cell 
have been implicated in this process, with the periconceptional folate 
supplementation increasing maternal blood folate levels and therefore driving these 
reactions across a defective receptor. Studies of the folate receptor which 
consists of 3 forms, FR-a , FR-p AND FR-y, have been disappointing with only 2 
mutations detected in the coding region of FR-a gene in nearly 2000 individuals, 
and of these two mutations only one occurred in an NTD individual (Barber et al 
1999). Although there appears from this data that no association exists between
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the receptor and the NTD risk, the nature of the multifactorial aetiology of NTD’s, 
suggests that a combination of other gene variations may be required with the 
receptor status for NTD risk to be increased. Whether it is the maternal, fetal or 
even the paternal genotype plays an part in this aetiology is as yet unclear, 
however the results obtained in this study suggest that if MTHFR is one of the 
factors implicated , that the maternal genotype may be a vital component. What is 
clear is that much further work in this area is subsequently required to elucidate 
these mechanisms.
As the intricate nature of folate metabolism implicates a large number of potential 
candidate genes, it is certain that many other loci will be exam ined as risk factors 
involved for NTDs. Recently a number gene families notably those of Msx and 
PAX, have been Implicated in the development of the neural tube. While these 
candidate genes have ostensibly provided insight into the mechanisms of formation 
of the neural tube in animal models, the question remains whether this data can be 
translated into the elucidation of the aetiology of NTD's in humans (Davidson 1995; 
Hoi ef a/ 1996; Trembath ef a/ 1999).
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APPENDIX A
Copy of the consent form used in the neural tube defect study.
A study of a Possible Genetic Cause of Neural Tube Defects in Scotland
There is good evidence that folic acid in the diet at the time of conception and in the earliest 
stages of pregnancy can prevent most cases of neural tube defect (NTD). We are trying to find 
out why not all cases of NTD can be prevented by folic acid, and if there is a difference in the 
benefit of folic add between different families.
Recently, it has been found that some people in the population have an unusual form of an 
enzyme called MTHFR which prevents folic add from being used so effectively by the body. 
Although such people are perfectly healthy, some women in this group may have an increased 
risk of having an affected pregnancy. Researchers have found that people with NTD and their 
parents had the non-standard form of MTHFR more often than people with no family history of 
NTD.
As this form of MTHFR is inherited, it is possible Üiat this may be a genetic cause of at least some 
cases of NTD. To learn more about this, a study is about to begin at the Institute of Medical 
Genetics in Glasgow of families with NTD to see how common the non-standard form of MTHFR 
is in Scotland.
To carry out the study we require to collect blood samples from people who have a history, and 
from others who do not have a history of NTD in their family. Taking part in the study is entirely 
voluntary. Only one sample (about 20 mis taken from your arm) is required. It is not essential that 
all members of the family donate blood. All samples will be most valuable contributions to the 
study.
If you wish to volunteer please fill in your details below and return the whole form in the envelope 
provided to the Institute of Medical Genetics, Someone from the Institute will then contact you 
and arrange for the blood sample to be taken, either by your GP or at a convenient dinic.
Thank you for taking time to read this leaflet. If you have further questions please telephone 0141 
201 0365 and ask for Dr. Margo Whiteford or Mr Gordon Graham.
X
CONSENT FORM
I wish to help the study of a possible genetic cause of NTD in Scotland by donating a sample of 
my blood
Name       dob / !
Address _________________ ______ _____________________ __________
_______     Telephone: ________ _
Postcode._______ __L Signature:.
(Signature of Parent/Guardian _____     if under 16 years)
Family Details (please tick):
□  I have spina bifida
□  I have had a spina bifida pregnancy and prenatal diagnosis
□  I have a son/daughter/other relative with spina bifida (Name:..............................
(.....................dob)
□ There is no history of spina bifida In my family\
Name and Address of GP:  '
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APPENDIX B
Summary of the patient data obtained for the gout study.
LABNO DOB HGPRT APRT PRPP-S SEX HGPRT/APRT AGE 
RATIO OF ONSET
PRE-TEST
URATE
FAMILY
HISTORY
JME 10/17/45 97.1 28.1 0.64 M 3.5 28 626 N
MSH 12/20/28 71.6 30.6 0.36 F 2,3 55 633 N
AGS 04/09/19 69.8 29.2 0.24 F 2.4 47 622 N
RMA 08/02/35 73,7 15.2 0.34 M 4.8 460 N
TGR 03/20/36 68.6 11.4 0.36 M 6.0 54 390 N
MRE 02/04/34 74.2 16,7 0.43 F 4.4 53 510 N
TDS 12/06/52 95.8 49.0 0.39 M 1.96 33 640 Y
TTN 109,5 23.3 0.38 M 4.7
JDM 12/02/36 74.2 21.6 0.39 M 3.4 52 N
WMR 03/28/42 84.2 7.6 0.32 M 11.1 528 N
CHS 04/28/45 77.2 11.5 0.40 M 6.7 24 688 N
TME 08/16/57 79.9 11.0 0.51 M 7.3 33 592 N
AWS 06/04/20 86.2 19.2 0.37 M 4.5 68 710 N
WBH 07/05/33 74.9 11.9 0.35 M 6.3 39 550 Y
FFR 07/10/50 49.3 10.4 0.56 M 4.7 481 N
WMA 10/14/41 72.5 11.7 0.42 M 6.2 50 820 Y
TWN 01/15/60 82.5 12.2 0.31 M 6.8 20 972
TMA 05/16/37 94.8 15.9 0.43 M 5.9 42 627 N
DJN 12/27/23 91.0 15.4 0.57 M 5.9 50 N
MBE 03/01/21 92.2 9.9 0.40 F 9.3 68 680 Y
PCK 12/02/39 80.2 18.9 0.31 M 4.2 36 712 N
SMY 04/30/54 74.4 7.6 0.29 M 9.8 38 182 Y
RMN 11/10/44 92.9 19.2 0.41 M 4.8 42 500 N
JGN 12/14/83 68.8 22.4 0.26 M 3.1 43 >500 N
ASE 11/27/29 90.2 11.2 0.41 F 8.1 58 640 N
GET 01/20/34 87.2 18.4 0.41 M 4.7 55 460 N
WMN 04/28/42 72.5 12.3 0.37 M 5.9 42 470 N
JHE 04/24/29 76.9 17.1 0.16 M 4.5 45 690 N
JSH 08/11/20 101.9 20.3 0.20 M 5.0 64 N
EME 01/24/20 105.4 15.7 0.49 F 6.7 39 N
GIN 02/09/50 141.6 24.9 0,27 M 5.7 N
JTO 06/17/21 89.4 13.6 0.48 M 6.6 71 709 N
FMF 10/02/24 99.6 7.5 0.33 M 13.3 60 610 N
ESD 91.4 37.7 0.27 F 2.4
JTR 96.3 15.8 0.31 M 6.1
JST 100.1 13.6 0.35 M 7.4
WCM 07/30/43 82.6 28.8 0.19 M 2.9 31 251 N
JGL 11/05/35 106.2 25.1 0.35 M 4.3 20 656 Y
WSE 07/12/54 74.9 12.4 0.25 M 6.0 30 519 Y
JWE 08/19/29 85.9 32.9 0.19 M 2.6 60 620 N
Î
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Appendix B (continued)
Continuation of summary in Appendix B of the patient data obtained for the gout 
study.
LABNO DOB HGPRT APRT PRPP-S SEX HGPRT/APRT 
RATIO
AGE OF 
ONSET
PRE-TEST
URATE
FAMILY
HISTORY
ACD 12/11/41 83.7 12.4 0.20 F 6.8 12 515 N
RHY 08/07/50 87.3 17.3 0.20 M 5.0 40 553 N
HWN 03/06/34 92,7 18.9 0.24 M 5 56 465 N
JKN 03/20/35 95.1 9.7 0.23 M 9.8 615
JCK 07/18/47 92.5 11.2 0.17 M 8.3 37 706
ASL 06/10/50 91.7 23.4 0.15 M 4 27 N
WWH 12/24/44 77.5 14.1 0.20 M 5.5 45 N
RMY 11/08/42 97.4 13.3 0.19 M 7.3 42 700 Y
PBE 09/08/58 99.5 12.9 0.29 M 7.7
ASN 09/26/32 108.7 32.2 0.29 F 3.4 46 HIGH Y
APR 11/12/48 82.5 20.2 0.17 M 4.1 31 456 Y
ABL 07/08/31 89.2 16.9 0.24 M 5.3 53 460 Y
AFN 11/04/41 95.7 12.9 0.23 M 7.4 Y
TGR 08/27/36 42.7 6.2 0.37 M 6.9 27 N
208
BIBLIOGRAPHY
209
Aitken DA, Ferguson-Smith MA. Regional assignment of nucleoside phosphorylase 
by exclusion to 14q13. Cytogenet Cell Genet 1978; 22:
490-492.
Aitken DA, Morrison NM, Ferguson-Smith MA. Predictive value of amniotic 
acetylcholinesterase analysis in the diagnosis of fetal abnormality in 3700 
pregnancies. Prenat Diagn 1984; 4: 329 - 340.
Aitken DA, Gilmore DH, Frew CA, Ferguson-Smith ME, Carty MJ, Chatfield WR. 
Early prenatal diagnosis of a pregnancy at risk of adenosine deam inase deficiency 
using chorionic villi. J. Med. Genet. 1986; 23: 52-54.
Akaoka I, Fujimori S, Kamatani N, et al. A gouty family with increased 
phosphoribosylpyrophosphate synthetase activity: case reports, familial studies, 
and kinetic studies of the abnormal enzyme. J Rheumatol 1981; 8: 4: 563-574.
Al-Awadi SA, Farag Tl, Teebi AS, Naguib KK, El-Khalifa MY. Anencephaly; 
disappearing in Kuwait? [letter]. Lancet 1984; 2: 701-702.
Alford RL, Redman JB, O'Brien WE, Caskey CT. Lesch-Nyhan syndrome: Carrier 
and prenatal diagnosis. Prenat Diagn 1995; 15: 329-338.
Amniotic fluid acetylcholinesterase electrophoresis as a secondary test in the 
diagnosis of anencephaly and open spina bifida in early pregnancy. A report of the 
collaborative acetylcholinesterase study Lancet ii 1981; 2: 321-324.
Aust MR, Andrews LG, Barrett MJ, Norby-Slycord CJ, Marked ML. Molecular 
analysis of mutations in a patient with purine nucleoside phosphorylase deficiency. 
Am J Hum Genet 1992; 51: 763-772.
Bakay B, Nyhan W. Heterogeneity of Hypoxanthine-Guanine Phosphoribosyl 
Transferase form Human Erythrocytes. Arch Biochem Biophys 1975; 168: 26-34.
Barber RC, Lammer EJ, Shaw GM, Greer KA, Finneil RH. The Role of folate 
transport and metabolism in neural tube defect risk. Mol Genet Met. 1999; 66: 1-9.
Becker MA, Kostel PJ, Meyer LJ. Human phosphoribosylpyrophosphate 
synthetase. Comparison of purified normal and mutant enzymes. J Biol Chem 
1975; 250: 17: 6822-6830.
Becker MA. Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate 
concentration and generation in fibroblasts from patients with gout and purine 
overproduction. J Clin Invest. 1976; 57: 308-318.
Becker, M.A.; Losman, M.J.; Itkin, P.; Simkin, P.A. Gout with superactive 
phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J 
Lab Clin Med 1982; 99: 4: 495-511.
Becker MA, Losman MJ, Kim M. Mechanisms of accelerated purine nucleotide 
synthesis In human fibroblasts with superactive phospho-ribosylpyrophosphate 
synthetases. J Biol Chem 1987; 262: 12: 5596-5602.
210
Becker MA, Puig JG, Mateos FA, Jimenez ML, Kim M, Simmonds HA. Inherited 
superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid 
overproduction and sensorineural deafness. Am J Med 1988; 85: 383 -390.
Becker MA, Heidler SA, Beil Gl et al. Cloning of cDNAs for human 
phosphoribosylpyro-phosphate synthetases 1 and 2 and X chromosome 
localization of PRPS1 and PRPS2 genes. Genomics 1990; 8: 555-561.
Becker MA, Nogol JM, Switzer RL, Smith, RP, Palella TD, Roessler, BJ. Point 
mutations in the PRPS1 gene encoding th PRPP synthetase (PSS) 1 isoform, 
underlie X-linked PRS superactivity associated with purine nucleotide inhibitor- 
resistance. Adv Exp Med Biol 1995: 370: 707-710.
Becker MA, Roessler BJ. Hyperuricemia and Gout. In: Scriver CR, Beaudet AL, Sly 
WS, Valle D, editors. The metabolic and inherited bases of inherited disease. 7^  ^
ed. New York: McGraw-Hill Inc, 1995a: 1655-1677.
Becker M.A, Smith PR, Taylor W, Mustafi R, Switzer RL. The genetic and 
functional basis of purine nucleotide feedback-resistant phosphoribosyl­
pyrophosphate synthetase superactivity. J Clin Invest 1995b; 96: 2133-2141.
Becker MA, Taylor W, Smith PR, Ahmed M. Overexpression of the normal 
phosphoribosylpyrophosphate synthetase 1 isoform underlies catalytic superactivity 
of human phosphoribosylpyrophosphate synthetase. J Biol Chem 1996; 271: 33: 
19894-19899.
Bendich A, Mallick R, Leader S. Potential health econom ic benefits of vitamin 
supplementation. West J Med 1997; 166: 306-312.
Besley GTN, Young EP, Fenson, AH, Cooper A. First trimester diagnosis of 
inherited metabolic disease. Experience in the UK. J Inher Metab Dis 1991; 14: 
128-133.
Besley GTN. Enzyme Analysis. In: Brock DJH, Rodeck C, Ferguson-Smith MA, 
editors. Prenatal diagnosis and screening. London: Churchill-Livingstone, 1992: 
127-145. ■1Beutler E. Red cell metabolism. A manual of biochemical methods. 3^ "" ed. Grune 
and Stratton Inc. London, NewYork 1984..
Black AE, Paul AA, Hall C. Footnotes to food tables. 2. The underestimations of 
intakes of lesser B vitamins by pregnant and lactating women as calculated using 
the fourth edition of McCance and W iddowson's The composition of foods'. Hum 
NutrAppI Nutr 1985; 39; 19-22.
Blaese RM, Culver KW, Miller AD et al. T lymphocyte-directed gene therapy for 
ADA-SCID: initial trial results after 4 years. Science 1995: 270: 475-480.
Borman B, Cryer C. Fallacies of international and national comparisons of disease 
occurrence in the epidem iology of neural tube defects. Teratology 1990; 42; 405- 
412.
211
Curto R, Voit EO, Sorribas A, Cascante M. Mathematical models of purine 
metabolism in man. Math Biosciences 1998a; 1-48.
Bory C, Chantin C, Boulieu R. Abnormal purine and pyrimidine metabolism in 
inherited superactivity of PRPP synthetase. In: Sahota A, Taylor M, editors. Purine 
and Pyrimidine Metabolism in Man VIII. New York: Plenum Press 1995: 15-18.
Brennand J, Chinault AC, Konecki DS, Melton DW, Caskey CT. Cloned cDNA 
sequences of the hypoxanthine/guanine phosphoribosyltransferase gene from a 
mouse neuroblastoma cell line found to have amplified genom ic sequences. Proc 
Natl Acad Sci USA 1982; 79: 1950-1954.
Buchanan JM, Hartman SC. Enzymatic reactions in synthesis of the purines. Adv 
Enzymol 1959; 2: 199-261.
Burgemeister R, Gutensohn W. Normal ranges of the activities of ten differenct 
enzymes in 100 independent properties of chorionic villi. Comparison of specimens 
from induced abortions, biopsies and cultured cells. Prenat Diagn 1989; 9: 195- 
204.
Burton BK. Positive amniotic fluid acetylcholinesterase; Distinguishing between 
open spina bifida and ventral wall defects. Am J Obstet Gynecol 1986; 155: 5: 984- 
986.
Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a 
marker for ovarian cancer. Cancer Res. 1991; 51: 5329-5338.
Carapella de Luca E, Stegagno M, Dionisi VC et ai. Prenatal exclusion of purine 
nucleoside phosphorylase deficiency. EurJ Pediatr 1986; 145:51-53.
Carson DA, Kaye J, Seegmiller JE. Lymphospedfic toxicity in adenosine 
deam inase deficiency and purine nucleoside phosphorylase deficiency: Possible 
role of nucleoside kinase(s). Proc Natl Acad Sci USA 1977; 74: 12: 5677-5681.
Carter CO, Clues to the aetiology of neural tube malformations. Dev Med Child 
Neurol 1974; 16: 3-15.
Chen SH, Scott CR, Swedberg DR. Heterogeneity for adenosine deaminase 
deficiency; Expression of the enzyme in cultured skin fibroblasts and amniotic fluid 
cells. Am J Hum Genet 1975; 27: 46-52.
Chen SH, Ochs HD, Scott CR, Giblett ER, Tingle AJ. Adenosine deaminase 
deficiency: disappearance of adenine deoxynucleotides from a patient's 
erythrocytes after successful marrow transplantation. J Clin Invest 1978; 62: 1386- 
1389.
Chung, CS, Myrianthopoulos NO. Racial and prenatal factors in major congenital 
malformations. Am J Hum Genet 1968; 20,: 44-60.
Connor JM, Ferguson-Smith MA. Congenital Malformations; In Essential Medical 
Genetics (4"’ ed). Oxford, Blackwell Scientific Publications 1993; 193-212.
Curto R, Voit EO, Cascante M. Analysis of abnormalities in purine metabolism lead 
to gout and to neurological dysfunctions in man. Biochem J 1998b; 329: 477-487.
212
J '
Czeize! AE, Dudas I. Prevention of the first occurrence of neural-tube defects by 
periconceptional vitamin supplementation. N Engl J Med 1992;
Danois J, Cox RP, Berman PH, Jansen V, Balls ME. Cell population density and 
phenotypic expression of tissue culture fibroblasts from heterozygotes of Lesch- 
Nyhan's disease (inosinate pyrophosphorylase deficiency). Biochem Genet 1969; 
3: 609-615.
Davidson BL, Pashmforoush M, Kelley WN, Palella TD. Genetic basis of 
hypoxanthine guanine phosphoribosyltransferase deficiency in a patient with the 
Lesch-Nyhan syndrome (HPRTpw). Gene 1988; 63: 331-336.
Davidson BL, Pashmforoush M, Kelley W.N Palella TD. Human hypo-xanthine- 
guanine phosphoribosyltransferase deficiency. The molecular defect in a patient 
with gout (HPRTAshviiie). J Biol Chem 1989a; 264: 1: 520-525.
Davidson BL, Tarie SA, Palella TD, Kelley WN. Molecular basis of hypo-xanthine-
guanine phosphoribosyltransferase deficiency in ten subjects determined by direct 
sequencing of amplified transcripts. J Clin Invest 1989b; 84: 342-346.
Davidson BL, Tarie SA, Van Antwerp M et al. Identification of 17 independent 
mutations responsible for human Hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) deficiency. Am J Hum Genet 1991; 48: 951-958.
Davidson D. The function and evolution of Msx genes; pointers and pardoxes. TIG
1995; 11: 10: 405-411.
De Bruyn CHMM, Oei TL, Geerdink RA, Lommen EJP. An atypical case of 
Hypoxanthine-Guanine phosphoribosyltransferase deficiency (Lesch-Nyhan 
syndrome ). II. Genetic Studies. Clin Genet 1973; 4: 353-349.
De Bruyn CHMM, Oei, TL, Ter Haar BGA. Studies on hair roots for carrier 
detection in hypoxanthine-guanine phosphoribosyl transferase deficiency. Clinical 
Genetics 1974, 449-456.
De Bruyn CHMM. Hypoxanthine-guanine phosphoribosyltransferase deficiency. 
Hum Genet 1976; 31: 127-150.
De Franchis R, Sebastio G, Mandate C, Andria G, Mastroiacovo P. Spina bifida, 
677C-^T mutation, and role of folate. Lancet 1995; 346: 1703.
Dobrovic A, Gareau P, Seifert AM, Messing K, Bradley WE. A Hindlll RFLP for the 
HPRT pseudogene on chromosome 3 (HPRTP1). Nucleic Acids Res 1987; 15: 3: 
1346.
Dooley T, Fairbanks LD, Simmonds HA et al. First trimester diagnosis of 
adenosine deaminase deficiency. Prenat Diagn 1987; 7: 561-565.
Duran M, Dorland L, Meuleman EEE, Allers P, Berger R. Inherited defects of purine 
and pyrimidine metabolism. Laboratory methods for diagnosis. J Inher Metab Dis 
1997; 20: 227-236
213
■ Ï
Econom ides DL, Ferguson J, Mackenzie IZ, Parley J, Ware II, Holmes-Siedle M. 
Folate and vitamin B12 concentrations in maternal and fetal blood, and amniotic 
fluid in second trimester pregnancies complicated by neural tube defects. Br J 
Obstet Gynaecol 1992; 99; 23-25.
Emerson BT, Thomson L. The spectrum of hypoxanthine-guanine phospho-ribosyl 
transferase (HGPRT) deficiency. Q J Med 1973; 42: 423-440.
Engbersen AMT, Franken DG, Boers HJ, Stevens, EMB, Trijbels FJM, Blom HJ. 
Thermolabile 5,10-metheylenetetrahydrofolate reductase as a cause of mild 
hyperhomocystelnaemia. Am J Hum Genet 1995; 56: 142-150.
Fairbanks LD, Simmonds HA, Webster DR. Use of intact erythrocytes In the 
diagnosis of Inherited purine and pyrimidine disorders. J Inherit Met Dis 1987; 10: 
174-186.
Fan J, Vitols KS, Huennekens FM. Multiple folate transport systems in L1210 cells. 
Adv Enzyme Regul 1992; 32: 3-15.
Fox IH, Kelley WN. Human phosphoribosylpyrophosphate synthetase. Distribution, 
purification, and properties. J Biol Chem 1971; 246: 5739-5748.
Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular 
disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 
1987; 10: 111-113.
Fujimori S, Hidaka Y, Davidson BL, Palella TD, Kelley WN. Identification of a 
single nucleotide change in a mutant gene for hypoxanthineguanine 
phosphoribosyltransferase (HPRT Ann Arbor)- Hum Genet 1988; 79: 39-43.
Fujimori S, Davidson BL, Kelley WN, Palella TD. Identification of a single 
nucleotide change in the hypoxanthine-guanine phosphoribosyltransferase gene 
(H P R Tvaie ) responsible for Lesch-Nyhan syndrome. J Clin Invest 1989; 83: 11-13.
Fujimori S, Kamatani N, Nishida Y, Ogasawara N, Akaoka I. Hypoxanthine- 
Guanine phosphoribosyltransfrase deficiency: Nucleotide substitution causing 
Lesch-Nyhan syndrome identified for the first time among Japanese, Hum Genet 
1990; 84: 483-486.
Fujimoto WY, Seegmiller JE, Uhlendorf BW, Jacobson CB. Biochemical diagnosis 
of an X-linked disease in utero. Lancet 1968; 2: 511-512.
Galjaard H. Genetic Metabolic Diseases. Early diagnosis and prenatal diagnosis. 
Amsterdam, Oxford: Elsevier/North Holland Biomedical Press, 1980.
Gartler SM, Scott RC, Goldstein JL, Campbell B. Lesch-Nyhan Syndrome: Rapid 
detection of heterozygotes by the use of hair follicles. Science 1971; 172: 572- 
574.
Gaull GE, Testa CA, Thomas PR, Weinreich DA. Fortification of the food supply 
with folic acid to prevent neural tube defects is not yet warranted. J Nutr 1996; 
126; 3: 773S-780S.
214
:¥;
I
Geerdink RA, de Vries WHM, Willemse J, Oei TL, de Bruyn CHMM. An atypical 
case of Hypoxanthine-guanine phosphoribosyltransferase deficiency (Lesch-Nyhan 
syndrome). 1. Clinical Studies. Clin Genet 1973; 4: 348-352.
Ghidinî A, Sepulveda W, Lockwood C, Romero R. Complications of fetal blood 
sampling. Am J Obs Gyn 1993; 168: 5: 1339-1344.
Gibbs DA, McFadyen LR, d'A.Crawfurd M. First trimester diagnosis of Lesch-Nyhan 
Syndrome. Lancet 1984; 2; 1180-1183.
Gibbs RA, Caskey CT. Identification and localization of mutations at the Lesch- 
Nyhan locus by ribonuclease A cleavage. Science 1987; 236: 303-305.
G ibbs RA, Nguyen P, McBride LJ, Koepf SM, Caskey CT. Identification of 
mutations leading to the Lesch-Nyhan syndrome by automated direct DNA 
sequencing of in vitro amplified cDNA. Proc Natl Acad Sci USA 1989; 86: 1919- 
1923.
Gibbs RA, Nguyen PN, Edwards A, Civitello AB, Caskey CT. Multiplex DNA 
deletion detection and exon sequencing of the hypoxanthine 
phosphoribosyltransferase gene in Lesch-Nyhan families. Genom ics 1990; 7; 235- 
244.
Giblett ER, AndersonJE, Cohen F, Pollara B, Meuwissen HJ. Adenosine 
deaminase deficiency in two patients with severely impaired cellular immunity. 
Lancet 1972; 1: 1067-1069.
Giblett ER, Ammann, AJ, Wara DW, Sandman R, Diamond LK. Nucleoside- 
phosphorylase deficiency in a child with severely defective T-cell immunity and 
normal B-cell immunity. Lancet 1975: 1: 1010-1013.
Goyette P, Sumner J.S, Milos R et al. Human methylenetetrahydrofolate 
reductase: Isolation of cDNA, mapping and mutation Identification. Nat Genet 
1994; 7; 195-200.
Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the 
methylenetetrahydrofolate gene and genetype/phenotype correlations in severe 
methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052- 
1059
Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 
1970; 29: 461-468.
Gutman AB, Yu TF. Uric acid metabolism in normal man and in primary gout N 
Engl J Med 1965; 273: 252-260.
Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and 
hyperuricemia. A long-term population study. Am J Med 1967; 42: 27-37.
Hall JG, Friedman JM, Kenna BA, Popkin J, Jawanda M, Arnold W. Clinical, 
genetic, and epidem iological factors in neural tube defects. Am J Hum Genet 
1988; 43: 827-837.
215
Hirschhorn R, Beratis N, Rosen FS. Characterization of residual enzyme activity in 
fibroblasts from patients with adenosine deaminase deficiency and combined 
immunodeficiency: evidence for a mutant enzyme. Proc Natl Acad Sci USA 1976; 
73: 1:213-217
Hara K, Kashiwamata S, Ogasawara N et al. A female case of the Lesch-Nyhan 
syndrome. Tohoku J Exp Med 1982; 137: 275-282.
Haworth JC, Dilling LA, Surtees RA et al. Symptomatic and asymptomatic 
methylenetetrahydrofolate reductase deficiency in two adult brothers. Am J Med 
Genet 1993; 45: 572-576.
Henderson JF, Brox LW, Kelley WN, Rosenbloom FM, Seegmiller JE. Kinetic 
studies of hypoxanthine-guanine phosphoribosy tansferase. J Biol Chem 1968: 
243: 10: 2514-2522.
Hershfield MS, Buckley RH, Greenberg ML et ai. Treatment of adenosine 
deam inase deficiency with polyethylene glycol modified adenosine deaminase. N 
Engl J Med 1987; 316: 589-596.
iHershfield MS, Mitchell B. Immunodeficiency diseases caused by adenosine deam inase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver 
CR, Beaudef al, Sly WS, Valle D, editors. The metabolic and inherited bases of 
inherited disease. 7”' ed. New York: McGraw-Hill Inc, 1995: 1725-1768.
Hershfield MS, Arredondo-Vega FX, Santisteban I. Clinical expression, genetics 
and therapy of adenoside deaminase (ADA) deficiency. J Inher Metab Dis 1997; 
20: 179-185.
Hibbard BM. The role of folic acid in pregnancy, with particular reference to 
anaemia, abruption and abortion. J Obstet Gynaecol Br Commonw 1964; 71: 529- 
542.
Hirschhorn R, Beratis N, Rosen FS, Parkman R, Stern R, Polmar S. Adenosine 
deam inase deficiency in a child diagnosed prenatally. Lancet 1975; 1: 73-75.
Hirschhorn R, Paageorgiou PS, Kesarwala HH, Taft LT. Amerioration of neurologic 
abnormalities after "enzyme replacement" in adenosine deam inase deficiency. N 
Engl J Med 1980; 303: 7: 377-380. %
Hirschhorn R. Genetic deficiencies of adenosine deaminase and purine nucleoside 
phosphorylase; overview, genetic heterogeneity and therapy. In: Wedgewwod 
RRF, Paul NW, editors. Primary Immunodeficiency Diseases; Birth Defects. New 
York,: Liss 1983 73-83.
Hirschhorn R, Ellenbogen A. Genetic heterogeneity in adenosine deam inase (ADA) 
deficiency: Five different mutations in five new patients with partial ADA deficency. 
Am J Hum Genet 1986; 38: 13-25.
Hirschhorn R, Tzall S, Ellenbogen A. Hot spot mutations in adenosine deaminase 
deficiency. Proc Natl Acad Sci USA 1990; 87: 6171-6175
%
&
IHirschhorn R. Adenosine deam inase deficiency: molecular basis and recent developments. Clin Immunol Immunopathol 1995; 76: S219-S227.
216
Hoefnagal D, Andrew ED, Mireault NG, Berndt WO. Hereditary choreo-athetosis, 
self mutilation and hyperuricaemia in young males. New Eng J Med 1965; 273: 3: 
130-135.
Hoi FA, Guerds MP, Chatkupt S et a l . PAX genes and human neural tube defects: 
and amino acid substitution PAX1 in a patient with spina bifida. J Med Genet 1996; 
33: 8: 655-660.
Holden JA, Kelley WM. Human hypoxanthine-guanine phosphoribosyl transferase. 
Evidence for tetrameric structure. J Biol Chem 1978; 253: 4459-4463.
Holmes-Siedle M, Lindenbaum RH, Galliard A. Recurrence of neural tube defect in 
a group of at risk women: a 10 year study of Pregnavite Forte F. J Med Genet 
1992; 29: 134-135.
Holmes EW, Wyngaarden JB, Kelley WM. Human glutamine phosphoribosyl­
pyrophosphate amidotransferase. Two molecular forms interconvertible by purine 
nucleotides and phosphoribosyltransferase. J Biol Chem 1973; 248:17: 6035-40.
Holmes EW. Kinetic, physical and regulatory properties of amidophosphoribosyl 
transferase. Adv Enzyme Reg 1980; 19: 215-231.
Hooft C, van Nevel C, de Schaepdryver AF. Hyperuricosuric encephalopathy 
without hyperuricaemia. Arch Dis Child 1968; 43: 734-737.
Hoogerbrugge PM, van Beusechem VW, Fischer A et al. Bone marrow gene 
transfer in three patients with adenosine deaminase deficiency. Gene Ther 1996; 
3: 179-183.
Hosli P, de Bruyn CHMM, Oerlemans FJJM, Verjaal M, Nobrega RE. Rapid 
prenatal diagnosis of HG-PRT deficiency using ultra-microchemical methods. Hum 
Genet 1977; 37: 195-200.
Hull D, Johnstone Dl. Brain, Nerve and Muscle. In: Essential Paediatrics, 3^ "" ed. 
Churchill Livingstone 1981; 261-264. .
Jankovic J, Caskey CT, Stout JT, Butler IJ. Lesch-Nyhan Syndrome: A study of 
motor behaviour and cerebrospinal fluid neurotransmitters. Ann Neurology 1988; 
23: 466-469.
Jinnah HA, Wojcik BE, Hunt M, Norang N. Lee KY et al. Dopamine deficiency in a 
genetic mouse model of Lesch-Nyhan disease. J Neuroscience 1994; 14: 3: 1164- 
1175.
Jolly DJ, Esty AC, Bernard HU, Friedmann T. Isolation of a genom ic clone partially 
encoding human hypoxanthine phosphoribosyltransferase. Proc Natl Acad Sci USA 
1982; 79: 5038-5041.
Jolly DJ, Okayama H, Berg P et a i Isolation and characterization of a full-length 
expressible cDNA for human hypoxanthine phosphoribosyl- transferase. Proc Natl 
Acad Sci USA 1983; 80: 477-481.
Joule JA, Smith GF. Purines: Reactions and synthesis. In: Heterocyclic Chemistry. 
London. Van Nostrand Reinhold Co., 1972.
217
i :
Khoury MJ, Erickson JD, James LM. Etiologic heterogeneity of neural tube 
defects: clues from epidemiology. Am J Epidemiol 1982; 115: 4: 538-548.
Kohn DB, Weinberg Kl, Nolta JA et al. Engraftment of gene-modified umbilical cord 
blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995; 1: 
10: 1017-1023.
Kredich N and Hershfield MS.Immunodeficiency diseases caused by adenosine 
deaminase deficiency and purine nucleoside phosphorylase deficiency. In: 
Stanbury JB, Wyngaarden, J.B., FredericK-Son, D,, Goldstein, J .L , and Brown, M. 
(eds), 5‘ ed. New York,London, McGraw-Hill Inc 1983;
118
Kang S-S, Wong PW, Zhou JM, Sora J et al. Thermolabile methylenetetra­
hydrofolate reductase in patients with coronary artery disease. Metabolism 1988a;
37: 7: 611-613.
Kang S-S, Wong PWK, Kowalisyn J, Strokosch G. Intermediate Homocysteinemia:
A thermolabile variant of Methelenetetrahydrofolate Reductase. Am J Hum Genet 
1988b; 43: 414-421.
Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile 
Methylenetetrahydrofolate Reductase: An inherited risk factor for coronary artery 
disease. Am J Hum Genet 1991; 48: 536-545.
Kelley WM, Rosenbloom FM, Henderson JF, Seegmiller JE. A specific enzyme 
defect in gout associated with over production of uric acid. Proc Natl Acad Sci 
USA 1967; 57: 1735-1739
Kelley WM. Hypoxanthine-guanine phosphoribosyltransferase deficiency in the 
Lesch-Nyahn Syndrome and gout. Fed Proc 1968; 4: 1047-1052.
Ii
Kelley WM, Greene ML, Rosenbloom FM, Henderson JF. Seegmiller JE. 
Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern 
Med 1970; 70: 1: 155-206.
Kelley WM, Wyngaarden JB. Clinical Syndromes Associated W ith Hypoxanthine- 
Guanine Phosphoribosyitrasferase Deficiency. In: Stanbury JB, Wyngaarden, J.B., 
Frederickson, D., Goldstein, J.L., and Brown, M. (eds), 5 ed. New York,London,
McGraw-Hill Inc. 1983
I
Kleijer WJ, Hussaarts-Odijk LM, Los FJ, Pijpers L, De Bree PK, Duran M. Prenatal 
diagnosis of purine nucleoside phosphorylase deficiency in the first and second 
trimesters of pregnancy. Prenat Diagn 1989; 9: 401-407.
::v:|
Krenitsky TA, Papaloannou R, Ellion GB. Human hypoxanthine phosphoribosyl­
transferase. 1. Purification, properties and specificity. J Biol Chem 1969; 244: 5: 
1263-1270
Kushi LH, Lenart EB, Willett WC. Health implications of Mediterranean diets in 
light of contemporary knowledge. 1. Plant foods and dairy products. Am J Clin Nutr 
1995; 61: 1407S-1415S.
Lally EV, Ho GJ, Kaplan SR. The clinical spectrum of gouty arthritis in women. 
Arch Intern Med 1986; 146; 2221-2225.
Langford HG, Biaufox MD, Borhani NO et al. Is thiazide-produced uric acid 
elevation harmful? Analysis of data from the Hypertension Detection and Follow-up 
Program. Arch Intern Med 1987; 147: 645-649.
Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind 
randomised controlled trial of folate treatment before conception to prevent 
recurrence of neural-tube defects. Br Med J (Clin Res Ed.) 1981; 282: 1509-1511.
Lawry GV, Fan PT, Bluestai R. Polyarticular versus monoarticular gout: A 
prospective, comparitive analysis of clinical features. Med (Baltimore) 1988; 5: 335- 
343.
Lemire RJ. Neural tube defects. JAMA 1988; 259: 4: 558-562.
Lesch M and Nyhan W. A familial disorder of uric acid metabolism and central 
nervous system function. Am J Med 1964; 36: 561- 570.
Linch DC, Levinsky RJ, Rodeck CH, Maclennan KA, Simmonds HA. Prenatal 
diagnosis of three cases of severe combined immunodeficiency: severe T cell 
deficiency during the first half of gestation in fetuses with adenosine deaminase 
deficiency. Clin Exp Immunol 1984; 56: 223-232.
Lloyd KG, Hornykiewicz O, Davidson L et al. Biochemical evidence of dysfunction 
of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 1981; 
305: 1106-1111.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the 
Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
Markert ML, Hershfield MS, Schiff Rl, Buckley RH. Adenosine deaminase and 
purine nucleoside phosphorylase deficiencies: evaluation of therapeutic
interventions in eight patients. J Clin Immunol 1987; 7: 5: 389-399.
Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev 1991; 
3: 45-81.
Markert ML, Finkel BD, McLaughlin TM et al. Mutations in purine nucleoside 
phosphorylase deficiency. Hum Mutat 1997; 9: 118-121.
Marks JF, Baum J, Keele DK, Kay JL, MacFarlen A. Lesch-Nyhan syndrome 
treated from the early neonatal period. Pediatrics 1968: 42: 357-359.
Mateos FA, Puig JG. Purine metabolism in Lesch-Nyhan Syndrome versus Kelley- 
Seegmiller Syndrome. J Inher Metab Dis 1994; 17: 138-148.
McDonald JA, Kelley WM. Lesch-Nyhan Syndrome: Altered kinetic properties of mutant 
enzyme. Science 1971; 171: 689-691.
Melton DW. Cell fusion-induced mouse neuroblastomas HPRT revertants with 
variant enzyme and elevated HPRT protein levels. Somatic Cell Genet 1981; 7: 
331-344.
Meuwissen HJ, Pollara B, Pickering RJ. Combined immunodeficiency disease 
associated with adenosine deaminase deficiency. Report on a workshop held in 
Albany, New York, October 1, 1973. J Pediatr 1975; 86: 2: 169-181.
219
Meyer LJ, Becker MA. Human erythrocyte phosphoribosylpyrophosphate 
synthetase. Dependence of activity on state of subunit association. J Biol Chem 
1977; 252: 3919-3925.
Migeon BR, Der Kaloustian VM, Nyhan WL, Yough WJ, Childs B. X-linked 
hypoxanthine-guanine phosphoribosyltransferase deficiency: Heterozygote has two 
clonal populations. Science 1968; 160: 425-427.
Migeon BR. X-linked hypoxanthine-guanine phosphoribosyl transferase deficiency: 
detection of heterozygotes by selective medium. Biochem Genet 1970; 4: 377-383.
Mizuno T, Segawa M, Kurumada T, Maruyama H, Onisawa J. Clinical and 
therapeutic aspects of the Lesch-Nyhan syndrome in Japanese children. 
Neuropadiatrie 1970; 2: 38-52.
Molloy AM, Kirke P, Hillary I, Weir DG, Scott JM. Maternal serum folate and vitamin 
B i2 concentrations in pregnancies associated with neural tube defects. Arch Dis 
Child 1985; 60: 660-665.
Molloy AM, Scott JM. Microbiological assay for serum, plasma and red cell folate 
using cry op reserved, microtiter plate method. Methods Enzymol 1997; 281: 43-53.
Molloy AM, Mills JL, Kirke PN, Whitehead AS, Weir DG, Scott JM. Whole-blood 
folate values in subjects with different methylenetetrahydrofolate reductase 
genotypes: differences between the radioassay and micro-biological assays. Clin 
Chem 1998 44; 1; 186-188.
Morgan G, Levinsky RJ, Hugh-Jones K, Fairbanks LD, Morris GS, Simmonds HA. 
Heterogeneity of biological, clinical and immunological parameters in severe 
combined immunodeficiency due to adenosine deaminase deficiency. Clin Exp 
Immunol 1987; 70: 3: 491-499.
Morris GS, Simmonds HA. Use of a fundamental elution protocol for the 
development of reversed phase high-performance liquid chromatography enabling 
rapid simultaneous determination of purines, pyrimidines and allied compounds 
commonly found In biological fluids. J Chromatog 1985; 344: 101-113.
MRC Vitamin Study Research Group. Prevention of neural tube defects: results of 
the Medical Research Council Vitamin Study. Lancet 1991; 1:338:131-137.
Munan L, Kelly A, Petitclerc C. Serum urate levels between ages 10 and 14: 
changes in sex trends. J Lab Clin Med 1977; 90: 6: 990-996.
Murray AW, Elliot DC, Atkinson MR. Nucleotide biosynthesis from preformed 
purines in mammalian cells: Regulatory mechanisms and biological significance. 
Prog Nucleic Acid Res Mol Biol 1970; 10: 87-119.
Nakayama DA, Barthélémy C, Carrera G, Lightfoot RWJ, Wortmann RL. 
Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984; 
27: 4: 468-471.
Nyhan WL, Bakay B, Connor JD, Marks JF, Keele DK. Hemozygous expression of 
glucose-6-phosphate dehydrogenase in erythrocytes for the Lesch-Nyhan 
Syndrome. Proc Natl Acad Sci USA 1970;
220
O'Duffy JD, Hunder GG, Kelly PJ. Decreasing prevalence of tophaceous gout. 
Mayo Clin Proc 1975; 50: 227-228.
O'Rahilly R. The embryonic period [letter]. Teratology 1986; 34: 119.
Ogasawara N, Stout J.T, Goto H, Sonta S, Matsumoto A, Caskey CT.Molecular 
Analysis of a Female Lesch-Nyhan Patient. J Clin Invest 1989; 84: 1024-1027.
Olsen AS, Milman G. Human hypoxanthine phosphoribosyltransferase: Purification 
and properties. Biochemistry 1977; 16: 11: 2501-2505.
Ou Cy, Stevenson RF, Brown VK et al. V677T homozygosity associated with 
thermolabile 5,10-methylenetetrahydrofolate reductase as a risk factor for neural 
tube defects. Am J Hum Genet 1995; 57 (suppi): A223.
Page T, Bakay B, Nyhan W. An improved procedure for detection of 
hypoxanthine-guanine phosphoribosyltransferase heterozygotes. Clin Chem 1982; 
28; 5: 1181-1184.
Page T, Broock RL. A pitfall in the prenatal diagnosis of Lesch-Nyhan syndrome by 
chorionic villus sampling. Prenat Diagn 1990; 10: 153-157.
Pahwa, RN, Pahwa SG, Good RA. T-lymphocyte differentiation in severe 
combined immunodeficiency: Defects of the thymus. Clin Immunol Immunopathol 
1978; 11: 437-444.
Pai GS, Sprenkle JA, Do TT, Mareni CE, Migeon BR. Localization of loci for 
hypoxanthine phosphoribosyltransferase and glucose-6-phosphate dehydrogenase 
and biochemical evidence of nonrandom X chromosome expression from studies 
of a human X- autosome translocation. Proc Natl Acad Sci USA 1980; 77: 5: 2810- 
2813.
Papapetrou C, Lynch SA, Burn j, Edwards H. Methylenetetrahydrofolate reductase 
and neural tube defects. Lancet 1996; 348: 58.
Parkman R, Gelfand EW, Rosen FS, Sanderson A, Hirschhorn R. Severe 
combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med 
1975; 292: 714-719.
Patel PI, Nussbaum RL, Gramson PE, Ledbetter DH, Caskey CT, Chinault AC. 
Organization of the HPRT gene and related sequences in the human genome. 
Somat Cell Mol Genet 1984; 10: 5: 483-493
Patel PI, Framson PE, Caskey CT, Chinault AC. Fine structure of the human hypo­
xanthine phosphoribosyltransferase gene. Mol Cell Biol 1986; 6: 2: 393-403.
Perignon JL, Durandy A, Peter MO, Frey con F, Dumez Y, Griscelli C. Early 
prenatal diagnosis of inherited severe immunodeficiencies linked to enzyme 
deficiencies. ; J Pediatr 1987; 111:4: 595-598.
Posey DL, Khoury MJ, Mulinare J, Adams MJ, Ou CY. Is mutated 
methylenetetrahydrofolate reductase a risk factor for neural tube defects?. Lancet 
1996; 347: 686-687.
221
I
Rasmussen Loft AG, Nanchahal K, Cuckle HS et al. Amniotic fluid 
acetylcholinesterase in the prenatal diagnosis of open neural tube defects and 
abdominal wall defects: A comparison of gel electrophoresis and a monoclonal 
antibody assay. Prenat Diagn 1990; 10: 449-459.
Remes GH, Fisher RA, Hackel E, Cousineau AJ, Higgins J. SRO refinement for 
nucleoside phosphorylase by deletion mapping of chromosome 14. Cytogenet Cell 
Genet 1984; 37: 568.'
Riccluti F, Ruddle FH. Assignment of nucleoside phosphorylase to D-14 and 
localization of X- linked loci in man by somatic cell genetics. Nat New Biol 1973; 
241: 180-182.
Roessler BJ, Nosal JM, Smith PR ef al . Human X-linked phosphoribosyl 
pyrophosphate synthetase superactivity Is associated with distinct point mutation in 
the PRPS1 gene. J Biol Chem 1993; 268: 35: 26476-26481.
Rosenblatt DS, Erbe RW. Methylenetetrahydrofolate reductase in cultured human 
cells. II. Genetic and biochemical studies of methylene-tetrahydrofolate reducatase 
deficiency. Pediat Res 1977; 11: 1141-1143.
Rosenbloom FM, Kelley WM, Henderson JF, Seegmiller JE. Lyon hypothesis and 
X-linked disease. Lancet 1967a; II: 305-306.
Rosenbloom FM, Kelley WM, Miller J, Henderson JF, Seegmiller JE. Inherited 
disorder of purine metabolism: correlation between central nervous system 
dysfunction and biochemical defects. JAMA 1967b; 202: 175-177.
Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of 
methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997; 78: 523- 
526.
Sakuma R, Nishina T, Yamanaka H et al. Phosphoribosylpyrophosphate 
synthetase in human erythrocytes: assay and kinetic studies using high- 
performance liquid chromatography. Clin Chim Acta 1991; 203: 143-152.
Santisteban I, Arredondo-Vega FX, Kelly S et al. Novel splicing, missense, and 
deletion mutations in seven adenosine deaminase-deficient patients with 
late/delayed onset of combined immunodeficiency disease. Contribution of 
genotype to phenotype. J Clin Invest 1993; 92: 2291-2302.
Scott CR, Chen SH, G iblett ER. Detection of the carrier state in combined immuno­
deficiency disease associated with adenosine deaminase deficiency. J Clin Invest 
1974; 53: 1194-1196
Seegmiller JE, Rosenbloom FM, Kelley WN. Enzyme defect associated with a 
sex-linked human neurological disorder and excessive purine synthesis. Science 
1967; 155: 1682-1684.
Seegmiller JE. Inherited deficiency of hypoxanthine-guanine phosphoribosyl­
transferase in X-linked uric aciduria (the Lesch-Nyhan syndrome and its variants) 
Adv Hum Genet 1976; 6: 75-163.
222
Sege-Peterson K, Chambers J, Page T, Jones OW, Nyhan WL. Characterization 
of mutations in phenotypic variants of hypoxanthine phosphoribosyl transferase 
deficiency. Hum Moi Genet 1992; 6:427-432.
Shields DC, Peador KN, Mills JL et a i The “thermolabile” variant of 
methylenetetrahydrofolate reductase and neural tube defects: An evaluation of 
genetic risk and the relative importance of the genotypes of embryo and mother. 
AM J Hum Gen 199; 64: 1045-1055
Shovlin CL, Hughes JM, Simmonds HA et a i Adult presentation of adenosine 
deaminase deficiency [letter]. Lancet 1993; 341: 1471.
Silvers DN, Cox RP, Balls ME, Danois J. Detection of the heterozygote in Lesch- 
Nyhan disease by hair-root analysis. N Engl J Med 1972; 286; 8: 390-395.
Silverstein FS, Johnston MV, Hutchinson RJ, Edwards NL. Lesch-Nyhan 
syndrome: CSF neurotransmitter abnormalities. Neurology 1985; 35; 907-911.
Simmonds HA, Panayi GS, Corrigall V. A role for purine metabolism in the immune 
response: Adenosine-deam inase activity and deoxyadenosine catabolism. Lancet 
1978; 1: 60-63.
Simmonds HA, Duley JA, Davies PM. Analysis of purines and pyrimidines in blood, 
urine and other biological fluids, in: Techniques in diagnostic and human 
biochemical genetics. A laboratory manual. Wiley-Liss Inc. 1991; 307-424.
Simmonds HA, Duley Ja, Fairbanks LD, McBride MB. When to investigate for 
purine and pyrimidine disorders. Introduction and review of clinical and laboratory 
indications. J. Inherit Metabol Dis 1997; 214-226.
Singh S, Willers I, Goedde HW. A rapid micromethod for prenatal diagnosis of 
Lesch Nyhan syndrome. Clin.Genet 1976; 10: 12-15.
Smithells RW, Sheppard S, Schorah CJ. Vitamin dificiencies and neural tube 
defects. Arch Dis Child 1976; 51: 944-950
Smithells RW, Ankers C, Carver ME, Lennon D, Schorah CJ, Sheppard S. 
Maternal nutrition in early pregnancy. Br J Nutr 1977; 38: 497-506.
Smithells RW, Nevin NC, Seller MJ et a i Further experience of vitamin 
supplementation for prevention of neural tube defect recurrences. Lancet 1983; 1: 
1027-1031.
Spielman RS; McGinnis RE, Ewans WJ. Transmission test for linkage 
disequilibrium: the insulin region and insulin dependent diabetes melitus (IDDM). 
Am J Hum Genet 1993; 52: 3: 506-516.
Spencer N, Hopkinson D, Harris H. Adenosine deaminase polymorphism in man. 
Ann Hum Genet 1968; 32: 9-14.
Sperling O, Eilam G, Sara PB, De Vries A. Accelerated erythrocyte 5- 
phosphoribosyl-1-pyrophosphate synthesis. A familial abnormality associated with 
excessive uric acid production and gout. Biochem Med 1972; 6: 310-316.
223
■Sperling O, Persky-Brosh S, Boer P, De Vries A. Human erythrocyte phospho- 
ribosylpyrophosphate synthetase mutationally altered in regulatory properties 
Biochem Med 1973; 7: 389-395.
Stone OH. Possible prevention of neural-tube defects by perlconceptional vitamin 
supplementation [letter] Lancet 1980; 1: 647.
Stoop JW, Zegers BJ, Hendrickx GF et al. Purine nucleoside phosphorylase 
deficiency associated with selective cellular immunodeficiency. N Engl J Med 
1977, 296: 12: 651-655.
■■Stone T and Simmonds HA. Clinical consequences. In: Purines: Basic and clinical
aspects. Dordrecht, Boston, London: Kluwer Academic Publications, 1991: 187- 
215.
Determination of the mutations responsible for the Lesch-Nyhan Syndrome in 17 
subjects. Genomics 1991; 10: 499-501.
Tischfield JA, Creagan RP, Nichols EA, Ruddle PH. Assignment of a gene for 
adenosine deaminase to human chromosome 20. Hum He red 1974; 24: 1-11.
224
Stout JT, Caskey T. HPRT:Gene Structure, Expression, and Mutation. Ann Rev 
Genet 1985a; 19: 127-148.
Stout JT, Jackson LG, Caskey CT. First trimester diagnosis of Lesch-Nyhan 
syndrome: applications to other disorders of purine metabolism. Prenat Diagn 
1985b 5; 183-189.
Taira M, lizasa T, Shimada H, Kudoh J, Shimizu N, Tatibana M. A human testis- 
specific mRNA for phosphoribosylpyrophosphate synthetase that initiates from a 
non-AUG codon. J Biol Chem 1990; 265: 16491-16497.
TarleSA, Davidson BL, WU VC, ZidarFJ, Seegmilier JE, Kelley WN, Palella T.
Trembath D, Sherbbondy AL, Vandyke DC et al. Analysis of select folate pathway 
genes, PAX3, and human T in a Midwestern neural tube defect population. 
Teratology 1999; 59: 5: 331-341. f
Van Allen Ml. Multisite neural tube defect closure in humans. Birth Def Org Artie 
Ser 1996; 30:1: 203-205.
Van der Put NMJ, Steegers-Theunissen RPM, Frosst at a i Mutated 
methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 
356: 1070-1071.
Van der Put NMJ, van den Heuvel LP, Steegers-Theunissen RPPM et al. 
Decreased methylenetetrahydrofolate reductase activity due to the 677C ^T  
mutation in families with spina bifida offspring. J Mol Med 1996; 74: 691-694.
Van der Put NM, Eskes TK, Blom HJ. Is the common 677C-^T mutation in the 
methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A 
meta-analysis. Q J Med 1997; 90: 111-115.
Van Heeswijk PJ, Blank CH, Seegmilier JE, Jacobson CB. Preventive control of 
the Lesch-Nyhan syndrome. Obstet Gynecol 1972; 40: 109-113.
I
Wallace SL, Singer JZ. Therapy in gout Rheum Dis Clin North Am 1988; 14: 2; 
441-457.
Watkins D, Cooper BA. A critical intracellular concentration of fully reduced non- 
methyiated folate polyglutamates prevents macrocytosis and diminished growth 
rate of human cell line K562 in culture. Biochem J 1983; 214: 465-470.
Watts RW, Harkness RA, Spellacy E, Taylor NF. Lesch-Nyhan syndrome: growth 
delay, testicular atrophy and a partial failure of the 11 beta-hydroxylation of 
steroids. J Inherit Metab Dis 1987; 10: 210-223.
Williams SR, Goddard JM, Martin DWJ. Human purine nucleoside phosphorylase 
cDNA sequence and genom ic clone characterization. NucI Acids Res 1984; 12: 
14: 5779-5787.
Wilson JM, Landa LE, Kobayashi R, Kelley WN. Human hypoxanthine-guanine 
phosphoribosyltransferase. Tryptic peptides and post-translational modification of 
the erythrocyte enzyme. J Biol Chem 1982a; 257: 24: 14830-14834.
225
Î
Van Kampen EJ and Ziljstra WG. Standardization of hemoglobinometry. II The 
hemoglobincyanide method. Clin Chim Acta 1961; 6: 538-544.
Wald NJ, Polani PE. Neural-tube defects and vitamins: the need for a randomized 
clinical trial. Br J Obstet Gynaecol 1984; 91: 516-523.
Wald N. Folic acid and the prevention of neural tube defects. Ann N Y Acad Sci 
1993; 678: 112-29.
Wald NJ. Folic acid and neural tube defects: the current evidence and Implications 
for prevention. Ciba Found Symp 1994; 181: 192-211.
Wald NJ. Folic acid and the prevention of neural tube defects: the need for public 
health action. BibI Nutr Dieta 1995; 56-65.
Wald NJ, Hackshaw AD, Stone, R, Sourial, N.A. Blood folic acid and vitamin B12 
in relation to neural tube defects. Br J Obstet Gynaecol 1996; 103: 4: 319-324.
I
Weinberg K, Hershfield MS, Bastian J, Kohn D, Sender L, Parkman R, Lenarsky C.
T lymphocyte ontogeny in adenosine deam inase-deficient severe combined 
immune deficiency after treatment with polyethylene glycol-modified adenosine 
deaminase J Clin Invest 1993; 92: 596-602.
Whitehead AS, Gallagher P, Mills JL et al. A genetic defect in 5,10 
methylenetetrahydrofolate reductase in neural tube defects. Q J Med 1995; 88:
763-766. IW iginton DA, Kaplan DJ, States JO et al. Complete sequence and structure of the 
gene for human adenosine deaminase. Biochemistry 1986; 25: 8234-8244.
Williams SR, Gekeler V, Mclvor RS, Martin, D.W.J. A human purine nucleoside 
phosphorylase deficiency caused by a single base change J Biol Chem 1987; 262: 
5: 2332-2338. i
f:
W ilson JM, Tarr GE, Mahoney WC, Kelley WN. Human hypoxanthine-guanine 
phosphoribosyltransferase. Complete amino acid sequence of the erythrocyte 
enzyme. J Biol Chem 1982b; 257: 18: 10978-10985.
W ilson JM, Kobayashi R, Fox IH, Kelley WN. Human hypoxanthine-guanine 
phosphoribosyltransferase. J Biol Chem 1983; 258: 6458-6460.
W ilson JM, Stout JL, Palella T, Davidson BL, Kelley WN, Caskey T. A 
Molecular study of Hypoxanathine-Guanine Phosphoribosyl Transferase Deficiency 
in Man. J Clin Invest 1986; 77: 188-195.
Yang TP, Patel PI, Chinault AC, Stout JL, Jackson LG, Hildebrande BM, Caskey T 
Molecular evidence for new mutation at the HPRT locus in the Lesch-Nyhan 
patients. Nature 1984; 310: 412-414.
Yang TP, Stout JT, Konecki DS, Patel PI, Alford RL, Caskey CT. Spontaneous 
rearrangement of novel Lesch-Nyhan mutation by HPRT gene rearrangement. 
Somatic Cell and Molecular Genetics 1988; 14: 2: 293-303.
Yates JR, Ferguson-Smith MA, Shenkin A, Guzman-Rodriguez R, White M, Clark 
BJ. Is disordered folate metabolism the basis for the genetic predisposition to 
neural tube defects?. Clin Genet 1987; 31: 279-287.
Yu TF, Berger L. Impaired renal function gout: its association with hypertensive 
vascular disease and intrinsic renal disease. Am J Med 1982; 72: 95-100.
Yukawa T, Akazawa H, Miyake Y, Takahashi Y, Nagao H, Takeda E. A female 
patient with Lesch-Nyhan Syndrome. Dev Med and Child Neur 1992; 34: 534-546.
Zaiokar J, Lellouch J, Claude JR. Serum urate and gout in 4663 young male 
workers. Sem.Hop.1981; 57: 664-670.
Zannis V, Doyle D, Martin DW. Purification and characterization of human 
erythrocyte purine nucleoside phosphorylase and its subunits. J Biol Chem 1978; 
253: 504-510.
Ziegler JB, van der Weyden MB, Lee CH, Daniel A. Prenatal diagnosis for 
adenosine deaminase deficiency. J Med Genet 1981; 18: 154-156.
Zoref-Shani E, Bromberg Y, Goldman B et al. Prenatal Diagnosis of Lesch-Nyhan 
Syndrome: Experience with three fetuses at risk. Pren Diagn 1989; 9: 657-661.
226
